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Abstract of Dissertation 
 
Vena cava filters (VCFs) are mechanical devices implanted in the inferior vena cava 
to trap thrombi from travelling to the pulmonary circulation, resulting in pulmonary 
embolism. VCFs are available as permanent or non-permanent, retrievable devices 
and are generally indicated for use in patients unable to receive systemic 
anticoagulation or at exceedingly high risk for pulmonary embolism (PE). 
Retrievable devices allow for removal of the VCF once the contraindication to 
anticoagulation or high risk of PE has abated. Since the introduction of retrievable 
VCFs in the early 2000’s, use of VCFs has increased three-fold, with >85% of all VCFs 
placed being retrievable. Complications due to indwelling VCFs are time-dependent 
and the FDA-recommended time periods for retrieval fall within 50-70 days post-
implantation. However, retrieval rates are low. Generally around 30% of all VCFs 
are retrieved in eligible patients, with the remainder becoming permanent despite 
no indication for the VCF to remain in place. These studies sought to quantify the 
epidemiology of VCF use, and retrieval in Kentucky and nationally, and to inform 
future clinical interventions to increase retrieval rates. The following objectives 
were achieved: 1) describe treatment patterns for patients hospitalized with PE or 
other venous thromboembolism including VCF utilization and anticoagulation, 2) 
characterize patients who do and do not receive VCFs, 3) evaluate retrieval rates 
among subgroups of patients and identify factors associated with retrieval, and 4) 
evaluate a minimal intervention performed in the University of Kentucky hospital 
aimed at increasing VCF retrieval rates. Finally, a review of the literature was 
conducted to identify interventions that have increased retrieval rates at individual 
hospitals. All these data will be useful in developing a future institutional-level 
intervention to increase retrieval rates to better improve the quality of patient care. 
 
Key words: vena cava filters, venous thromboembolism, pulmonary embolism, 
retrieval, quality of care 
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CHAPTER 1: INTRODUCTION TO VENA CAVA FILTERS 
Venous thromboembolism epidemiology and treatment 
Venous thromboembolism (VTE) includes both deep vein thrombosis (DVT) of the 
legs or pelvis and pulmonary embolism (PE). VTE incidence is estimated to be about 
124 to 138 events per 100,000 person-years – equally divided between DVT alone 
and PE with or without DVT, with recurrence in approximately 30% of patients 
within 10 years. 1,2 VTE carries a high risk of mortality, with 30-day case-fatality 
rates of nearly 17% for PE and nearly 7% for DVT, a risk which increases with age. 2 
The majority (~60%) of VTE is secondary to known major risk factors such as 
hospitalization, trauma, surgery, and cancer while also influenced by myriad of 
other clinical factors, treatment regimens, and acquired or inherited thrombophilia.  
3 
 
Treatment of VTE is addressed by the American College of Chest Physicians (ACCP 
or CHEST) guidelines. 4 Updated as recently as 2016, the ACCP guidelines generally 
recommend systemic anticoagulation in the form of oral anticoagulants (OAC, 
warfarin, rivaroxaban, dabigatran, apixaban, edoxaban) or low-molecular weigh 
heparin (LMWH, tinzaparin, dalteparin, enoxaparin) for at least 3 months after VTE. 
Vena cava filters (VCFs) are devices usually implanted in the inferior vena cava to 
mechanically prevent thrombi migrating from the lower extremities to the 
pulmonary circulation (Figure 1.1). Designs of these device differ by manufacturer 
and model, but generally include an umbrella-like design to catch thrombi, barbed 
 2 
arms that embed into the endothelium of the vena cava, and snare hooks to facilitate 
retrieval (Figure 1.2). ACCP recommendations are limited for VCFs in saying that 
they are considered only a last resort in patients with severe risk of PE and should 
never be used in patients that can use anticoagulants. As an introduction to VCFs, 
the utilization of and evidence supporting their use will be reviewed.  
 
Vena cava filter utilization 
Despite strong, Grade 1B (“high evidence”) recommendations by the ACCP guideline 
panel to not utilize VCFs but in the most severe cases, VCFs are still used in 
approximately 10% of all VTE cases and nearly 20% of all PE cases.  5,6 Overall 
utilization has steadily increased, especially with the introduction of retrievable, or 
optional, VCFs in 2003. 5,7,8 Use of VCFs is associated with patients deemed at high 
risk of recurrent VTE and/or high bleed risk including those with active cancer, 
advanced age, prior bleeding, trauma, surgery, and unstable patients. 5,7 Estimates of 
VCF placements in the U.S. have increased from ~3,000 devices per year during 
1979 through 1984, up to 92,000 devices placed in 2006.  5 Utilization of VCFs may 
be excessive in the U.S., with utilization outpacing European nations by 25 to 40-
fold. 
 
Evidence for vena cava filters 
Prior to 2015, only one randomized controlled trial had evaluated the efficacy of 
VCFs for prevention of pulmonary embolism. The Prévention du Risque d’Embolie 
 3 
Pulmonaire par Interruption Cave (PREPIC) study randomized patients with 
proximal DVT with or without PE to receive standard anticoagulant treatment with 
or without a VCF. 9 At this time, only permanent VCFs were available on the market. 
After eight years of follow-up, there was a significant protective effect of VCFs on 
pulmonary embolism (6.2% vs. 15.1%, P=0.008), a significant increase in DVTs 
associated with VCFs (35.7% vs. 27.5%, P=0.042), and no difference in mortality. In 
2015, PREPIC2 data were released which updated the evidence for retrievable VCFs. 
10 With a similar design applied to 399 patients, results at six months of follow-up 
showed a non-significant reduction in PE and other outcomes including DVT, major 
bleeding, and death. Overall, the PREPIC and PREPIC2 studies did not supply clear 
evidence for the use of VCFs, mainly due to the fact that the population studied is 
not considered the population in whom VCFs are usually indicated, i.e. those who 
have absolute or relative contraindications to anticoagulation. However, given that 
it would likely be difficult and unethical to conduct such a study, observational 
studies must fill in the evidence gap.  
 
Observational studies have shown mixed results both in favor and against the 
utilization of VCFs in multiple patients groups. Stein et al showed an overall 
protective effect of VCFs for in-hospital mortality in stable, unstable, and elderly 
patients. 11,12 These studies are potentially biased given that the authors used 
National Inpatient Sample discharge data, which include no basis to establish 
temporality. Similarly, Isogai and colleagues associated VCFs with an overall 
protective effect for in-hospital mortality in a Japanese study of patients with 
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pulmonary embolism using propensity score techniques to reduce sample bias. 13 A 
pooled analysis of eight controlled studies evaluating prophylactic use of VCF filters 
(i.e. no VTE present) found a consistent protective benefit for PE and fatal PE with 
inconsistent findings for subsequent risk of DVT associated reduction in with VCF 
use. 14 This study found the number needed to treat to prevent one PE event ranged 
from 109 up to 962 patients in this setting. 
 
A number of studies have also refuted the effectiveness claims of VCFs. Using data 
from California, VCFs were found to be used in patients with greater comorbidity, 
PE, bleeding, cancer, and prior stroke. 15 In adjusted analyses, VCF placement was 
not associated with a significant reduction in recurrent PE but was associated with 
higher risk of DVT – consistent with the findings of the PREPIC trial. Another study 
conducted in patients with cancer-associated VTE found that those patients with a 
VCF had higher mortality and recurrent VTE events compared to those treated with 
anticoagulation in propensity score weighted analyses. 16 Muriel et al evaluated 
survival effects of VCFs in patients with VTE and high bleeding risk. 17 Using a 
propensity-score matched sample, they found a non-significant reduction in all-
cause death with VCF use (6.6% vs. 10.2%, P=0.12), a significant reduction in PE-
related mortality (1.7% vs. 4.9%, P=0.03), and much higher risk for recurrent VTE 
with VCF placement (6.1% vs. 0.6%, P<0.001). Hemmila and colleagues investigated 
the survival benefit for prophylactic use of VCFs found that patients with a VCF in 
place had no impact on mortality and increased the risk of DVT. 18  The most recent 
study by White et al also used propensity score matched samples and found that 
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VCFs had a protective effect in for 30- and 90-day risk of death only in patients with 
active bleeding with no effect observed in patients with no contraindication to 
anticoagulation. 19 
 
Although there is a general lack of consensus in the evidence, 20 VCFs are widely 
accepted and utilized – again in roughly 10% of all VTE cases and to an equal degree 
for prophylactic indications. 5 Some physicians have even called for alarm given that 
VCFs have generally been approved by the U.S. Food and Drug Administration (FDA) 
using the 510(k) process, which has been condemned by the Institute on Medicine.  
20 This process relies on existing information for a predicate device and allows for 
marketing of a new device with minimal data submission to the FDA, with few 
exceptions for prospective safety data collection or small trials to determine safety. 
21 In this article subtitled, “How Could a Medical Device Be So Well Accepted 
Without Any Evidence of Efficacy?” the authors conclude that while RCTs will 
continue to lag behind in the information needed to guide clinical practice around 
VCFs, informed consent must be offered to patients so that the lack of evidence and 
growing evidence of harm can be considered by patients at the point of care. 20 
 
Complication rates of vena cava filters 
In addition to the lack of evidence for efficacy, there are also complications related 
to VCF use that must be considered. Major complications can include the 
aforementioned increased risk of DVT, thrombosis in the inferior vena cava, device 
fracture and migration, and device perforation of the inferior vena cava and internal 
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organs. Complication rates appear to be on a device-by-device basis. 22 A study by 
Peterson and colleagues showed that roughly 1-in-5 patients with a VCF had a 
complication including: VCF thrombi (9.5%), DVT (4.7%), VCF penetration of the 
blood vessel (2.9%), and device migration (0.4%). 23 In the FDA’s own Manufacturer 
and User Facility Device Experience (MAUDE) database between 2009-2012, 1,606 
adverse events associated with VCFs were reported including 350 device fractures, 
215 whole device migrations, 154 partial device embolizations, 197 VCF tilts, and 
228 vena cava penetrations. 24 This, again, varied considerably across six individual 
types of filters included in the study and was mostly reported for retrievable VCFs. 24 
Although PE may be prevented, the observed increased risk of DVT is not benign 
with up to 30% of patients developing post-thrombotic syndrome, which can have 
long-term effects on quality of life. 25-27 
 
Complications reported with VCFs are generally outside of 30 days post-
implantation, i.e. they are associated with longer indwell times of retrievable VCFs. 
28,29 In response to this concern, the FDA released an initial Safety Communication 
regarding retrieval of VCFs in 2010. 30 Citing a study which modeled the inflection 
point of the net clinical benefit of VCFs, the FDA formally recommended that VCFs 
be removed within 29 to 54 days after implantation or when clinically indicated, 
which can be interpreted as when the patient can be anticoagulated or is no longer 
at a substantial risk for PE. 31 The communication also detailed ongoing data 
collection through post-market surveillance and ongoing clinical study. 30 
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Guidelines impacting use of vena cava filters 
Despite a lack of evidence and concern about complications, VCF utilization has 
been shown to continue to increase over the last several decades. 5 As mentioned, 
the ACCP guidelines, which are widely used for educating clinicians on treatment for 
VTE, are conservative in regards to VCF use and consider the device a “last resort.” 
However, these guidelines are not the sole influence on medical practice 
surrounding VCF. Two specialties that interact with decision-making for VCFs 
include (vascular) interventional radiology and trauma who have created 
independent guidelines.  
 
The American College of Radiology and Society of Interventional Radiology (SIR) 
guidelines cover the practice of interventional radiologists who are most often 
placing VCFs after patients are referred to their service from other specialties. The 
most recent 2011 guidelines are considered more liberal in VCF use compared to 
the ACCP guidelines, allowing and recommending VCF use for patients with VTE 
who are contraindicated to anticoagulation, prophylactically in those with trauma, 
bariatric surgery, or spinal cord injury and no VTE, as well as in patients with VTE 
treated with anticoagulation if there is recurrence or progression of the VTE, 
massive PE or massive clot burden, free-floating DVT, or in severe cardiopulmonary 
disease (Table 1.1). 32 To compare, ACCP guidelines recommend VCFs only when a 
contraindication to anticoagulation exists, specifically recommending against the 
other points made by the SIR guidelines and no recommendation for patients with 
recurrent VTE. It is logical to assume that those placing the devices will follow the 
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guidelines of their parent society. As a result, concordance with the ACCP guidelines 
is generally dismal with one study showing 41.3% of VCF placements following 
recommendations from ACCP. 33 This is contrasted with up to 95.7% concordance 
with SIR guidelines.  
 
 Trauma surgeons may also place VCFs in the acute care setting, relying on guidance 
from the Eastern Association for the Surgery of Trauma (EAST) guidelines.  34 
Dealing with a special patient population that may include multiple bone fractures, 
severe blunt or penetrating trauma, as well as the need for multiple surgeries, the 
inherent risk of VTE is high. These patients make up the vast majority of 
prophylactic use of VCFs, which is approximately 50% of the VCF utilization.  28 The 
EAST guidelines make “Level III” recommendations meaning there is only 
retrospective, opinion, or case study data to support the claim. Nevertheless, they 
call for prophylactic use only in “very-high risk” trauma patients who have high 
bleeding risk, noting particularly older age along with hemorrhagic injuries or risk 
factors. 34 EAST guidelines also acknowledge prophylactic use as controversial, 
owning to the lack of evidence but also the lack of approved indication according to 
the product labeling. They further suggest that identification of the proper trauma 
patient group, via risk factor assessment, is needed so VCFs are allocated efficiently. 
These guidelines have not been updated since 2002. 
 
The EAST and SIR guidelines have impacted the overall utilization of VCFs in the U.S. 
In a trend analysis, introduction of the EAST guidelines were associated with an 
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increase in VCF utilization of 138% while the SIR guidelines in 2006 were associated 
with an additional 122% increase. 35 The ACCP guidelines in 2008 and 2012 as well 
as decreased reimbursement from Medicare were also associated with a leveling off 
in utilization in that period.35 Further, there was an increase in legal suits against 
some manufacturers throughout this period that may have added to the cooling off 
of the VCF market. 
 
Comparisons of these guidelines vary given the different patient groups studied. 
However, one study conducted a cost effectiveness analysis in trauma patients, 
applying the guidelines as prophylactic (EAST, SIR) or non-prophylactic (ACCP) use 
of VCFs.  36 The authors found that for the overall trauma patient population, VCFs 
are more costly than no treatment and also result in in fewer quality-adjusted life-
years. However, to the point of better identifying more appropriate subgroups for 
prophylactic treatment made earlier in the EAST guidelines, the authors found that 
VCFs were cost-effective if the risk of VTE was around 10% or greater (i.e. greater 
than double the risk than the general trauma population). Prophylactic VCF 
utilization was cost-effective only if the likelihood of complications associated with 
anticoagulation was at least 10-times the risk in the general trauma population. 
During the initial hospitalization, VCFs were cost-effective at an incremental cost-
effectiveness ratio of nearly $400,000 per quality-adjusted life year, which would 
fail to reach the acceptable threshold by any normal cost-effectiveness 
considerations. 36 
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Variation in the utilization and retrieval of vena cava filters 
Multiple guidelines and limited evidence appears to have made a practice 
environment that varies from institution-to-institution and across state and 
geographical areas. White et al conducted a study of hospitals in California. Of the 
263 hospitals included, variation in use of VCFs for active VTE ranged from 0% to 
nearly 40% with an overall mean use of 15% of all VTE cases. Of this variation, 
18.5% was attributable to between hospital differences, with the rest attributed to 
patient factors or unmeasured characteristics. 37  
 
Using a trauma-specific database, Dossett et al observed what they referred to as 
“unwarranted national variation” in the use of prophylactic VCFs.  38 They observed 
variation in use of 0 to 13 prophylactic VCFs per 100 trauma patients. They also 
included a metric for “high-risk patients” in line with who would be considered high 
risk of VTE according to the EAST guidelines, with the goal of only utilizing VCFs in 
those patients at high risk. They found that median use was centralized around the 
EAST recommendations at 1.1 VCFs used per high-risk patient (i.e. patients who 
were not “high risk” received a VCF despite lack of need, indicating potential 
overuse by 50% of all trauma centers) but this ranged up to 206 VCFs used per high-
risk patient in the most extreme case. Each study contributed some of the 
unobserved factors potentially contributing to this variation as “regional culture,” 
hospital culture, and engrained physician practices. The Dossett study also notes 
that if high utilization of VCFs was clearly associated with improved outcomes, the 
push would be to increase utilization in centers found to be under-utilizing VCFs in 
 11 
their study. 38 However, prophylactic VCF use remains controversial, off-label, and 
lacks clinical trial evidence to support this use. 
 
Appropriateness of the use of VCFs is a moot point once placement has occurred. 
The shift in focus becomes the retrieval of the device once the indication for 
placement has abated, i.e. the patient is no longer at high risk for PE and/or the 
patient can initiate anticoagulation. Clinical studies like PREPIC2, even in a 
controlled environment with dedicated follow-up periods, retrieved roughly 80% of 
all VCFs placed after 3 months. In real-world clinical practice, however, this rate is 
closer to an estimated mean of 30%, 28 with some institutions reporting VCF 
retrieval as low as 8%. 39 Retrieval is pivotal to the safety of these devices, again 
because complication rates are correlated with longer indwell times.  28 Dismal 
retrieval rates are associated with poor patient follow-up and fractionated care 
given that the physicians placing the filters, mainly interventional radiologists, are 
not generally part of the follow-up plan. 40-42 Thus, the majority of patients are likely 
discharged without any plans for follow-up for VCF retrieval, making the device de 
facto permanent in these people. The previously mentioned FDA safety 
communication relays only that retrieval is a goal, not necessarily specifying the 
correct patient population or indications for which VCFs should be used.  30 Thus, 
VCFs are a medical device likely being overused given the paucity of data  and one 
that is not consistently retrieved in a timely fashion, which is likely due to a lack of 
planning in  post hoc patient care. 
  
 12 
Figure 1.1: Diagram of vena cava filter placement in the inferior vena cava to 
prevent clot movement from lower extremities.  
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Figure 1.2: Examples of four vena cava filter models showing filter sections, 
barbs, and retrieval hooks 
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Table 1.1: Comparison of guidelines impacting utilization of vena cava filters 
Scenario for VCF 
placement 
ACCP Guidelines SIR Guidelines  
VTE with anticoagulation Recommends 
against VCFs 
Recommends with 
progression, large clot 
burden, free-floating thrombi, 
or severe cardiopulmonary 
disease. 
VTE with contraindication 
to anticoagulation 
Recommends VCF Recommends VCF 
Recurrent VTE No specific 
recommendation 
Recommends VCF 
Trauma (prophylaxis) Recommends 
against VCF 
Recommends consideration of 
VCF 
Bariatric surgery 
(prophylaxis) 
Recommends 
against VCF 
No specific recommendation 
Spinal cord injury 
(prophylaxis) 
Recommends 
against VCF 
Recommends VCF 
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HYPOTHESIS AND AIMS OF THIS DISSERTATION 
 
I believe that the use of VCFs is highly variable and the outcomes poorly described.  
Understanding the epidemiology of VCF utilization can inform interventions to 
improve the quality of care for patients with VTE, ensuring that the correct patients 
receive VCFs and that post-implantation care is provided.  The goal of this 
dissertation work is to describe and model the use and retrieval of VCFs.  I will also 
be evaluate to efficacy and toxicity outcomes and provide some pilot work to 
address low retrieval rates as outlined in the Aims below.  
Specific Aims 
Thus, I present these specific aims for this dissertation and address them in the next 
five chapters.  
1)   Assess utilization and variation in utilization of VCFs in acute care hospitals 
in Kentucky 
2) Evaluate retrieval rates and factors associated with retrieval in a national 
cohort 
3) Compare outcomes between patients treated with VCFs with and without 
anticoagulation, versus anticoagulation alone in a cancer patient subgroup at 
high risk of recurrent events 
4) Evaluate an intervention to increase retrieval rates in the Interventional 
Radiology clinic at the University of Kentucky hospital 
5) Perform a literature review of interventions to increase retrieval rates at 
other institutions to inform future efforts 
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CHAPTER 2: HOSPITAL VARIATION AND PATIENT CHARACTERISTICS 
ASSOCIATED WITH VENA CAVA FILTER UTILIZATION IN ACUTE CARE 
HOSPITALS IN KENTUCKY 
 
 
Study 2.1: Addresses VCF utilization in Kentucky hospitals by evaluating patient and 
hospital factors associated with use. This study has been published in the journal 
Medical Care. 
 
Citation: Brown, Joshua D., and Jeffery C. Talbert. "Hospital Variation and Patient 
Characteristics Associated With Vena Cava Filter Utilization." Medical Care (2016). 
Ahead of print. 
 
 
Study 2.2: Evaluates hospital-level variation in VCF utilization to observe whether it 
is explained by patient and hospital-level factors and to observe outliers along this 
continuum. This study has been published in the journal JAMA Surgery as a research 
letter and is formatted accordingly. 
 
Citation: Brown, Joshua D., and Jeffery C. Talbert. “Variation in the Use of Vena Cava 
Filters for Venous Thromboembolism in Hospitals in Kentucky.” JAMA Surgery 
(2016). doi:10.1001/jamasurg.2016.1004 
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Study 2.1: Hospital Variation and Patient Characteristics Associated With Vena 
Cava Filter Utilization 
 
Abstract 
 
Introduction: There is wide variation in the use of vena cava filter (VCFs).  
Objectives: This study assessed the hospital and patient characteristics associated 
with VCF use in deep vein thrombosis (DVT) and pulmonary embolism (PE). 
Methods: Inpatient discharge data from all acute care hospitals with DVT/PE in 
Kentucky were used. Hierarchical logistic regression models were used to evaluate 
the relationships of study variables with VCF use. 
Results: During the study period, 81,922 discharges for DVT/PE were observed and 
10.5% of these received a VCF. This included 12,083 cases of PE+DVT, 18,571 cases 
of PE only, and 51,268 cases of DVT only. VCF use among these groups was 22.7%, 
6.0%, and 7.8%, respectively. In adjusted analyses, VCF use was associated with 
increasing age, indicating that those over age 65 were twice as likely to receive a 
filter compared to the reference (21-25 year-old) group. Significant comorbidities 
associated with VCF use included cancer, liver disease, cerebrovascular disease, 
atrial fibrillation, anemia, and concurrent bleeding. Lower extremity, proximal 
DVTs, and patients receiving thrombolytic therapy or embolectomy, those having 
surgery, and those who were unstable or had trauma, were also more likely to 
receive a filter. Among cancer types, brain and metastatic tumors were significantly 
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associated with VCF use. Between-hospital variation after controlling for all 
covariates was 7.1%. 
Conclusion: There was high variation in use of VCFs. Several high-risk subgroups 
were more likely to use VCFs including older adults and those with cancer and 
concurrent bleeding. 
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Introduction 
 
Increased utilization of vena cava filters (VCFs) for venous thromboembolism (VTE) 
has correlated with technical improvements in placement of VCFs as well as 
development of retrievable devices. 5 By 2006, roughly 9% of cases of deep vein 
thrombosis (DVT) and 12% of pulmonary embolism (PE) received a VCF and has 
continued to increase into 2012 with an estimated 259,000 VCFs placed in patients 
in the United States. 43,44  
 
This increase persists despite mixed recommendations and an overall lack of 
evidence for the use of VCFs. 20 American College of Chest Physicians guidelines 
recommend VCF use only if the patient has a contraindication to systemic 
anticoagulation as a last resort. 45 Conversely, The American College of Radiology 
and Society of Interventional Radiology guidelines support prophylactic VCF use for 
patients determined to be at high risk of developing DVT or PE.  46,47 These 
contrasting recommendations are important considering that in a study conducted 
at one academic medical center, nearly one-half of all VCFs placed were for 
prophylactic purposes and only a third of uses are associated with clear bleed-
related contraindications to anticoagulation. 44 Another study corroborated these 
findings showing that up to 50% of VCFs used in trauma patients are 
“unwarranted.” 48 
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Given the potential for suboptimal use of VCFs and the wide variation in use 
between hospitals, 37 it is important to understand the hospital- and patient-level 
factors associated with utilization. Identifying these factors will assist in assessing 
the quality of care for patients presenting with DVT/PE and can also indicate 
subpopulations that may be of interest for future research. Thus, this study sought 
to characterize patients with VTE who received VCFs and to observe the amount of 
variation between hospitals. A cancer subgroup will also be analyzed with the same 
methodology due the high rates of VTE and potential of high bleeding risk in that 
population. 
 
Methods 
 
Data source 
State Inpatient Database (SID) data from Kentucky (years 2008-2014) were used. 
SID data are analogous to National Inpatient Sample (NIS) data but are state-specific 
and include all discharges instead of a probabilistic sample.  49 Data include patient 
demographic variables (age, gender, race, insurance, ZIP codes) and diagnosis and 
procedure fields. Data are de-identified and do not include unique patient 
identifiers, so no longitudinal tracking is possible. Thus, data represent discharges 
and may contain multiple records for the same person representing unique 
hospitalizations for that person. We use the terminology “patients” to distinguish 
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each unique hospitalization/discharge. The University of Kentucky Institutional 
Review Board approved of this study.  
 
Study variables 
The coding algorithms used are presented in the Appendix and are based on 
previously published coding algorithms. 15,37,50-52 All diagnoses for DVT PE were 
identified for those 21 and older from acute care hospitals. VCF use was identified 
by ICD-9-CM procedure code 38.7. Discharges from hospitals where no VCFs were 
placed over the entire 7-year period were excluded to avoid bias due to hospitals 
lacking the ability to perform the procedure. Variation in VCF use was described by 
the mean, median, interquartile range (IQR), and coefficient of variation.  
 
Patients were classified as having DVT only, PE only, or having PE+DVT. 
Comorbidities identified included cancer, chronic obstructive pulmonary disease, 
cerebrovascular disease (CVD), atrial fibrillation (AFib), liver disease, hypertension, 
heart failure, hyperlipidemia, myocardial infarction, cellulitis, trauma, diabetes, 
infection, pneumonia, renal disease, bleeding, anemia, and sepsis/septic shock.  53 In 
addition, thrombolytic therapy and embolectomy/thrombectomy procedures were 
identified. Unstable patients were identified as those with shock or by use of a 
ventilator. Invasive surgical procedures were identified using a validated algorithm.  
54 Discharge statuses of “deceased” or “transferred” were also recorded. Age was 
categorized by 5-year intervals. Race was categorized white, black, or other and 
insurance was classified as commercial, Medicaid, Medicare, or other/self-pay. 
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Individual hospitals were classified as being urban or rural, teaching or non-
teaching, and categorized into quartiles by hospital bed size.    
 
Statistical analysis 
Comparisons were conducted between demographic and clinical characteristics 
using t-tests and chi-squared tests where appropriate using an a priori, two-sided 
significance level of 0.05. P-values are reported for comparisons between VCF users 
and non-users.  
 
Based on previous studies the likelihood of receiving a VCF has a moderate 
association with the hospital where treatment occurs. 37 This is likely influenced at 
the institutional level by physician preferences and hospital policies and practices. 
To account for this natural clustering effect and its impact on treatment, hierarchical 
generalized linear modeling was used (henceforth: hierarchical logistic models) for 
the binary outcome of VCF use. 55 These models included random effects for each 
hospital and fixed effects for other covariates. 55,56 The first model included hospital 
random effects only. The second model included level-1 fixed effects, which are 
patient demographic and clinical characteristics. Level-2 effects, i.e., hospital 
characteristics, were included in a separate model alone and in the final full model, 
which included all random and level-1 and level-2 fixed effects. A cancer-only model 
was also estimated in the cancer subgroup with additional variables for cancer site 
(Table 2.4).  
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Odds ratios (ORs) and their 95% confidence intervals are presented for each 
variable from the final, full model. The intraclass correlation coefficient (ICC) was 
calculated for each model, which measures the variation explained by the hospital 
random effects. The p-value associated with the ICC corresponds to the comparison 
of between-hospital variance with p<0.05 showing significant differences. In 
addition, c-statistics were calculated as a measure of model discriminatory power 
between VCF users and non-users. Akaike (AIC) and Bayesian (BIC) information 
criterion were included to compare across models, which measure the fit of the 
models while penalizing for added parameters. All analyses were conducted using 
SAS version 9.4 (SAS Institute, Cary, NC). 
Results 
A total of 70 acute care hospitals were included in the state. Of these, 11 hospitals 
placed no VCFs and were excluded (N=2,435 patients, 2.9% of total discharges). 
Among the remaining institutions (N=59), VCF use ranged from 0.4% to 15.2%, 
mean 7.2%, median 7.2%, IQR 4.1% to 10.1%, and coefficient of variation of 0.54. 
 
During the period 2008 to 2014, there were 81,922 VTE-related hospital discharges 
and 10.5% of patients (N=7,786) received a VCF. The VCF group tended to have an 
older age distribution, and have more PE+DVT, cancer, cerebrovascular disease, 
atrial fibrillation, anemia, and trauma compared to those without VCFs (Table 2.1). 
The VCF group was also likely to be unstable, have proximal and lower DVTs, have 
bleeding, and receive thrombolysis. 
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The random effects only model resulted in an ICC of 12.0% (p<0.001) and c-statistic 
0.62, showing that there was a significant difference between hospitals, which 
explained 12% of the overall variance in use (Table 2.2). Adding level-1 patient-level 
covariates, the ICC was 12.7% (p<0.001) and the c-statistic was 0.81 showing no 
change in the explained variance for the random effects parameter and an overall 
strong discriminatory ability for the model. The full model included random effects 
with both level-1 and level-2 fixed effects. This model had an ICC of 7.1% (p<0.001) 
and c-statistic of 0.81. The cancer only model had an ICC of 3.5% (p<0.001) and c-
statistic of 0.81.  
 
The results of the full model (Table 2.3) showed that beginning at 46-50 years of 
age, the odds of receiving a VCF increased compared to the reference group (21-25 
years-old). This trend continued with those over the age of 65 being roughly twice 
as likely to receive a VCF. VCFs were also associated with the commercial insurance 
category being more likely than those in the other/self-pay insurance category. 
Black race was also associated with lower odds of receiving VCFs compared to white 
race (OR=0.83 [0.75-0.92]). 
 
Clinical characteristics were highly associated with VCF use. Compared to patients 
with DVT only, those with PE only (OR=3.84 [3.46-4.25]) and PE+DVT (OR=2.73 
[2.57-2.90]) were much more likely to receive VCFs. Among DVTs, those with lower 
DVTs were more than six-fold more likely to receive a VCF compared to upper 
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extremity DVTs. Those with bleeding, cancer, liver disease, anemia, and atrial 
fibrillation were also more likely to receive VCFs.  
 
Among those with cancer (N=13,104), 1,613 (12.3%) used VCFs. In the cancer-only 
model, estimates for demographic and clinical characteristics were similar to the 
primary model and are not shown. The most common cancers were lung (N=3,931, 
30.0% of all cancers) and colorectal cancer (N=1,392, 10.6%). Of the twenty-two 
cancer sites identified, all but five had higher utilization of VCFs than in the average 
cohort (Table 2.4). The highest VCF use was associated with brain tumors (24.4%), 
cervical (17.0%), stomach and small intestine (16.3%), colorectal (16.2%), and 
bladder (15.6%). After controlling for all other variables, brain tumors (OR=2.31 
[1.65-3.23]) remained the only significantly associated tumor site with VCF use 
while leukemia and breast cancers were negatively associated with use. 
 
Discussion 
The primary findings suggest that while there is a wide variation in VCF utilization 
between institutions, most of that variation is controlled for by patient and hospital 
characteristics. In the final model, very little variation (~7%) in VCF use was 
attributed to differences between hospitals. This differs from an analogous study by 
White et al. using California SID data. Their results showed more variation (IQR 
6.23%-18.14%) in VCF use and more variation (>12%) attributed to between 
hospital comparisons. This indicates that VCF utilization between hospitals varies 
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widely not only within a state, but also between states, as our coefficient of variation 
was smaller (0.54 vs. 0.65).  
 
Among comorbid conditions considered, our results show strong associations with 
VCF use and cancer, cerebrovascular, atrial fibrillation, anemia, and concurrent 
bleeding. This suggests that consideration of baseline risk of thromboembolic and 
bleeding events is considered at the point of care. However, competing guideline 
statements make it difficult to assess the appropriateness of VCF use in subgroups at 
a high-risk of VTE, but not necessarily contraindicated to anticoagulation. The 
clearest indication for VCF use may be in those with concurrent bleeding in addition 
to the VTE already present. In this study, over 20% of patients with bleeding 
received a VCF and were 2.7 times more likely to receive a filter in adjusted 
analyses. VCF use was also associated with characteristics that potentially indicate 
severity including unstable patients, surgery, receipt of thrombolysis or 
embolectomy procedures, and trauma. 
 
The association between cancer, VTE, and presence of multiple risk factors for 
bleeding prompted a more detailed look into individual cancers. Patients with 
cancer are at an exceedingly high risk of VTE compared to the general population. 57 
Further, given the complexity of regimens, multiple drug-drug, and drug-disease 
interactions, and side effects of cancer treatments as well as many surgical 
procedures, it is possible that systemic anticoagulation is considered infeasible or is 
contraindicated for many cancer patients. 58 However, prior studies have shown that 
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anticoagulants are often used in addition to VCFs. 16,44 In this study, VCF use was 
highest for brain cancers, due to the high risk of intracranial bleeding, and with 
metastatic cancers. Surprisingly, lung cancers, which are often considered as a very 
high-risk group for cancer-associated VTE and highly prevalent in Kentucky, 59 were 
not associated with increased use. 
 
The evidence for VCFs for PE/DVT is mixed, making conclusive arguments for its use 
difficult. In the PREPIC 9 and PREPIC2 10 randomized trials, no significant benefits 
were observed with VCFs with anticoagulation versus anticoagulation alone during 
short- and long-term follow-up. Observational studies show that VCFs are 
associated with improvements in short-term outcomes such as in-hospital mortality, 
30-day mortality, and a reduction in subsequent PE events among all VTE patients 
and certain subgroups (trauma, unstable, and elderly). 11,13,14,60 Other studies have 
shown little or no benefit with VCFs, especially with longer follow-up. 15-18  
 
Retrievable filters have become widely used in the last decade. Sarosiek et al. 
evaluated the use of retrievable filters and subsequent complications at a single 
academic center. 44 Their main findings showed there was attempted retrieval in 
only 10% of VCFs. Of those retrieved, one-quarter were removed during the index 
hospitalization and the median time-to-retrieval was observed to be 122 days after 
placement. Their study further emphasized the lack of follow-up for patients 
receiving a VCF and a number of serious complications including filter fracture and 
migration. The authors emphasized the need for follow-up and proper retrieval of 
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devices to avoid complications associated with VCFs. This has been observed in 
other studies, as well, showing that utilization and retrieval rates as potential 
quality of care issues and deserve dedicated interventions to ensure quality 
outcomes for patients. 61-63  
 
It has also been suggested that use of VCFs, as well as their retrieval, is influenced by 
reimbursement rates. 44 Our findings seem to refute this strong assumption 
regarding use of VCFs, at least in a case-by-case (i.e. hospital) basis. Using the ICC to 
measure the impact of hospitals in the current study, the full model showed that 
only 7.1% of the variance in the model was explained by the discharge hospital. Our 
results suggest that there is not major variance between hospitals after controlling 
for patient and hospital characteristics and does not support the notion of pervasive 
overuse of VCFs in order to increase reimbursement.  
 
Although our results suggest no institutional deviance in VCF use, there may still 
exist a general overuse of these devices, which is not definitively supported by 
current evidence and is further confounded given the lack of consensus in treatment 
guidelines. There is a great need for additional research in the effectiveness of VCFs 
in real-world practice, especially for subgroups at highest risk of complications (e.g. 
cancer and high bleeding risk). While randomized studies are not likely to be 
conducted to fill these knowledge gaps, well-conducted effectiveness studies using 
observational data should be used. 
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Limitations 
Due to the nature of the data, detailed information on medication utilization is not 
possible with discharge data. This is important to distinguish those who would and 
would not use anticoagulants in place of, or concurrently with, VCFs as these groups 
may differ in clinical presentation and treatment course. Previous studies have 
shown that anticoagulants are often used with VCFs, likely proving that use persists 
without clear contraindications to anticoagulation therapy. 44 Further, as the data 
includes no unique patient-identifying variable, it is possible that multiple records 
for the same individual are included in the analyses. This would be due to multiple 
hospitalizations over the time period, including patients who transfer from one 
facility to another. To investigate the impact of transfers, we included an indicator 
for whether a patient transferred or not, as this may also indicate severity and 
influence whether a patient receives a VCF from that institution. At both a patient-
level and institutional-level, transfer status and transfer rate were not significantly 
associated with VCF utilization. Finally, the data represent the patient population 
and medical practice within Kentucky and may have limited generalizability to other 
areas due to differences in comorbid conditions and practices between regions.  
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Conclusion 
In this study of VCF use in Kentucky, we found that much of the between hospital 
variation is explained by observed hospital and patient characteristics and little 
variation existed between hospitals after controlling for these factors. More 
research is needed to assess the effectiveness of VCFs, especially in high-risk 
subgroups such as cancer, elderly, high bleed risk, and trauma patients. 
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Table 2.1: Comparison of patient characteristics between vena cava filter 
users and non-users 
 Characteristic 
No VCF 
N=74,136 
VCF 
N=7,786 
% 
Receiving 
VCF 
N % N %  
Age group 21-25 1,309 1.8% 64 0.8% 4.7% 
  26-30 1,958 2.6% 109 1.4% 5.3% 
  31-35 2,416 3.3% 140 1.8% 5.5% 
  36-40 3,092 4.2% 205 2.6% 6.2% 
  41-45 4,021 5.4% 292 3.8% 6.8% 
  46-50 5,225 7.1% 416 5.3% 7.4% 
  51-55 6,565 8.9% 605 7.8% 8.4% 
  56-60 7,148 9.6% 716 9.2% 9.1% 
  61-65 7,801 10.5% 875 11.2% 10.1% 
  66-70 7,780 10.5% 963 12.4% 11.0% 
  71-75 7,572 10.2% 950 12.2% 11.1% 
  76-80 7,188 9.7% 941 12.1% 11.6% 
  81+ 12,061 16.3% 1,510 19.4% 11.1% 
Gender Female 39,048 52.7% 3,982 51.1% 9.3% 
  Male 35,088 47.3% 3,804 48.9% 9.8% 
Race White 65,860 88.8% 7,068 90.8% 9.7% 
  Black 6,746 9.1% 540 6.9% 7.4% 
  Other 1,530 2.1% 178 2.3% 10.4% 
Insurance 
Other/Self-
pay 
10,187 13.7% 949 12.2% 
8.5% 
  Medicaid 2,930 4.0% 210 2.7% 6.7% 
  Medicare 24,275 32.7% 2,603 33.4% 9.7% 
  Commercial 36,744 49.6% 4,024 51.7% 9.9% 
Clot type DVT only 47,274 63.8% 3,994 51.3% 7.8% 
  PE only 17,466 23.6% 1,105 14.2% 6.0% 
  PE with DVT 9,396 12.7% 2,687 34.5% 22.2% 
Comorbidity Cancer 11,491 15.5% 1,613 20.7% 12.3% 
  
Metastatic 
cancer 
6,087 8.2% 959 12.3% 
13.6% 
  Heart failure 14,069 19.0% 1,470 18.9% 9.5% 
  Liver disease 3,224 4.3% 420 5.4% 11.5% 
  Renal disease 20,516 27.7% 2,233 28.7% 9.8% 
  Diabetes 20,656 27.9% 2,111 27.1% 9.3% 
  Stroke 4,893 6.6% 798 10.2% 14.0% 
  Hypertension 45,317 61.1% 4,954 63.6% 9.9% 
  Hyperlipidemi 23,826 32.1% 2,603 33.4% 9.8% 
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Table 2.1: Comparison of patient characteristics between vena cava filter 
users and non-users 
a 
  
Atrial 
Fibrillation 
10,868 14.7% 1,424 18.3% 
11.6% 
  Cellulitis 6,284 8.5% 398 5.1% 6.0% 
  COPD 23,630 31.9% 2,528 32.5% 9.7% 
  
Sepsis/Septic 
shock 
7,821 10.5% 908 11.7% 
10.4% 
  
Infection/ 
Pneumonia 
25,051 33.8% 2,712 34.8% 
9.8% 
  Anemia 24,874 33.6% 3,538 45.4% 12.5% 
  
Myocardial 
infarction 
6,700 9.0% 793 10.2% 
10.6% 
  Trauma 3,143 4.2% 558 7.2% 15.1% 
  
Thrombolytic 
therapy 
1,571 2.1% 546 7.0% 
25.8% 
  Embolectomy 249 0.3% 68 0.9% 21.5% 
  
Unstable/ 
ventilator 
3,455 4.7% 567 7.3% 
14.1% 
  Proximal DVT 12,651 17.1% 2,966 38.1% 19.0% 
  Lower DVT 31,538 42.5% 5,997 77.0% 16.0% 
  Bleeding 4,612 6.2% 1,173 15.1% 20.3% 
 Surgery 14,340 19.3% 2,177 28.0% 13.2% 
 Deceased 4,200 5.7% 436 5.6% 9.4% 
 Transfer 1,907 2.6% 155 2.0% 7.5% 
Urban/rural 
status 
Rural 19,096 25.8% 1,692 21.7% 
8.1% 
 Urban 55,040 74.2% 6,094 78.3% 10.0% 
Teaching 
status 
Non-teaching 36,792 49.6% 3,210 41.2% 
8.0% 
 Teaching 37,344 50.4% 4,576 58.8% 10.9% 
Bed size ≤75 beds 2,500 3.4% 99 1.3% 3.8% 
 76-135 beds 6,216 8.4% 331 4.3% 5.1% 
 136-275 beds 18,761 25.3% 1,718 22.1% 8.4% 
 ≥276 beds 46,659 62.9% 5,638 72.4% 10.8% 
Abbreviations: aOR=adjusted odds ratio; CI=confidence interval; VCF=vena cava 
filter; DVT=deep vein thrombosis; PE=pulmonary embolism; COPD=chronic 
obstructive pulmonary disease 
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Table 2.2: Fit statistics of hierarchical logistic models predicting vena cava filter use 
 Model 1: 
Random 
effects only 
Model 1  
+ level 1 
fixed 
effects 
Model 1  
+ level-2 
fixed 
effects 
Full model:  
Model 1 + 
level 1 and 
level-2 
fixed 
effects a 
Cancer 
model b 
Intercept (SE) -2.70 (0.09) -5.76 (0.18) -3.38 (0.20) -6.50 (0.26) -7.10 (0.86) 
Hospital 
random 
effects, 𝜏 (SE) 
 
0.45 (0.10) 0.48 (0.11) 0.22 (0.05) 0.25 (0.06) 0.12 (0.04) 
ICCc 12.0% 12.7% 6.4% 7.1% 3.5% 
C-statistic 0.62 0.81 0.62 0.81 0.81 
AICd 50326.46 42570.91 50301.07 42548.15 -- 
BICd 50330.61 42670.58 50315.61 42658.19 -- 
a Level 1 fixed effects are patient level fixed effects including all demographic and clinical 
characteristics. Level-2 fixed effects are hospital characteristics . 
b Cancer only model included only individuals with cancer and the individual sites of cancer 
(Table 4). Fit statistics are not included since it was not compared to other models. 
c Intraclass correlation coefficient: The proportion of the model variance explained by the 
“hospital” parameter; e.g. 12.0% of the Model 1 variance is explained by the hospital where 
a person is discharged. Calculated by 𝜏/ 𝜏+3.29 for a binary logit model. All ICC values 
between hospitals were significant at p<0.001. 
d Akaike information criterion and Bayesian information criterion fit statistics for 
comparison between models. Each measures the model fit but penalizes for additional 
parameters added to each model. Smaller values are preferred; thus, the full model is 
preferred over Model 1. 
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Table 2.3: Hierarchical logistic regression results of patient characteristics 
associated with use of vena cava filters 
Variable aOR 95% CI 
Age 21-25 Ref. Ref. Ref. 
  26-30 1.12 0.80 1.56 
  31-35 1.14 0.82 1.57 
  36-40 1.25 0.92 1.70 
  41-45 1.25 0.93 1.69 
  46-50 1.38 1.04 1.84 
  51-55 1.55 1.17 2.06 
  56-60 1.57 1.19 2.08 
  61-65 1.74 1.32 2.30 
  66-70 2.00 1.51 2.65 
  71-75 1.99 1.50 2.64 
  76-80 2.11 1.59 2.79 
  81+ 2.18 1.65 2.88 
Gender Female Ref. Ref. Ref. 
  Male 1.05 1.00 1.10 
Race White Ref. Ref. Ref. 
  Black 0.83 0.75 0.92 
  Other 1.13 0.95 1.35 
Insurance Other/self-pay Ref. Ref. Ref. 
  Medicaid 1.01 0.85 1.19 
  Medicare 1.05 0.96 1.15 
  Commercial 1.25 1.15 1.36 
Clot type DVT only Ref. Ref. Ref. 
  PE only 3.84 3.46 4.25 
  PE with DVT 2.73 2.57 2.90 
Comorbidities Cancer 1.27 1.18 1.38 
 
Metastatic cancer 1.28 1.16 1.41 
  Heart failure 1.01 0.94 1.08 
  Liver disease 1.23 1.09 1.38 
  Renal disease 0.94 0.88 1.00 
  Diabetes 1.03 0.97 1.09 
  Stroke 1.53 1.40 1.67 
  Hypertension 1.02 0.96 1.08 
  Hyperlipidemia 0.95 0.90 1.00 
  Atrial Fibrillation 1.24 1.15 1.33 
  Cellulitis 0.78 0.70 0.87 
  COPD 1.03 0.98 1.09 
  Sepsis/Septic shock 1.00 0.90 1.10 
  Infection/Pneumonia 1.03 0.97 1.10 
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Table 2.3: Hierarchical logistic regression results of patient characteristics 
associated with use of vena cava filters 
  Anemia 1.58 1.50 1.67 
  Myocardial infarction 0.99 0.91 1.08 
  Trauma 1.62 1.46 1.81 
  Thrombolytic therapy 2.32 2.06 2.61 
  Embolectomy 1.51 1.11 2.05 
  Unstable/ventilator 1.37 1.21 1.55 
  Proximal DVT 1.54 1.45 1.63 
  Lower DVT 6.49 5.92 7.11 
  Bleeding 2.72 2.51 2.94 
  Surgery 1.84 1.72 1.96 
Discharged Deceased 0.63 0.56 0.70 
 Transfer 0.89 0.74 1.06 
Metropolitan status Rural Ref. Ref. Ref. 
  Urban 0.87 0.62 1.23 
Teaching status Non-teaching Ref. Ref. Ref. 
  Teaching 1.46 1.04 2.06 
Bed size ≤75 beds Ref. Ref. Ref. 
  76-135 beds 1.41 0.85 2.32 
  136-275 beds 2.41 1.48 3.91 
  ≥276 beds 3.06 1.77 5.29 
Abbreviations: aOR=adjusted odds ratio; CI=confidence interval; VCF=vena cava 
filter; DVT=deep vein thrombosis; PE=pulmonary embolism; COPD=chronic 
obstructive pulmonary disease 
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Table 2.4: Association between vena cava filter use and cancer site (N=13,104) 
Cancer site Total N % Using 
VCF 
aORa 95% CI 
Oral 146 8.2% 0.67 0.35 1.30 
Skin 180 13.9% 1.06 0.66 1.73 
Bone/soft tissue 167 11.4% 0.90 0.52 1.56 
Stomach/small intestine 313 16.3% 1.17 0.80 1.70 
Colorectal 1,392 16.2% 1.25 0.99 1.57 
Liver 217 9.2% 0.85 0.50 1.45 
Pancreas 796 11.2% 0.76 0.57 1.03 
Lung/larynx/pleura 3,931 11.4% 1.02 0.83 1.25 
Breast 776 7.6% 0.65 0.47 0.91 
Uterus 312 15.1% 1.02 0.69 1.49 
Cervix 165 17.0% 1.37 0.84 2.22 
Ovarian 468 14.7% 1.13 0.81 1.58 
Prostate 613 14.2% 0.98 0.72 1.32 
Testicular 61 13.1% 1.62 0.66 3.95 
Bladder 360 15.6% 1.12 0.79 1.58 
Kidney 476 11.3% 1.09 0.76 1.55 
Brain 308 24.4% 2.31 1.65 3.23 
Thyroid 44 18.2% 1.22 0.46 3.24 
Myeloma 378 12.2% 0.96 0.66 1.39 
Leukemia 766 7.0% 0.64 0.46 0.90 
Lymphoma 293 7.2% 0.76 0.46 1.26 
Endocrine 121 14.0% 0.92 0.31 2.75 
Metastatic 7,046 13.6% 1.13 1.00 1.29 
aCancer-specific regression model included all covariates from the primary model. 
Results for those variables were not meaningfully different and are excluded here 
for brevity. 
Abbreviations: aOR=adjusted odds ratio; CI=confidence interval; VCF=vena cava 
filter 
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Appendix Table 2.1: Coding algorithm for conditions and procedures 
Disease/procedures Code type Codes 
Inferior vena cava filter ICD-9-CM Procedure 38.7 
Pulmonary embolism ICD-9-CM Diagnosis 415.1x 
Deep vein thrombosis ICD-9-CM Diagnosis 451.xx, 453.xx 
Unstable ICD-9-CM Diagnosis 785.5, V46.1 
Cancer ICD-9-CM Diagnosis 140.xx-195.xx, 200.xx-
208.xx 
Metastatic cancer ICD-9-CM Diagnosis 196.xx-199.xx, 209.71, 
209.74, 511.81, 789.51 
Heart failure ICD-9-CM Diagnosis 398.91, 402.01, 402.11, 
402.91, 404.01, 404.03, 
404.11, 404.13, 404.91, 
404.93 
Liver disease ICD-9-CM Diagnosis 570.xx-573.xx 
Diabetes ICD-9-CM Diagnosis 250.xx 
Renal disease ICD-9-CM Diagnosis 403.01, 403.11, 403.91, 
404.02, 404.03, 404.12, 
404.13, 404.92, 404.93, 
580.xx-588.xx, V42.0, 
V45.1, V56.x 
Cerebrovascular disease ICD-9-CM Diagnosis 362.34, 430.xx-438.xx 
Hypertension ICD-9-CM Diagnosis 401.xx-405.xx 
Hyperlipidemia ICD-9-CM Diagnosis 272.xx 
Atrial fibrillation ICD-9-CM Diagnosis 427.31 
Cellulitis ICD-9-CM Diagnosis 626.xx 
Chronic obstructive 
pulmonary disease 
ICD-9-CM Diagnosis 416.8, 416.9, 490.xx-
505.xx, 506.4, 508.1, 
508.8 
Sepsis/septic shock ICD-9-CM Diagnosis 038.x, 995.91, 785.52 
Infection/pneumonia ICD-9-CM Diagnosis 001.x-139.x, 480.xx-
488.xx 
Anemia ICD-9-CM Diagnosis 280.xx-285.xx 
Myocardial infarction ICD-9-CM Diagnosis 410.xx, 412.xx 
Trauma ICD-9-CM Diagnosis 800.xx-829.xx, 850.xx-
854.xx, 860.xx-897.xx, 
925.xx-929.xx, 940.xx-
957.xx 
Bleeding ICD-9-CM Diagnosis 430.xx, 431.xx, 456.0, 
456.20, 530.82, 531.xx-
534.xx, 578.1, 530.7, 
569.3, 578.0, 578.9, 
V12.71 
Thrombolysis ICD-9-CM Procedure 99.10 
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Appendix Table 2.1: Coding algorithm for conditions and procedures 
Embolectomy ICD-9-CM Procedure 38.00, 38.05, 38.07, 38.09, 
38.08 
Surgery ICD-9-CM Procedure Surgery Flag definition 
for invasive surgeries16 
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Study 2.2: Variation in the Use of Vena Cava Filters for Venous 
Thromboembolism in Hospitals in Kentucky 
 
Introduction 
 
Use of vena cava filters (VCFs) has increased over the last decade without clear 
indication in many patients. 64,65 This increase in use has been suggested to be 
partially motivated by upcoding for increased reimbursement, given that placement 
of a VCF increases the reimbursement rate for venous thromboembolism by 250%. 
65 
 
Wide variation in VCF utilization between institutions has been observed.  37 This 
variation may be influenced by many factors including the case-mix of patients, as 
well as institutional-level factors and physician preferences. 37 We analyzed the 
relationship of VCF use for venous thromboembolism (VTE) with institutional-level 
factors and patient variables to determine whether differences can be explained by 
observable factors rather than potential reimbursement upcoding.  
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Methods 
 
We used Kentucky inpatient discharge data from all acute care hospitals during 
2008-2014. These data represent all discharges in the state and include up to 
twenty-five diagnosis and procedure fields as well as hospital variables. 
 
Diagnoses for deep vein thrombosis (DVT) or pulmonary embolism (PE) were 
identified. 50 VCF use was identified by ICD-9-CM procedure code 38.7. Prophylactic 
VCF use without DVT or PE was excluded. Institution-level factors included bed size, 
teaching/non-teaching status, and urban status. Case-mix comorbidities included 
cancer, chronic obstructive pulmonary disease (COPD), cerebrovascular disease, 
atrial fibrillation, liver disease, hypertension, heart failure, hyperlipidemia, 
myocardial infarction, cellulitis, trauma, diabetes, infection, renal disease, bleeding, 
anemia, and sepsis/septic shock based on previously published coding algorithms.  
37,52,64 Case-mix variables were entered into the model as the proportion of patients 
with each condition at each hospital. The ratio of VTE events attributable to PEs 
versus DVTS at each hospital was included given that VCF use is more commonly 
used with PE. The proportion of patients dying or transferring and the percent 
receiving surgery, thrombolysis, or embolectomy was also included.  53  
 
A final linear model included the percent VCF utilization as the dependent variable 
and controlled for all covariates. Model assumptions were inspected including plots 
of the predicted values and the fitted model residuals. VCF use was plotted by year 
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and the overall trend from 2008 to 2014 was evaluated. All analyses were 
conducted using JMP Pro 12 (SAS Institute, Cary, NC). The University of Kentucky 
Institutional Review Board approved of this study. 
 
Results 
 
Seventy hospitals were included in the analysis including 84,357 VTE-related 
discharges with 7,337 (8.7%) receiving VCFs. Overall use was 10% in 2008 and 
decreased to 7.5% by 2014 (p<0.001 for all trends; Figure 2.1). Hospital use ranged 
from 0% up to 15.2% with mean utilization of 6.1% (standard deviation 4.4%, 
median 6.7%, coefficient of variation 0.73). The variation between institutions was 
consistent throughout the time period. In adjusted analysis, VCF use was most 
strongly associated with case-mix, mainly the PE-to-DVT ratio. Other case-mix 
variables associated with increased VCF use were atrial fibrillation and cancer 
(Table 2.5). The model fit the data well, with R2=0.97 and normally distributed 
residuals (Figure 2.2). Restricting the sample to hospitals with at least 50 PE/DVT 
discharges, similar results were observed with R2=0.99. Table 2.6 compares patients 
at the University of Kentucky hospital, which had the highest overall utilization of 
VCFs at 15.2%. Overall, patients at the University of Kentucky hospital are worse off 
based on the comorbidities measured, which makes the utilization lay on the curve 
of the expected utilization produced by the model. 
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Discussion 
 
These results showed a wide distribution in the utilization of VCF for VTE in 
Kentucky that is explained almost completely by patient case-mix and institutional 
characteristics. Lack of residual variation between institutions after controlling for 
these variables suggests that there may not be substantive overuse of VCFs to 
increase reimbursement. However, there may still be a systematic overuse of VCFs 
given conflicting guidelines and lack of apparent indications for many patients in a 
prior study. 64 Additional work is needed to determine whether the rate of VCF use 
is appropriate. 
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Figure 2.1: Trend in vena cava filter (VCF) use during 2008-2014. Tests for 
trend showed a 25% decrease in overall use (p<0.001), 33% decrease (p<0.001) for 
pulmonary embolism (PE) alone and with deep vein thrombosis (DVT), and a 19% 
(p<0.001) decrease for DVT alone.  
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Figure 2.2: Actual versus predicted VCF utilization of the full model. The 
goodness of fit for the model produced R2=0.97, showing a very strong fit to the 
data. Full model included all case-mix variables to control for differences in patient 
population between institutions. Red lines are the best-fit regression line and the 
95% significance limits of the fitted model. Blue horizontal line represents the 
predicted mean from the model. 
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Table 2.5: Scaled regression estimates of covariates predicting percent of 
PE/DVT patients receiving inferior vena cava filter 
Regression Term Scaled 
Estimatea 
p-value Lower 
95% 
Upper 
95% 
Intercept 6.29 <. 0001 5.87 6.71 
PE-to-DVT ratio 7.96 <. 0001 6.61 9.30 
Embolectomy 2.80 0.001 1.22 4.37 
Cancer 3.83 0.003 1.36 6.31 
Thrombolysis -2.17 0.007 -3.70 -0.64 
Trauma -2.00 0.032 -3.82 -0.18 
COPD -1.75 0.043 -3.44 -0.06 
Bed size 76-135 -0.73 0.046 -1.44 -0.01 
Atrial fibrillation 1.28 0.048 0.12 2.69 
Bed size ≥276 1.08 0.050 -0.07 2.24 
Cerebrovascular disease 0.97 0.075 -0.10 2.05 
Metropolitan area -0.51 0.077 -1.08 0.06 
Proximal DVT -2.21 0.095 -4.83 0.41 
Liver disease -0.73 0.326 -2.21 0.75 
Cellulitis 0.69 0.399 -0.94 2.31 
Renal disease 0.69 0.412 -1.00 2.39 
Rural area 0.34 0.415 -0.49 1.16 
Diabetes 0.47 0.450 -0.78 1.72 
Infection 0.56 0.479 -1.03 2.15 
Surgery -0.89 0.483 -3.43 1.65 
Heart failure 0.36 0.529 -0.79 1.51 
Micropolitan area 0.17 0.564 -0.44 0.79 
Bed size ≤75 -0.27 0.600 -1.29 0.75 
Transfer rate 0.40 0.603 -1.15 1.96 
Hypertension 0.69 0.648 -2.35 3.73 
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Table 2.5: Scaled regression estimates of covariates predicting percent of 
PE/DVT patients receiving inferior vena cava filter 
Myocardial infarction -0.26 0.651 -1.44 0.91 
Death -0.24 0.666 -1.36 0.88 
Unstable 0.35 0.759 -1.95 2.65 
Bed size 136-275 -0.09 0.789 -0.75 0.58 
Sepsis/septic shock -0.24 0.794 -2.08 1.60 
Concurrent bleeding -0.12 0.827 -1.27 1.02 
Non-teaching -0.07 0.835 -0.69 0.56 
Teaching 0.07 0.835 -0.56 0.69 
Metastatic cancer -0.16 0.909 -2.95 2.63 
Hyperlipidemia -0.09 0.924 -2.05 1.86 
Anemia -0.01 0.990 -1.50 1.48 
aNominal variables are expanded to each category. Continuous variables are centered on the 
mean and scaled by the range/2. Estimates are ordered by significance in the model. 
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Table 2.6: Comparison of University of Kentucky hospital patients with 
patients in similar size hospitals by vena cava filter utilization and case-mix 
comorbidities 
Characteristic UKHC Lexington 
hospital 
Lexington 
hospital 
Louisville 
teaching 
hospital 
Paducah 
hospital 
VCF utilization 15.2% 13.0% 12.1% 7.8% 5.5% 
Bed size 462 344 347 285 323 
Patient case-mix 
Cancer 26.4% 14.4% 16.1% 13.8% 13.3% 
Metastatic 13.8% 8.4% 10.9% 7.4% 5.5% 
Heart failure 17.6% 17.5% 18.6% 21.4% 12.3% 
Liver disease 8.9% 4.3% 4.3% 4.2% 1.3% 
Renal disease 37.4% 31.3% 24.7% 29.5% 12.3% 
Diabetes 24.0% 27.5% 27.6% 30.8% 20.5% 
Stroke 9.7% 7.0% 8.0% 7.1% 2.7% 
Hypertension 54.1% 58.9% 65.4% 66.5% 45.2% 
Hyperlipidemia 22.9% 30.3% 42.9% 40.3% 12.1% 
Atrial 
fibrillation 
13.1% 19.1% 18.2% 17.7% 9.3% 
Cellulitis 6.9% 9.0% 7.2% 9.7% 7.8% 
COPD 24.5% 28.5% 33.1% 36.4% 24.3% 
Sepsis 19.0% 12.2% 7.4% 11.8% 2.3% 
Infection 45.1% 34.7% 32.7% 32.8% 16.1% 
Anemia 40.7% 34.6% 39.0% 35.8% 21.1% 
Myocardial 
infarction 
13.3% 9.1% 9.9% 13.6% 2.7% 
Trauma 11.2% 3.0% 2.9% 3.8% 2.5% 
Thrombolysis 3.7% 8.7% 4.5% 2.6% 0.4% 
Embolectomy 1.3% 0.7% 0.4% 0.3% 0.2% 
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Table 2.6: Comparison of University of Kentucky hospital patients with 
patients in similar size hospitals by vena cava filter utilization and case-mix 
comorbidities 
Unstable 14.4% 5.7% 5.7% 3.4% 1.1% 
Bleed 10.7% 6.8% 7.8% 7.0% 5.1% 
Deceased on 
discharge 
9.4% 6.0% 6.5% 4.9% 3.8% 
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CHAPTER 3: VENA CAVA FILTER RETRIEVAL RATES AND FACTORS 
ASSOCIATED WITH RETRIEVAL IN A NATIONAL COHORT 
 
Abstract 
 
Introduction 
Retrieval of inferior vena cava filters (IVCFs) is important for the safety of these 
devices as complications increase with longer dwell times. This study sought to 
assess retrieval rates and patient demographic and clinical factors associated with 
retrieval in a national cohort. 
 
Methods 
Patients receiving IVCFs were identified by procedural codes from the Truven 
MarketScan administrative claims database. The indication for placement was 
identified as pulmonary embolism (PE) with or without deep vein thrombosis 
(DVT), DVT only, or prophylactic. Patient demographic and clinical characteristics 
were included in proportional hazard regression models to find associations with 
early (90-day) and one-year retrieval. 
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Results 
Of 54,766 patients receiving an IVCF, 36.9% had PE, 43.9% had DVT only, and 
19.2% had no apparent VTE present. Over the one-year of follow-up, the cumulative 
incidence of IVCF retrieval was 18.4%, which differed based on indication, age, and 
several other key patient factors.  Retrieval increased over time from a low of 14.0% 
in 2010 up to approximately 24% in 2014. In adjusted time-to-event models, 
increasing age, differing regions, and comorbidities associated with hyper- (e.g. 
prior stroke) or hypocoagulable (e.g. prior bleeding) states were associated with 
poorer retrieval. Those with and without retrieval, and those with early (≤90 day) 
and late (≥120 day) retrieval, did not differ in healthcare utilization of outpatient or 
inpatient visits prior to retrieval. Initiation of anticoagulation was poorly correlated 
with retrieval, with anticoagulation preceding retrieval by a median of 51 days and 
those without retrieval had a median of 278 days of exposure to anticoagulation. 
 
Conclusions 
IVCF retrieval has increase over time but remains suboptimal with only 1-in-5 being 
retrieved within one year. Improving retrieval rates can improve patient outcomes, 
prevent time-dependent complication rates, and improve clinic revenue with 
patient follow-up. Retrieval should be a priority for quality improvement initiatives 
at the institutional and national level. 
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Introduction 
 
Inferior vena cava filters (IVCFs) are used to mechanically prevent thrombi in the 
lower extremities from migrating to the pulmonary circulation. Generally, IVCFs are 
reserved for patients who have absolute or relative contraindications to systemic 
anticoagulation who are at a high risk of recurrent venous thromboembolism (VTE).  
45-47 With the advent of retrievable IVCFs (rIVCFs), there has been a marked 
increase in overall use, especially in trauma and surgery patients.  5,6 The intuition 
behind retrievable devices calls for removal once the contraindications have 
subsided and patients can be initiated on anticoagulation. 
 
In real-world settings, retrieval rates of rIVCFs are low, with reports ranging from 
10-50% within individual institutions, with an estimated average near 30%.  28,66 
Poor retrieval rates correspond to an increase in reported adverse events, as these 
temporary devices become de facto permanent. 28 Complications associated with 
VCFs include increased risk of deep vein thrombosis (DVT), inferior vena cava (IVC) 
thrombosis, IVC penetration, IVCF fracture, and IVCF embolization.  28,31,67,68 Given 
these trends, the U.S. Food and Drug Administration (FDA) has issued several safety 
communications highlighting the need to remove IVCFs once the risk of pulmonary 
embolism (PE) has subsided and anticoagulation is no longer contraindicated.  30  
 
Little is known regarding IVCF retrieval on a national scale given most studies have 
been conducted at single institutions. 31 Given the continued growth in IVCF use and 
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the variation that has been observed between institutions,  37,48,69-71 assessments of 
factors that drive retrieval rates on a national scale is needed to aid clinical decision-
making. 72 This study utilized a large national database to assess IVCF retrieval and 
patient factors related to retrieval as well as differences in healthcare utilization. 
Further, we assessed the relationship between time to retrieval and time to 
initiation of anticoagulant therapy. 
 
Methods 
 
Data source 
This observational cohort study utilized the Truven Health Analytics MarketScan 
database. The MarketScan data are administrative healthcare claims data including 
medical diagnostic and procedural information and pharmacy fill records. The data 
include information for roughly 40 million unique individuals per year and is 
generally representative of those with commercial insurance and Medicare 
supplemental coverage. The University of Kentucky Institutional Review Board 
approved use of the data. 
 
 
Cohort identification 
All patients during the years 2010-2014 who had a IVCF placed were identified and 
assigned an index based using Current Procedural Terminology (CPT: 37191, 37620, 
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35940) and International Classification of Diseases, 9th revision (ICD-9: 38.7) 
procedural codes. The indication for VCF was identified by ICD-9 diagnosis codes as 
PE (415.1x) with or without DVT, DVT only (451.xx or 453.xx), or no apparent VTE 
(prophylactic). 50 For inclusion, patients were required to be 18 years or older and 
have a minimum of 6 months of pre-index time prior to IVCF placement. 
 
Cohort characteristics 
Demographic variables included age, sex, geographic region, and residence status. 
Age was divided into 18-34, 35-44, 45-54, 55-64, 65-74, and 75 and older categories. 
Geographic region included U.S. census regions (Northeast, North Central, South, 
West, and unknown) and residence status was divided into urban or rural based on 
metropolitan statistical area classifications. Patients’ insurance status was classified 
as commercial or Medicare and whether or not they were enrolled in a fully or 
partially capitated insurance plan and if they had a primary care provider (PCP) 
assigned. 
 
Certain concurrent conditions and procedures present during IVCF implantation 
were recorded. Concurrent bleeding, unstable condition, sepsis or septic shock, 
infection, anemia, trauma, and pregnancy were all recorded using ICD-9 diagnosis 
codes. 15,37 Patients receiving thrombolytic therapy, embolectomy procedures, or 
major surgery were identified using a combination of procedural codes.  53 Patients 
who died during the hospitalization during which the IVCF was placed were also 
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noted. Comorbid conditions observed in the pre-index period consisted of Charlson 
comorbidities and a summed Charlson Comorbidity Index (CCI).  52,73 
 
Outcome events 
The primary outcome was IVCF retrieval identified by CPT (37193, 37203) and ICD-
9 (38.7) procedure codes. Given the ICD-9 procedure code for placement and 
retrieval is the same, retrievals for those patients only having the ICD-9 procedure 
code present had to be on separate days to record a retrieval. However, since CPT 
codes and not ICD-9 codes are used for billing purposes, patients lacking the CPT 
codes were the exception with >95% of all patients having CPT codes recorded. 
Patients were followed forward from the index date (IVCF placement) until the IVCF 
was retrieved, they died, they were lost to follow-up, or the end of the study period. 
The 30, 60, 90, 180-day and one-year cumulative incidence of IVCF retrieval was 
estimated using Fine and Gray’s method, accounting for death as a competing risk. 74 
Time to IVCF retrieval was also reported.  
 
Time to anticoagulation initiation 
Anticoagulation initiation was assessed as the first filled prescription for an 
injectable (dalteparin, enoxaparin, tinzaparin, fondaparinux) or oral (warfarin, 
dabigatran, rivaroxaban, apixaban) anticoagulant. Time to anticoagulation and was 
compared with the time to retrieval and described for those who did not have 
retrieval during follow-up. Time for both events was calculated based on the date of 
discharge from a hospitalization, if the IVCF was placed during hospitalization, or 
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the day of IVCF placement if it was placed in an outpatient setting, given that 
prescription medications would not be observed during a hospitalization.  
 
Survival analysis 
To identify factors associated with IVCF retrieval, we developed a Cox proportional 
hazards regression model including patient demographic and clinical characteristics 
typically associated with either VTE, bleed risk, or IVCF use. Additionally, measures 
of comorbidity were included to scale individual’s overall health. The 
proportionality assumption for all variables was evaluated for using Schoenfeld 
residuals as well as using time as an interaction term for each variable. Both 
methods showed that this assumption held true. Due to collinearity with age, 
insurance status of commercial or Medicare was excluded in the model. Two models 
were estimated predicting 90-day and one-year retrieval. Patients who had not had 
retrieval or had not died at the end of the 90-day or 365-day period were censored. 
Cause-specific hazard ratios (HR) and their 95% confidence intervals (CI) were 
estimated for the effect of each covariate on the retrieval rate with HR<1 indicating 
lower retrieval and HR>1 indicating higher retrieval. 
 
Case-control analysis 
To understand if there are differences in recurrent events, complications, and 
healthcare utilization during the post-implantation period, two post hoc nested case-
control analyses were performed. Non-cancer patients who had a retrieval event 
were matched with up to three non-cancer controls who did not have a retrieval. 
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Likewise, patients who had retrieval within 90 days post-implantation (“early 
retrieval”) were matched 1:1 (due to sample size) with controls who had retrieval 
≥120 days post-implantation (“late retrieval”). Pairs were matched on variables 
found significant in the survival analysis as well as factors related to higher 
healthcare utilization including age, region, residence status, CCI score, and year of 
IVCF placement. Incidence density sampling without replacement was used for 
matching, allowing for controls who had at overlapping follow-up periods with 
cases. Controls were given the same length of time between IVCF placement as their 
respective cases to provide a consistent look-back period. Conditional logistic 
regression was used to assess the association between retrieval and non-retrieval as 
well as early versus late retrieval with complications (DVT, PE) and healthcare 
utilization (anticoagulation use, emergency room [ER] visits, hospitalizations, and 
outpatient visits) in the look-back period. VTEs coded on outpatient visits are 
assumed to be for the management of the initial VTE event while hospitalizations 
and emergency visits with VTEs as the primary diagnosis were assumed to be new 
VTE events, thus considered to be complications. For outpatient visits, the reference 
group was considered to be those who had less than the median number of visits 
compared to those who had equal or more median visits. For hospitalizations and 
emergency visits, those with none were used as the reference group for those with 
one and those with two or more. Utilization for IVC thrombosis and IVC injury were 
excluded due to low occurrence in the cohort. All analyses were conducted using 
SAS Enterprise Guide version 7.1 (Cary, NC).  
 57 
Results 
 
Patient characteristics 
During 2010-2014, 54,766 patients received an IVCF and met the eligibility 
requirements to be included in the study. Of these, 36.9% presented with a PE, 
43.9% with DVT alone, and 19.2% had no apparent VTE present (Table 3.1). The 
mean (standard deviation, SD) age of the cohort was 65 (16), 51% were female, 
geographically diverse with nearly 85% residing in urban areas. Insurance details 
included 13.9% of the cohort having a PCP and 8.6% having insurance with full or 
partial capitated payments. A total of 1,628 (3.0%) of the cohort died during the 
initial hospitalization and were not included in subsequent analyses. 
 
Concurrent with IVCF placement, 9.1% had active bleeding, 10.5% had trauma, 
1.6% were unstable, nearly 17% had active infections, and nearly 19% had anemia 
(Table 3.1). Roughly one of every four patients had a major surgical procedure 
performed during the same hospitalization the IVCF was placed. The most common 
comorbid conditions in the cohort were hypertension (56.5%), hyperlipidemia 
(33.2%), cancer (30.4%), diabetes (24.9%), and chronic obstructive pulmonary 
disease (COPD, 23.6%).  
 
Overall, 14.3% (N=7,619) of the cohort who survived the index hospitalization had 
the IVCF retrieved within one-year and 8% (N=4,228) died (Table 3.2). For those 
who had retrieval, the mean (SD) time-to-retrieval was 93 (78) days, with a median 
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of 71 days and interquartile range  (IQR) of 35-130 days. Those with PE had the 
highest mean and median times-to-retrieval (101 and 81 days) compared to those 
with DVT only (91 and 68 days) and compared to those with no VTE (83 and 61 
days). 
 
Figure 3.1 shows the cumulative incidence of IVCF retrieval by the index indication 
and Table 3.3 shows the cumulative incidence for selected variables. At one-year, 
retrieval was highest for those with no VTE on index, reaching nearly 25% (23.9%-
25.8%). Retrieval increased with each year of study, going from 14.0% (13.3%-
14.7%) in 2010 up to 38.2% (19.4%-57.0%, skewed by low follow-up time) in 2014 
(P <0.001). Differences in retrieval between age groups were significant with 
younger age groups having higher retrieval. For example, those aged 18-34 had one-
year retrieval of 42.8% (40.4%-45.2%) while retrieval in those 75 and older was 
just 5.4% (5.0%-5.8%, P <0.001). Likewise, those without cancer had higher 
retrieval compared to those with cancer (20.8% vs. 11.7%, P <0.001). Those with 
commercial insurance had much higher retrieval compared to those with Medicare. 
However, this effect was associated with age distribution between these two 
insurance groups, i.e. 98% of the Medicare insured were ≥65 years of age. 
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Factors related to retrieval 
In fully adjusted analyses (Table 3.4), age remained significantly associated with 
IVCF retrieval at both 90-days and 365-days of follow-up, although the association 
was much stronger for the one-year model. Patients with no VTE were more likely 
to have retrieval compared to those with DVT only, and there was no difference in 
retrieval between those with PE compared to those with DVT. Geographic region 
was also significant, with those residing in the North Central (90-days and one-year) 
and West (one-year only) regions being more likely to have retrieval compared to 
those in the Northeast. Likewise, urban residence was associated with slightly 
higher retrieval compared to rural residence (90-days and one-year). At one-year, 
capitated payment insurance types were associated with lower retrieval. 
 
Among concurrent conditions, infection and anemia were associated with lower 
retrieval at 90 days and one year while pregnancy was associated with higher 
retrieval at one-year of follow-up. Other comorbid conditions associated with lower 
one-year retrieval included myocardial infarction, congestive heart failure, 
peripheral vascular disease, dementia, COPD, severe liver disease, paralysis, cancer, 
stroke, hypertension, and coronary heart disease.  
 
Year of filter placement was modeled both as a covariate as well as used to stratify 
the analysis. In stratified analysis, no differences were observed between the 
covariates and their association with IVCF retrieval compared to the base model 
with year as a covariate. As a covariate, each year of IVCF placement was associated 
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with increased 90-day and one-year retrieval compared to year 2010. For the final 
year 2014, this corresponded to nearly a two-fold difference in retrieval rate 
compared to 2010 (HR=1.90, 95% CI 1.76-2.06). 
 
Time to anticoagulation 
During follow-up, the dataset had follow-up prescription information for 37,272 
persons in the cohort. Among these, 23,510 (63.1%) initiated anticoagulation with 
median time to anticoagulation initiation of 17 (IQR 6-50) days. Initiation of 
anticoagulation differed significantly for those who eventually had retrieval (median 
11, IQR 5-31 days) and those that did not have retrieval (median 17, IQR 6-50 days, 
p<0.001). Overall, time to anticoagulation and time to retrieval were poorly 
correlated, with anticoagulation preceding retrieval by a median of 51 (IQR 13-110) 
days. Figure 3.2 shows the correlation between the time to anticoagulation and the 
time to retrieval after hospitalization. As observed, anticoagulation occurs much 
earlier than retrieval (black line shows best fit of data). The red line shows the ideal 
best fit line assuming that anticoagulation would be started 4 weeks prior to 
retrieval so that anticoagulation can reach therapeutic levels and/or dissolution of 
any clots present in the IVCF. The area between the black and red lines represents 
excess exposure to IVCF indwell time beyond need, effectively exposing the 
individual to complications of IVCFs for a longer period. Those who were treated 
with anticoagulation had marginally longer time to retrieval than those who did not 
initiate anticoagulation. For those who never had retrieval, there was a median of 
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278 (IQR 98-350) days of anticoagulation treatment during the one-year follow-up 
period.    
 
Healthcare utilization 
Healthcare utilization in the time period between placement and retrieval was 
compared for those with retrieval versus those without and between those with an 
early retrieval (≤90 days) and late retrieval (≥120 days). Total and VTE-related 
outpatient visits for those with retrieval were significantly higher than those 
without (Table 3.5). Meanwhile, inpatient and emergency visits were more similar 
between groups. Outpatient, inpatient, and emergency visits were more similar 
between early and late retrieval groups (Table 3.5). In adjusted analyses, having 
more than the median number of total outpatient or VTE-related outpatient visits 
was associated with over twice the odds of having a retrieval versus not (Table 3.6). 
Having ≥2 hospitalizations, VTE-related and overall, was also associated with higher 
odds of retrieval. For early compared to late retrieval, having ≥2 hospitalizations of 
any kind was significantly associated with more early retrieval compared to late 
retrieval.  
 
Discussion 
 
The increased utilization of IVCFs corresponded with new technology allowing for 
retrieval of these devices once the indication for placement has abated. This has led 
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to nearly 10% of all VTE events being treated with IVCF placement for secondary 
prevention and increased IVCF utilization for prophylactic indications. Safety 
studies and the one randomized trial of retrievable IVCFs have shown these devices 
to be generally safe with retrieval being completed within a short period after 
implantation. In PREPIC2, the only randomized trial for rIVCFs, the retrieval rate 
was >90% with a dedicated 3-month follow-up visit. 10 However, in real-world 
practice, estimates of the retrieval rates range much lower with an average of about 
one-third of all IVCFs eventually being retrieved. 28  
 
Eventual retrieval of IVCFs improves the safety profile of these devices as the 
incidence for complications generally increases with increasing indwell times. 
Patients with IVCFs are at risk for complications including IVC thrombosis, device 
fracture, device migration, and DVT – risks persisting as long as the IVCF remains in 
place. One study by Morales et al. evaluated the net clinical benefit of IVCFs taking 
into account the known reduction in the risk of PE along with the increased 
incidence of complications. This study found that there is an optimal net clinical 
benefit if an IVCF is retrieved within 29-54 days after placement in prophylactic 
indications. This estimate remained in favor of IVCF up to 180 days post-
implantation, but data regarding complication rates beyond this time period are 
scarce, and does not address the net clinical benefit in patients with active VTE. This 
article was also referenced in a U.S. Food and Drug Administration (FDA) safety 
communication, which responded to multiple reports of complications with IVCFs 
and increasing publicity through litigation and media. The safety communication 
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also detailed ongoing safety data collection through clinical studies and post-
marketing surveillance.  
 
The current analysis is consistent with other reports regarding IVCF retrieval, with 
an overall retrieval of nearly 20% within 1-year. Considering that approximately 
10% of all IVCFs placed are permanent devices, the effective retrieval rate was 
nearer 22%. Encouragingly, the retrieval rate has increased over time, from roughly 
every one out of every seven filters being retrieved in 2010 up to one out of every 
four retrieved in 2014 (extrapolated due to limited follow-up in 2014). This effect is 
explained by the increased attention IVCFs received over this time period including 
FDA safety alerts, as well as guideline updates which called for more conservative 
use of IVCFs. For those who did have their IVCF retrieved in our study, time to 
retrieval was within an acceptable range with mean and median times of 93 and 71 
days post-implantation. However, retrieval was poorly correlated with 
anticoagulation initiation – an indicator that the IVCF is no longer indicated in that 
patient and should be removed as soon as possible. 
 
Several patient-related factors were also associated with retrieval including 
demographic and clinical characteristics. Most notably, increasing age of the patient 
was associated with lower retrieval, likely contributed to perceived ongoing risk of 
PE or a desire to not treat older individuals with anticoagulation. Region of 
residence was also strongly associated with retrieval, which may indicate regional 
practice differences as well as differences in patient demography. Patients living in 
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an urban setting were more likely to have their filter retrieved as well, suggesting 
that patients being referred to a distant medical center for IVCF placement may have 
limited follow-up for retrieval. Among patient comorbidities, those considered pro-
thrombotic (cancer, stroke, hyperlipidemia, MI) and related to bleeding (liver 
disease) were associated with lower retrieval. These disease states are intuitively 
associated with lower retrieval in that they reference underlying diseases which 
have high clot risk or high bleed risk and are more permanent than other transient 
contraindications to anticoagulation (e.g. surgery or trauma).  
 
Other studies investigating factors associated with retrieval rates have focused on 
poor patient follow-up as the primary reason IVCFs are not removed. 40,75,76 
However, patient follow-up in itself can be a multi-faceted factor associated with 
both institutional and patient related characteristics. To investigate this further in 
our data, we matched those who had retrieval to those who did not and assessed 
their healthcare utilization during follow-up, assuming that utilization of the 
healthcare system is a surrogate for patient follow-up. We observed a significant, 
but likely meaningless, difference in the number of outpatient visits overall and 
VTE-related visits for those without retrieval. While this may indicate poorer patient 
follow-up in the non-retrieval, the mean number of outpatient visits was 11.8 in the 
non-retrieval group, with 75% of this group having at least 1 outpatient visit. In 
comparing those with an early retrieval versus a late retrieval, we found that there 
were not any differences in the number of follow-up visits between these groups. 
Thus, opportunities exist to follow-up with patients regarding their IVCF, although it 
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remains alarming that a quarter of patients have no follow-up recorded after 
placement of an IVCF. Patient follow-up is generally left to the referring or primary 
physician, with some studies showing improved retrieval if the responsibility of 
follow-up is placed on the implanting physician instead. 40-42,75,76 Thus, it is likely not 
a question of the amount of follow-up, but more who is following up with the 
patient. This is supported further by the observation that patients who are 
hospitalized with new VTE events are more likely to have retrieval, possibly due to 
more specialists involved with their care (e.g. hematologists, etc.). 
 
While there is inherent concern for patient safety associated with these low 
retrieval rates, clinical practices are also financially incentivized to increase 
retrieval of IVCFs. A study by d’Othée et al. showed that due to the increased cost 
between retrievable and permanent devices, retrievable devices are only cost-
effective in interventional radiology clinics if at least 40% are eventually retrieved, 
driven by separate billable procedure codes for implantation and retrieval.  77 Even 
without the cost differential between permanent and retrievable devices, it is 
inherent that clinic revenue will be increased with improved patient follow-up, 
management, and retrieval. At least one study at a single institution evaluated the 
financial feasibility of implementing a quality improvement initiative within their 
clinical practice. 78 They had a staggered intervention and compared baseline 
retrieval rates to those achieved by issuing letters to patients and then to those 
achieved with prospective follow-up of patients. Overall, their retrieval rates 
increased from 8% to 40% with mailed letters and up to 52% with prospective 
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follow-up. Moreover, the interventions increased the revenue to the clinic by over 
$1,000 per IVCF placed via increased billing for retrieval and follow-up procedures. 
Thus, although improving IVCF retrieval requires a paradigm shift in patient 
management, retrieval will improve patient outcomes and provides financial 
incentive to the clinic. Further, this study demonstrates that even a low cost 
intervention such as mailing letters can have a large impact on retrieval rates, 
potentially utilizing few resources compared to the marginal improvement 
observed with more intensive follow-up. 
 
Limitations 
This study has limitations inherent to all studies utilizing administrative claims data. 
79,80 Most notably, detailed clinical data are not available, including laboratory data, 
tumor staging, etc. which may have impacted the study results. Further, detailed 
information on the hospital or physician by whom the patient received care is not 
available. Wide variation in the utilization of IVCFs has been shown in prior studies 
and the general practice environment and physician practice patterns are likely to 
vary. 37,70 Procedural codes were utilized to identify IVCF placement; however, these 
codes are not specific to permanent or retrievable devices. As of 2006, retrievable 
devices made up about 85% of the IVCF market, which likely increased to over 90% 
since then. 22,25,81 Therefore, the retrieval estimates presented here are conservative. 
While we only followed patient up to one-year, there was a strong plateauing of the 
retrieval rate. With maximal follow-up, overall retrieval would have only reached 
roughly 25% compared to the 20% observed. 
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Conclusion 
 
In this national study of IVCF retrieval, less than one out of every four filters was 
retrieved within one-year. Retrieval rates differ based on patient characteristics but 
increased over the study time period (2010-2014). Retrieval of IVCFs once clinically 
indicated is required to optimize the net clinical benefit by removing the risk of 
complications associated with these devices. 
 68 
 
Table 3.1: Demographic and clinical characteristics of patients receiving vena cava 
filters by indication 
 All Pulmonary 
Embolism 
Deep Vein 
Thrombosis 
No PE/DVT 
 N % N % N % N % 
 54,766 100.0% 20,202 36.9% 24,060 43.9% 10,504 19.2% 
Age Group 
Mean (SD) 65 (16) 64 (15) 69 (16) 60 (17) 
18-34 2,196 4.0% 728 3.6% 610 2.5% 858 8.2% 
35-44 3,551 6.5% 1,347 6.7% 1,183 4.9% 1,021 9.7% 
45-54 7,888 14.4% 3,337 16.5% 2,757 11.5% 1,794 17.1% 
55-64 13,076 23.9% 5,530 27.4% 4,881 20.3% 2,665 25.4% 
65-74 9,422 17.2% 3,452 17.1% 4,334 18.0% 1,636 15.6% 
75 and older 17,846 32.6% 5,492 27.2% 10,038 41.7% 2,316 22.0% 
Gender of Patient 
Male 26,839 49.0% 10,217 50.6% 11,542 48.0% 5,080 48.4% 
Female 27,927 51.0% 9,985 49.4% 12,518 52.0% 5,424 51.6% 
Region 
Northeast 11,526 21.0% 4,154 20.6% 5,191 21.6% 2,181 20.8% 
North Central 15,678 28.6% 5,752 28.5% 7,142 29.7% 2,784 26.5% 
South 18,448 33.7% 6,666 33.0% 7,882 32.8% 3,900 37.1% 
West 7,891 14.4% 3,158 15.6% 3,361 14.0% 1,372 13.1% 
Unknown 1,223 2.2% 472 2.3% 484 2.0% 267 2.5% 
Residence 
Rural 8,496 15.5% 3,119 15.4% 3,381 14.1% 1,996 19.0% 
Urban 46,270 84.5% 17,083 84.6% 20,679 85.9% 8,508 81.0% 
Concurrent conditions during hospitalization 
Bleed 5,004 9.1% 1,418 7.0% 2,779 11.6% 807 7.7% 
Unstable 
condition 
870 1.6% 243 1.2% 464 1.9% 163 1.6% 
Sepsis 2,351 4.3% 619 3.1% 1,360 5.7% 372 3.5% 
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Table 3.1: Demographic and clinical characteristics of patients receiving vena cava 
filters by indication 
 All Pulmonary 
Embolism 
Deep Vein 
Thrombosis 
No PE/DVT 
 N % N % N % N % 
Infection 9,202 16.8% 3,105 15.4% 4,680 19.5% 1,417 13.5% 
Anemia 10,195 18.6% 3,193 15.8% 5,433 22.6% 1,569 14.9% 
Trauma 5,777 10.5% 1,600 7.9% 3,027 12.6% 1,150 10.9% 
Thrombolytic 
therapy 
841 1.5% 452 2.2% 316 1.3% 73 0.7% 
Embolectomy 
procedure 
367 0.7% 176 0.9% 149 0.6% 42 0.4% 
Major surgery 13,371 24.4% 5,249 26.0% 5,836 24.3% 2,286 21.8% 
Pregnant 441 0.8% 148 0.7% 221 0.9% 72 0.7% 
Died during 
hospitalizatio
n 
1,628 3.0% 720 3.6% 461 1.9% 447 4.3% 
Comorbid conditions during pre-index look back 
CCI score, 
mean (SD) 
3.1 (3.3) 2.9 (3.3) 3.5 (3.4) 2.9 (3.3) 
History of 
VTE 
4,864 8.9% 1,522 7.5% 2,149 8.9% 1,193 11.4% 
History of 
bleeding 
8,483 15.5% 2,587 12.8% 4,577 19.0% 1,319 12.6% 
MI 3,254 5.9% 1,122 5.6% 1,623 6.7% 509 4.8% 
CHF 8,464 15.5% 2,620 13.0% 4,514 18.8% 1,330 12.7% 
PVD 7,450 13.6% 2,147 10.6% 4,030 16.7% 1,273 12.1% 
Dementia 2,366 4.3% 621 3.1% 1,518 6.3% 227 2.2% 
COPD 12,925 23.6% 4,872 24.1% 5,735 23.8% 2,318 22.1% 
Rheumatism 2,286 4.2% 801 4.0% 1,087 4.5% 398 3.8% 
PUD 1,593 2.9% 503 2.5% 829 3.4% 261 2.5% 
Mild liver 
disease 
4,344 7.9% 1,586 7.9% 1,958 8.1% 800 7.6% 
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Table 3.1: Demographic and clinical characteristics of patients receiving vena cava 
filters by indication 
 All Pulmonary 
Embolism 
Deep Vein 
Thrombosis 
No PE/DVT 
 N % N % N % N % 
Severe liver 
disease 
549 1.0% 135 0.7% 315 1.3% 99 0.9% 
Diabetes 13,623 24.9% 4,483 22.2% 6,322 26.3% 2,818 26.8% 
Diabetes w/ 
complications 
3,663 6.7% 1,040 5.1% 1,853 7.7% 770 7.3% 
Paralysis 2,244 4.1% 672 3.3% 1,228 5.1% 344 3.3% 
Renal disease 6,684 12.2% 1,713 8.5% 3,836 15.9% 1,135 10.8% 
Cancer 16,672 30.4% 6,251 30.9% 7,856 32.7% 2,565 24.4% 
Metastatic 
cancer 
7,534 13.8% 3,013 14.9% 3,433 14.3% 1,088 10.4% 
Stroke 9,744 17.8% 2,957 14.6% 5,240 21.8% 1,547 14.7% 
Hypertension 30,918 56.5% 10,719 53.1% 14,541 60.4% 5,658 53.9% 
CHD 11,125 20.3% 3,604 17.8% 5,597 23.3% 1,924 18.3% 
Hyperlipidem
ia 
18,195 33.2% 6,676 33.0% 8,047 33.4% 3,472 33.1% 
Insurance Source 
Commercial 26,350 48.1% 10,821 53.6% 9,281 38.6% 6,248 59.5% 
Medicare 28,416 51.9% 9,381 46.4% 14,779 61.4% 4,256 40.5% 
Insurance 
Details 
        
Assigned Care 
Provider 
7,586 13.9% 2,910 14.4% 3,116 13.0% 1,560 14.9% 
Capitated 
Payment 
4,718 8.6% 1,821 9.0% 1,969 8.2% 928 8.8% 
Year of IVC filter placement 
2010 11,784 21.5% 4,250 21.0% 5,239 21.8% 2,295 21.8% 
2011 12,750 23.3% 4,565 22.6% 5,672 23.6% 2,513 23.9% 
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Table 3.1: Demographic and clinical characteristics of patients receiving vena cava 
filters by indication 
 All Pulmonary 
Embolism 
Deep Vein 
Thrombosis 
No PE/DVT 
 N % N % N % N % 
2012 12,210 22.3% 4,369 21.6% 5,393 22.4% 2,448 23.3% 
2013 9,395 17.2% 3,596 17.8% 4,062 16.9% 1,737 16.5% 
2014 8,627 15.8% 3,422 16.9% 3,694 15.4% 1,511 14.4% 
Abbreviations: venous thromboembolism (VTE); myocardial infarction (MI); congestive 
heart failure (CHF); peripheral vascular disease (PVD); chronic pulmonary obstructive 
disease (COPD); peptic ulcer disease (PUD); coronary heart disease (CHD); inferior vena 
cava (IVC) 
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Table 3.2: Outcomes of patients receiving vena cava filters at one-year of follow-up 
Outcome Overall PE DVT No VTE 
IVC filter 
retrieval 
7,619 14.3% 2,884 14.8% 2,686 11.4% 2,049 20.4% 
Died 4,228 8.0% 1,627 8.4% 1,950 8.3% 651 6.5% 
Censored 41,291 77.7% 14,971 76.8% 18,963 80.4% 7,357 73.2% 
Follow-up time 
Mean (SD) 202 (144) 202 (143) 202 (145) 200 (144) 
Median (IQR) 186 (56-365) 188 (58-365) 187 (54-365) 176 (56-365) 
Time to retrieval 
Mean (SD) 93 (78) 101 (81) 91 (79) 83 (73) 
Median (IQR) 71 (35-130) 81 (38-143) 68 (33-132) 61 (32-113) 
Time to death 
Mean (SD) 96 (91) 94 (91) 97 (91) 100 (90) 
Median (IQR) 63 (26-142) 58 (24-140) 66 (26-144) 67 (32-141) 
Abbreviations: pulmonary embolism (PE); deep vein thrombosis (DVT); venous 
thromboembolism (VTE); standard deviation (SD); interquartile range (IQR) 
 
 
Figure 3.1: Cumulative incidence of vena cava filter retrieval by indication over one-year of follow-up accounting for 
death as a competing risk 
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Table 3.3: Cumulative incidence of vena cava filter retrieval at time intervals by key demographic and clinical factors 
 30 days 60 days 90 days 180 Days 365 days 
Overall 3.3%  
(3.1%-3.5%) 
6.9%  
(6.7%-7.2%) 
9.8%  
(9.5%-10.1%) 
14.9%  
(14.6%-15.2%) 
18.4%  
(18.0%-18.8%) 
Index VTE No VTE 5.2%  
(4.7%-5.6%) 
11.0%  
(10.4%-11.7%) 
15.0%  
(14.3%-15.8%) 
21.3%  
(20.4%-22.2%) 
24.8%  
(23.9%-25.8%) 
 DVT 2.8%  
(2.6%-3.0%) 
5.8%  
(5.5%-6.1%) 
7.9%  
(7.5%-8.2%) 
12.1%  
(11.6%-12.6%) 
14.9%  
(14.3%-15.4%) 
 PE 2.9%  
(2.7%-3.1%) 
6.1%  
(5.8%-6.5%) 
9.3%  
(8.9%-9.8%) 
14.8%  
(14.3%-15.4%) 
19.2%  
(18.5%-19.8%) 
Year 2010 3.1%  
(2.8%-3.5%) 
6.0%  
(5.6%-6.5%) 
8.0% 
 (7.5%-8.6%) 
11.3%  
(10.7%-11.9%) 
14.0%  
(13.3%-14.7%) 
 2011 3.0%  
(2.7%-3.3%) 
6.3%  
(5.9%-6.8%) 
8.8%  
(8.3%-9.3%) 
13.2%  
(12.6%-13.9%) 
16.1%  
(15.4%-16.8%) 
 2012 3.4%  
(3.1%-3.8%) 
7.5%  
(7.0%-8.0%) 
9.9%  
(9.4%-10.5%) 
15.6%  
(14.9%-16.3%) 
19.2%  
(18.4%-20.0%) 
 2013 3.3%  
(3.0%-3.7%) 
7.5%  
(7.0%-8.1%) 
11.2% 
(10.5%-11.9%) 
17.1%  
(16.3%-18.0%) 
21.6%  
(20.7%-22.6%) 
 2014 3.7%  
(3.3%-4.2%) 
7.7%  
(7.1%-8.3%) 
12.4%  
(11.6%-13.3%) 
20.5%  
(19.4%-21.6%) 
38.2%  
(19.4%-57.0%) 
Age 18-34 6.8%  
(5.8%-7.9%) 
15.2%  
(13.7%-16.8%) 
22.8%  
(21.0%-24.7%) 
34.9%  
(32.7%-37.1%) 
42.8%  
(40.4%-45.2%) 
 35-44 6.1%  
(5.3%-6.9%) 
13.9%  
(12.7%-15.1%) 
18.9%  
(17.6%-20.3%) 
28.4%  
(26.8%-30.0%) 
35.5%  
(33.7%-37.2%) 
 45-54 4.9%  
(4.5%-5.5%) 
11.4%  
(10.7%-12.2%) 
15.9%  
(15.0%-16.8%) 
23.7%  
(22.6%-24.7%) 
29.3%  
(28.1%-30.4%) 
 55-64 3.9%  
(3.5%-4.2%) 
8.0%  
(7.5%-8.5%) 
11.5%  
(10.9%-12.1%) 
17.8%  
(17.0%-18.5%) 
21.8% (21.0%-
22.7%) 
 
Table 3.3: Cumulative incidence of vena cava filter retrieval at time intervals by key demographic and clinical factors 
 30 days 60 days 90 days 180 Days 365 days 
 65-74 2.7%  
(2.4%-3.1%) 
5.3%  
(4.8%-5.8%) 
7.4%  
(6.9%-8.0%) 
11.4%  
(10.7%-12.1%) 
14.1%  
(13.3%-15.0%) 
 75 and older 1.4%  
(1.2%-1.6%) 
2.4%  
(2.1%-2.6%) 
3.1%  
(2.8%-3.3%) 
4.5%  
(4.1%-4.8%) 
5.4%  
(5.0%-5.8%) 
Cancer Yes 2.6%  
(2.3%-2.8%) 
4.5%  
(4.2%-4.9%) 
6.3%  
(5.9%-6.7%) 
9.1%  
(8.6%-9.7%) 
11.7%  
(11.1%-12.4%) 
 No 3.6%  
(3.4%-3.8%) 
7.9%  
(7.6%-8.2%) 
11.1%  
(10.8%-11.5%) 
17.0%  
(16.6%-17.5%) 
20.8%  
(20.4%-21.3%) 
Insurance 
source 
Commercial 4.8%  
(4.5%-5.0%) 
10.5%  
(10.1%-10.9%) 
14.9% (14.5%-
15.4%) 
22.6%  
(22.1%-23.2%) 
28.0%  
(27.4%-28.6%) 
 Medicare 1.9%  
(1.7%-2.0%) 
3.4%  
(3.2%-3.6%) 
4.6%  
(4.3%-4.9%) 
7.0%  
(6.6%-7.3%) 
8.6%  
(8.2%-8.9%) 
Abbreviations: venous thromboembolism (VTE); deep vein thrombosis (DVT); pulmonary embolism (PE) 
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Figure 3.2: Plot of times to anticoagulation and vena cava filter retrieval.  
Black line represents the fit of the data, red line represents the preferred line if 
anticoagulation was initiated 4 weeks prior to retrieval. Time is based on follow-up 
after the discharge date from the hospitalization where the IVCF was placed. 
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Table 3.4: Regression results showing patient factors associated with 90-day 
(early) retrieval and 1-year retrieval 
 90-day retrieval 1-year retrieval 
 HR 95% CI HR 95% CI 
Age 
18-34 Ref. Ref. Ref. Ref. Ref. Ref. 
35-44 0.97 0.94 1.00 0.88 0.80 0.97 
45-54 0.95 0.92 0.98 0.79 0.72 0.86 
55-64 0.91 0.88 0.93 0.62 0.57 0.68 
65-74 0.87 0.84 0.89 0.41 0.37 0.45 
75 and older 0.82 0.80 0.84 0.17 0.15 0.19 
Gender 
Male Ref. Ref. Ref. Ref. Ref. Ref. 
Female 1.01 1.01 1.02 1.04 0.99 1.09 
Region 
Northeast Ref. Ref. Ref. Ref. Ref. Ref. 
North Central 1.03 1.02 1.04 1.29 1.20 1.38 
South 0.99 0.98 1.00 0.89 0.83 0.95 
West 1.10 1.09 1.12 1.89 1.76 2.04 
Unknown 1.01 0.98 1.04 1.24 1.05 1.46 
Residence 
Rural Ref. Ref. Ref. Ref. Ref. Ref. 
Urban 1.01 1.00 1.02 1.13 1.06 1.21 
Index VTE 
DVT only Ref. Ref. Ref. Ref. Ref. Ref. 
No VTE 1.05 1.03 1.06 1.24 1.17 1.32 
PE 0.99 0.98 1.00 0.99 0.93 1.04 
Concurrent conditions during hospitalization 
Bleed 1.00 0.99 1.02 1.10 0.93 1.29 
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Table 3.4: Regression results showing patient factors associated with 90-day 
(early) retrieval and 1-year retrieval 
 90-day retrieval 1-year retrieval 
 HR 95% CI HR 95% CI 
Unstable condition 0.98 0.96 1.00 0.80 0.60 1.06 
Sepsis 1.00 0.98 1.01 0.92 0.76 1.12 
Infection 0.98 0.97 0.99 0.84 0.76 0.91 
Anemia 0.99 0.98 0.99 0.91 0.84 0.98 
Trauma 0.99 0.98 1.00 1.00 0.92 1.09 
Thrombolytic therapy 1.06 1.02 1.09 1.29 1.11 1.49 
Embolectomy procedure 1.00 0.96 1.04 0.89 0.68 1.17 
Major surgery 0.98 0.97 0.99 0.92 0.87 0.97 
Pregnant 1.05 0.99 1.11 1.36 1.15 1.60 
Comorbid conditions during pre-index look back 
CCI score (per 1 unit) 1.00 0.99 1.01 0.97 0.90 1.05 
History of VTE 1.03 1.02 1.04 1.17 1.08 1.26 
History of bleeding 0.98 0.97 0.99 0.77 0.67 0.87 
Myocardial infarction 0.99 0.98 1.00 0.82 0.71 0.96 
Heart failure 0.98 0.97 0.99 0.67 0.60 0.74 
Peripheral vascular disease 0.99 0.98 1.00 0.85 0.77 0.94 
Dementia 0.97 0.96 0.98 0.31 0.22 0.43 
COPD 0.99 0.98 1.00 0.88 0.83 0.94 
Rheumatism 1.00 0.98 1.01 0.96 0.84 1.08 
Peptic ulcer disease 1.02 1.00 1.04 1.16 0.95 1.41 
Mild liver disease 1.00 0.98 1.01 1.00 0.91 1.11 
Severe liver disease 0.99 0.98 1.00 0.86 0.81 0.92 
Diabetes 0.99 0.98 1.00 0.96 0.85 1.09 
Diabetes w/ complications 0.98 0.97 1.00 0.76 0.65 0.89 
Paralysis 0.98 0.97 0.99 0.81 0.73 0.90 
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Table 3.4: Regression results showing patient factors associated with 90-day 
(early) retrieval and 1-year retrieval 
 90-day retrieval 1-year retrieval 
 HR 95% CI HR 95% CI 
Renal disease 0.99 0.98 1.00 0.94 0.87 1.00 
Cancer 0.91 0.89 0.94 0.28 0.17 0.46 
Metastatic cancer 0.92 0.90 0.93 0.43 0.38 0.49 
Stroke 0.98 0.98 0.99 0.80 0.73 0.88 
Hypertension 1.00 0.99 1.00 0.95 0.90 0.99 
Coronary heart disease 1.00 0.99 1.00 0.87 0.80 0.94 
Hyperlipidemia 1.02 1.01 1.03 1.23 1.17 1.30 
Insurance Details 
Assigned Care Provider 1.00 0.99 1.02 1.03 0.94 1.12 
Capitated Payment 0.99 0.97 1.00 0.84 0.75 0.94 
Year filter placed 
2010 Ref. Ref. Ref. Ref. Ref. Ref. 
2011 1.01 1.00 1.02 1.19 1.11 1.28 
2012 1.03 1.02 1.04 1.41 1.32 1.52 
2013 1.04 1.03 1.05 1.63 1.51 1.75 
2014 1.05 1.04 1.07 1.90 1.76 2.06 
Abbreviations: venous thromboembolism (VTE); deep vein thrombosis (DVT); 
pulmonary embolism (PE); chronic obstructive pulmonary disease (COPD) 
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Table 3.5: Comparison of utilization for matched patients based on retrieval 
status 
  No 
retrieval  
Retrieval  Late 
retrieval  
Early 
retrieval 
 N 11,122 5,561 1,297 1,297 
Outpatient visits Mean (SD) 11.8 (15.8) 14.3 (16) 14.8 (10.6) 15.4 (10.8) 
Median (IQR) 6 (1-16) 9 (2-20) 14 (7-20) 14 (8-21) 
Outpatient VTE 
visits 
Mean (SD) 6.4 (6.5) 6.9 (6.4) 6.9 (5.2) 7.2 (5.1) 
Median (IQR) 4 (2-8) 5 (2-10) 6 (2-10) 6 (3-10) 
Hospitalizations Mean (SD) 1.8 (1) 1.8 (0.8) 1.8 (0.7) 1.7 (0.8) 
Median (IQR) 2 (1-2) 2 (1-2) 2 (1-2) 1 (1-2) 
PE 
Hospitalizations 
Mean (SD) 1.3 (0.7) 1.3 (0.5) 1.5 (0.7) 1.2 (0.4) 
Median (IQR) 1 (1-1) 1 (1-2) 1 (1-2) 1 (1-1) 
DVT 
hospitalizations 
Mean (SD) 1.2 (0.5) 1.2 (0.5) 1.3 (0.6) 1.2 (0.4) 
Median (IQR) 1 (1-1) 1 (1-1) 1 (1-2) 1 (1-1) 
Emergency visits Mean (SD) 2 (1.9) 1.7 (1.4) 1.7 (1.5) 1.7 (1.3) 
Median (IQR) 1 (1-2) 1 (1-2) 1 (1-2) 1 (1-2) 
PE Emergency 
visits 
Mean (SD) 1.2 (0.4) 1.3 (0.6) 1.2 (0.5) 1.3 (0.8) 
Median (IQR) 1 (1-1) 1 (1-1) 1 (1-1) 1 (1-1) 
DVT Emergency 
visits 
Mean (SD) 1.2 (0.6) 1.2 (0.5) 1.2 (0.4) 1.2 (0.9) 
Median (IQR) 1 (1-1) 1 (1-1) 1 (1-1) 1 (1-1) 
Abbreviations: pulmonary embolism (PE); deep vein thrombosis (DVT); venous 
thromboembolism (VTE); standard deviation (SD); interquartile range (IQR) 
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Table 3.6: Adjusted analysis comparing the association of utilization with 
retrieval status 
  
Retrieval vs. no 
retrieval 
Early (≤90 days) vs. Late 
(≥120 days) retrieval 
 
Odds 
ratio 
95% CL Odds ratio 95% CL 
≥ Median Outpatient visits 
(vs. <Median) 
2.32 2.05 2.62 0.87 0.73 1.04 
≥ Median VTE outpatient 
visits (vs. <Median) 
2.18 1.98 2.39 1.10 0.90 1.33 
 1 hospitalization (vs. 0) 1.08 0.97 1.20 0.96 0.75 1.22 
≥2 hospitalizations (vs. 0) 1.63 1.48 1.80 1.80 1.43 2.27 
1 PE hospitalization (vs. 0) 1.28 1.06 1.56 1.03 0.67 1.59 
≥2 PE hospitalizations  
(vs. 0) 
1.70 1.25 2.31 5.37 2.33 12.37 
1 DVT hospitalization  
(vs. 0) 
1.16 0.98 1.37 1.35 0.94 1.95 
≥2 DVT hospitalizations 
(vs. 0) 
1.42 1.02 1.99 2.62 1.30 5.29 
 1 Emergency visit (vs. 0) 0.95 0.85 1.06 0.81 0.64 1.02 
≥2 Emergency visit (vs. 0) 0.64 0.56 0.73 0.93 0.70 1.23 
1 PE emergency visit  
(vs. 0) 
0.80 0.60 1.07 0.70 0.36 1.34 
≥2 PE emergency visit  
(vs. 0) 
1.14 0.62 2.13 0.58 0.14 2.44 
1 DVT emergency visit  
(vs. 0) 
0.66 0.53 0.84 0.84 0.51 1.39 
≥2 DVT emergency visit 
(vs. 0) 
0.46 0.29 0.74 1.67 0.55 5.04 
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CHAPTER 4: COMPETING RISKS ANALYSIS OF CANCER-ASSOCIATED 
RECURRENT THROMBOSIS, MAJOR BLEEDS, AND DEATH IN A GERIATRIC 
COHORT RECEIVING ANTICOAGULATION OR VENA CAVA FILTERS 
 
This study details an outcomes study looking at the effectiveness of treatments, 
including vena cava filters, for cancer-associated VTE. It has been published in the 
Journal of Health Economics and Outcomes Research. 
 
Citation: Joshua D. Brown, Kelley L. Ratermann, Jeffery C. Talbert, Val R. Adams. 
Competing Risks Analysis of Cancer-associated Recurrent Thrombosis, Major 
Bleeds, and Death in a Geriatric Cohort. JHEOR 2015;3(2):214-23 
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Abstract 
 
Background: Individuals with cancer are at an increased risk of venous 
thromboembolism (VTE). There is a continued increased of recurrent VTE after the 
initial event as well as increased bleed risk related to VTE treatment. 
Objectives: This study sought to observe the incidence of recurrent VTE, major 
bleeding, and death in a geriatric oncology population during treatment for a 
cancer-associated VTE. 
Methods: We utilized an insurance claims database of Medicare Advantage 
beneficiaries 65 and older. The index VTE was identified and individuals were 
followed up to 180 days to observe an outcome event. Treatment groups were 
classified among those receiving warfarin, low-molecular weight heparins (LMWH), 
vena cava (VC) filters with or without anticoagulation, or no treatment. Treatment 
groups were compared on baseline demographic and clinical characteristics and an 
inverse probability of treatment weight was used to balance these factors between 
the groups. A competing risks, time-to-event analysis was performed including 
treatment only models as well as adjusted models with additional covariates. Cause-
specific hazards ratios (HR) and their 95% confidence intervals were reported. 
Results: Treatment groups differed on baseline variables including age, 
comorbidities, and tumor sites. After balancing the treatment groups on baseline 
characteristics, those receiving LMWHs had no difference in recurrent VTE 
compared to warfarin but had less than half the risk of major bleeding (HR=0.48 
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[0.27-0.85]). Those receiving VC filters had increased risk of all outcome events 
relative to warfarin. 
Conclusions: Patients over the age of 65 with cancer are at a high risk of 
experiencing recurrent VTE and major bleeding during treatment for a cancer-
associated VTE. These results are consistent with United States guidelines which 
recommend LMWHs over warfarin for treatment and secondary prevention of VTE.  
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Background 
 
Compared to the general population, individuals with cancer are at 4 to 7 times the 
risk of developing a venous thromboembolism (VTE). 57,82-84 Malignancy induces a 
prothrombotic state which includes activation of the coagulation cascade and is 
further exacerbated by cancer treatment and surgery. 85 Additional risk factors for 
VTE in cancer include the site and stage of the tumor, older age, prior history of 
clots, and comorbidities. 86,87 Although at an already increased risk of death from 
cancer, VTE carries a substantial risk of mortality with clotting events accounting 
for up to 10% of all deaths in patients with cancer. 88-90 VTE events, including deep 
vein thrombosis (DVT) and pulmonary embolism (PE) account for significant 
lengths of stay and costs in this population with the mean hospital stay ranging from 
11 days for DVT and up to 21 days for those with PE.  91 
 
In the United States (U.S.), prevention and treatment of VTE in patients with cancer 
is addressed in American Society of Clinical Oncology guidelines.  92 These guidelines 
recommend the use of low molecular weight heparins (LMWHs, dalteparin, 
enoxaparin, tinzaparin) for the initial and long term treatment of VTE for this 
population. Warfarin is recommended when LMWHs are contraindicated or limited 
in use because of cost or other factors including perceived intolerance.  93 In fact, 
LMWHs have been shown to outperform warfarin in randomized controlled trials 
and have further benefit in having weight based dosing, fewer drug and food 
interactions, little monitoring throughout treatment, and maintain positive patient 
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preference despite being an injectable. 88,94-97 However, real-world evidence shows 
that warfarin is used for a vast majority of cases. 98,99 In addition to anticoagulation 
therapy, vena cava (VC) filters are commonly utilized in the oncology patient 
population despite no survival benefit and excess risk compared to other treatment 
modalities. 100 
 
Individuals who have had a VTE remain at high risk of experiencing a recurrent VTE 
event and have high rates of bleeding. 91,101 Recurrent VTE has been reported as high 
as 21% and bleeding rates as high as 12.4% in cancer patients.  102 Risk factors 
related to recurrent VTE and adverse bleeding events include tumor site and 
histology, presence of metastases, age, and certain biomarker or laboratory findings 
as well as choice of anticoagulant therapy for acute treatment and long-term 
secondary prophylaxis. 103-106 To our knowledge, no studies have identified risk 
factors related to recurrent VTE, bleeding, and mortality related to geriatric patients 
experiencing a cancer-associated VTE and compared treatments on these outcomes. 
We sought to compare treatment selections on each of those three outcomes after 
an initial VTE event. Treatment will be observed for individuals treated with 
LMWHs, warfarin, VC filters, or who are untreated in a cohort of oncology patients 
in a large administrative claims database. Demographic and clinical variables 
associated with each of these three competing outcomes will also be explored. 
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Materials and Methods 
 
Data source and cohort identification 
This retrospective cohort study used an extract from a large administrative claims 
database comprised of 1.4 million unique lives with Humana Medicare Advantage 
medical and pharmacy benefits from 2007 to 2009. The data included inpatient and 
outpatient medical encounters with procedural codes and diagnoses fields, filled 
prescription medication claims, and demographic and insurance coverage 
information linked at the individual level. 
 
The data extract required that an individual have a diagnosis for a malignant 
neoplasm (104.xx-208.xx) and a DVT (451.xx, 453.xx) or a PE (415.1x) using ICD-9-
CM codes for primary diagnosis fields. The earliest date of diagnosis with a DVT or 
PE was confirmed where at least one claim had a primary diagnosis of DVT or PE 
and a specific imaging study indicative of diagnostic procedures codes (Appendix).  
107 Individuals were excluded if their initial VTE event occurred before their cancer 
diagnosis or if they were less than 65 years of age at cancer diagnosis. The 
remaining cohort was required to have at least 180 days of continuous medical and 
pharmacy coverage during the pre-index period. The 180-day pre-index period was 
used to assess clinical characteristics including comorbidities and cancer treatment 
patterns preceding the index event. Lastly, individuals receiving anticoagulant 
treatment during the 30 days preceding their index event were excluded to ensure 
 88 
that temporality with diagnosis and treatment and to identify treatment naïve 
patients. 
 
Cohort characteristics 
Individual demographics and insurance coverage were determined during the pre-
index period. Age was categorized 65-69, 70-74, and 75 or older. Race was 
categorized white, black, and other/unknown. Region was categorized by census 
regions including South, Midwest, West, and North. Insurance coverage was based 
on product type (fee-for-service, FFS; health maintenance organization, HMO; or 
preferred provider organization, PPO). 
 
Tumor site was specified by ICD-9-CM codes including prostate, breast, lung, 
lymphoma, colon, kidney, pancreas, brain, liver, ovarian, and others. Claims data are 
limited so that tumor staging is not available. Metastases of the lymph nodes, 
respiratory, digestive, and other sites were identified using ICD-9-CM codes (195.xx-
199.xx). Comorbidities were based on the Charlson Comorbidity Index using the 
ICD-9-CM coding algorithms by Quan et al. and recorded as a continuous weighted 
score and categorized by quartiles. 52 Other comorbidities and clinical 
characteristics were identified by ICD-9-CM codes available in Appendix 4A and 
were classified as binary variables. 
 
Medications of interest were identified using Generic Product Identifier (GPI) codes 
or Healthcare Common Procedure Coding System (HCPCS) codes. Placement of VC 
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filters was identified by procedural codes in the medical claims. VTE treatment 
choice was determined within the 21 days preceding the index event and was 
recorded as the last outpatient anticoagulation used to allow for the possibility of 
bridge therapy or treatment changes. The timing of chemotherapy or radiation 
therapy was categorized based on its relative timing during the pre-index period to 
the clotting event as occurring within 30 days, between 31 and 90 days, 91-180 
days, or unobserved during the pre-index period using a combination of procedural 
and medication codes within both the medical and pharmaceutical claims.  
 
Inverse probability of treatment weight 
A multinomial logistic regression model was estimated for treatment choice 
predicting the probability of each subject to receive warfarin, a LMWH, a VC filter, a 
VC filter and anticoagulation, or no treatment. All pre-index subject characteristics 
deemed by the clinical team to be potential predictors of treatment choice as well as 
related to the outcomes of interest were included. For each subject receiving a 
particular treatment, the inverse of the probability of receiving that treatment and 
the sample size within each treatment group was used to create a stabilized inverse 
probability of treatment weight (IPTW) for each subject. IPTW is a variant of 
propensity score methods that can be used to weight a regression analysis and has 
strengths in that no matching or stratification are required; thus, no reduction in 
sample size compared to other propensity score techniques. 108,109 Treatment group 
comparisons and the performance of the IPTW method were assessed using 
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standardized differences between the groups where a value of >0.10 is considered 
significant. 
 
Recurrent VTE, major bleeds, and mortality 
Subjects were followed from the index date for up to 180 days or until: 1) they 
experienced a recurrent VTE; 2) they experienced a major bleed; 3) they died; or 4) 
they were lost to follow-up due to end of the study period or end of eligibility. The 
earliest of these events was considered the event of interest. In the case where a 
death occurred on the same date as one of the other events, that outcome was noted 
as a death. Recurrent VTE were classified using the same coding algorithm as index 
event identification and required: a primary diagnosis of a DVT or PE with a specific 
diagnostic imaging study at least one day after the index event. This was done to 
help mitigate the chance of the initial event being recoded on a medical 
management claim as it is unlikely that additional imaging would be required for the 
index event. Major bleeding events were classified by an algorithm developed by 
Fang et al. considering a primary diagnosis of intracranial hemorrhage or a bleed 
requiring a hospitalization or emergency department visit. 110 
 
A competing risks, time-to-event analysis was performed taking into account the 
interdependence of the outcome events and producing a cumulative incidence 
function (CIF) for each outcome. This approach allowed for multivariable analyses 
with cause-specific coefficient estimates of the predictors for each outcome. Further, 
competing risks regression allows for the use of the IPTW detailed above so that 
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better direct comparisons could be made between treatment options. We computed 
the overall CIF for the cohort for each outcome as well as each outcome separately 
stratified by the treatment received. We fitted a competing risks regression model 
and included the baseline variables of interest that may still be predictive of 
outcome events even after IPTW weighting. Hazard ratios and 95% confidence 
intervals of these final variables are reported. 
 
Data management and analysis was conducted using SAS 9.4 (SAS Institute, Cary, 
NC) and the manuscript was drafted adhering to the STROBE Statement guidelines 
for reporting observational studies. The use of de-identified, Humana administrative 
claims database was approved by the University of Kentucky Institutional Review 
Board. 
Results 
 
Characteristics of treatment groups 
A total of 12,965 subjects met the inclusion and exclusion criteria. Nearly two-thirds 
of the index events were lower DVTs, 25.6% were PEs, and 8.7% were upper DVTs. 
Treatment groups, assessed in the acute treatment phase included: 30.4% treated 
with warfarin, 3.5% treated with LMWHs, 4.1% received a VC filter, 4.4% received a 
VC filter and anticoagulation, and 57.5% had no observed treatment. Distribution of 
the index event type was significant between treatment groups with most (82.3%) 
of the upper DVT index events untreated compared to 60% of lower DVTs and 
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42.6% of PEs (data not shown). Treatment groups differed significantly across 
multiple demographic characteristics including age categories, gender, race, region, 
plan type, and CCI score as well as comorbidities and tumor sites. Baseline 
demographic and clinical characteristic comparisons between the treatment groups 
are summarized in Table 4.1. 
 
IPTW weighting 
An IPTW was calculated for each individual based on the probability of receiving 
each treatment based on the covariates included in Table 4.1. The IPTW performed 
well when used to reweight the population to balance between the covariates. The 
standardized differences were compared and are shown in Appendix B relative to 
the warfarin group. Although the IPTW balanced well across all groups, some group-
to-group comparisons included significant standardized differences (>0.10) 
showing the need for some further adjustment in outcome models. 
 
Outcome events 
During the 180-day follow-up period, there was a median follow-up of 87 days with 
a total of 3,323 person-years of follow-up time contributed by the cohort. Recurrent 
VTE had a median time-to-event of 4 days (IQR 1-21 days).  Median time-to-event 
for death was 8 days (IQR 1-48 days) and for major bleeding the median was 14 
days (IQR 2-57 days). There were a total of 1,661 recurrent VTEs (12.8% of total 
cohort; 500 recurrent VTEs per 1,000 person-years) consisting of 614 PEs. Major 
bleeds occurred in 6.1% (N=794) of the cohort (245 major bleeds per 1,000 person-
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years) including 117 intracranial hemorrhages. Additionally, 3,690 individuals 
(28.5%) in the cohort died within the 180-day period (1,110 deaths per 1,000 
person-years) while the remainder (N=6,820; 52.6%) of the cohort was censored or 
lost to follow-up before an event could be observed.  
 
Competing risks analysis 
Figure 4.1 graphs the CIF of each outcome by treatment group. The CIF curves 
differed significantly across treatment groups and overall group comparisons by 
Gray’s method were significant at p<0.001. Three models were estimated including 
an unweighted, treatment-only model, a IPTW weighted treatment-only model, and 
an IPTW weighted model including covariates which were not balanced by the IPTW 
method or that were thought to potentially have residual impact on the outcomes of 
interest. Table 4.2 details the outcome-specific HRs and 95% CIs for each treatment 
group in the treatment-only models with warfarin as the referent treatment group. 
Some major differences are observed between the unweighted and weighted models 
further showing some bias in treatment group assignment. In the weighted analysis, 
those treated with LMWH had similar hazard of experiencing a recurrent VTE and 
over 50% reduced hazard of experiencing a major bleed (HR 0.48; 95% CI 0.27-
0.85). Those receiving a VC filter or a VC filter with anticoagulation were much more 
likely than the warfarin group to have both recurrent VTE (80-94% increased 
hazard) and major bleeds (235-492% increased hazard). The untreated group had 
lower hazard of experiencing a recurrent VTE and no difference in the hazard of 
experiencing a major bleed. All treatment groups had higher hazards of death but 
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should be interpreted with caution as will be discussed in more detail in the 
Discussion section. 
 
Further adjustment for the study covariates had marginal effects on the point 
estimates between the treatment groups. Table 4.3 includes the outcome-specific 
HRs and 95% CIs for the IPTW weighted model which included additional 
covariates other than treatment group. Those with an index PE event had an 
HR=1.83 (95% CI 1.64-2.03) for recurrent VTE compared to lower DVT index 
events. Individuals who had a history of prior bleeding events during the baseline 
period had over a 150% increased hazard of major bleed events as well as a 20% 
increase in recurrent VTE.  
 
Discussion 
 
This study is the first study to our knowledge to assess the incidence of outcome 
events after an initial cancer-associated VTE in a geriatric oncology population. This 
population is of particular interest given the increased risk of treatment related 
complications as well as a high baseline risk of mortality from multiple causes.  
 
Our findings are consistent with previous studies showing a high rate of recurrent 
VTE and major bleeding after an index VTE which differed across the treatment 
modality. 98,99,102,103,111 After balancing the treatment groups on baseline 
characteristics, we found no differences between warfarin and LMWHs and risk of 
recurrent VTE but showed that warfarin treated patients had more than twice the 
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hazard of a major bleed. Those receiving a filter had very large increases in all 
outcome events relative to both LMWH and warfarin. This generally confirms the 
recommendations made by U.S. clinical oncology practice guidelines which prefer 
LMWHs over warfarin and only recommend VC filters when other treatments are 
contraindicated. 58 VC filters have mixed results in randomized controlled trials  9,10 
and observational studies 19 unless distinct population groups with high risk of VTE 
or high risk of bleeding are preferentially given this treatment over the general 
patient population. 
 
LMWHs have been shown to have a large incremental cost-effectiveness ratio 
compared to warfarin 112 as well as perceived patient intolerance and higher 
pharmacy costs. 93 Nevertheless, oral anticoagulation with warfarin can be difficult 
in practice given the patient variability in dosing, diet limitations, and required 
monitoring as well as potential drug-drug interactions with chemotherapy, changes 
in body weight, altered liver or renal function, and unpredictable gastrointestinal 
absorption due to vomiting or mucositis. 58 These considerations will become more 
important as novel oral anticoagulants (NOACs; apixaban, rivaroxaban, dabigatran, 
edoxaban) are beginning to see use in this population and are currently being 
investigated for efficacy and safety for primary and secondary prophylaxis of 
cancer-associated VTE. 113-118 
 
There is likely significant bias in the choice of treatment for a given individual and is 
shown in our baseline comparisons. Using the IPTW in the regression analysis helps 
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to balance these differences in a way analogous to the randomization process of a 
randomized controlled trial. However, the IPTW is limited to the logistic regression 
model specification and may not capture all the bias that is present. We included 
several demographic and clinical characteristics which could drive the choice of 
treatment in this population. Important factors, which could not be controlled for 
given the nature of claims data, include tumor staging and histology as well as other 
important clinical history that may contribute to treatment choice or baseline risk of 
outcome events. However, our study is strengthened by a large sample size which 
includes some relatively rare cancers, such as multiple myeloma, brain, and renal 
cancers, that have lacked investigation in previous studies. 87,119 
 
Of particular interest throughout the conduct of this study is the untreated group 
which comprised the majority of the identified cohort. This finding is not unique to 
our study with a recent study of real-world data in another population in the U.S. 
reporting a treatment rate of 50%. 113,120,121 We hypothesize that this group could 
consist of several unique profiles of individuals. For one, a proportion of this group 
may include those that are unfit to receive any treatment given a poor prognosis 
related to the underlying cancer or the index event. There may also be cases which 
the index VTE event was considered asymptomatic or not a high priority for 
treatment based on unobservable patient factors. Further, there may have been 
some false positive misclassification of index events which met the coding criteria. 
However, as discussed below in the limitations, the sensitivity and specificity of the 
algorithm is expected to be >90% given the high risk of events in this population.  107 
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It would further be expected that misclassification would not necessarily differ 
between treatment groups and would be evenly distributed among the treatment 
groups. While some groups have used treatment as confirmation of index VTE 
events, 122 the inclusion in our study would not impact the direct comparisons made 
between the other treatment groups and was considered a more thorough analysis.  
 
Lastly, it is possible that other, non-guideline recommended treatments were used 
or that medications were purchased out-of-pocket or using another insurance 
benefit. Anywhere from 10-20% of warfarin prescription are purchased through 
low-cost generic programs in the United States and may contribute to exposure 
misclassification in this population. 123-125 
 
Limitations 
Our study is subject to several limitations inherent to claims-based studies.  79,80 We 
relied on ICD-9-CM coding available in the claims to diagnose study subjects in 
addition to requiring the presence of specific imaging modalities to confirm index 
and recurrent VTE events. It is impossible to confirm a positive diagnosis using 
these data; however, claims-based coding algorithms for VTE have been shown to 
perform strongly especially when there is a high risk of VTE in the population  50,126. 
In addition to this validated algorithm, we further required the presence of an 
imaging procedure specific for diagnosis of VTE events to indicate an event of 
interest which will have likely increased the specificity of our coding algorithm and 
insured that a recurrent VTE event was a new event and not management of the 
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previous index event. Further, we considered treatment group assignments based 
on the pattern of medication use or procedural codes within the first 10 days of the 
index events and held the treatment group assignment throughout the 180 days 
follow-up. Realistically, treatment, as well as other factors, may change drastically 
over the course of the study period. However, the majority of outcome events 
occurred during the first 30 days post-index where treatment choice and individual 
factors would generally remain stable. Future work should identify and account for 
important factors that may vary over time for inclusion in analytic models. 
 
We used a competing risks framework given that the outcome events cannot be 
considered independent of each other, i.e. experiencing one may preclude 
experiencing another or one event may cause another. Failure to do so can 
overestimate survival for traditional Kaplan-Meier based analyses. 119 In this 
population especially, the competing risk of death is a contribution by many factors 
including the advanced age of the cohort, having cancer, as well as the risk of death 
from the other outcome events. 119 Given the nature of the data, we could not assign 
cause of death in this study. For example, if death was caused by a major bleed or 
recurrent VTE but not submitted for claims adjudication, the alternative outcome 
would not be observed. Thus, the findings related to the death should be interpreted 
with caution. Lastly, our results are from a commercially insured population of 
individuals with Medicare Advantage plans over the age of 65. Thus, our results may 
not be generalizable to the general geriatric population but do provide insight into 
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the burden of these outcome events in this population which makes of about 30% of 
those with Medicare insurance in the United States. 127 
 
Conclusions 
 
There is a high rate of recurrent VTE and major bleeding events within 180 days of a 
cancer-associated VTE. The risk of experiencing these outcomes varied across 
treatment groups showing no difference between warfarin and LMWHs for 
recurrent VTE but twice the risk of major bleeding with warfarin. Patients receiving 
VCFs with or without anticoagulation were at largely increased risk of all outcome 
events. These findings are consistent with U.S. clinical oncology practice guidelines 
which prefer LMWH over warfarin in both the acute and long-term treatment after a 
cancer-associated VTE and only recommend vena cava filters if other treatments are 
contraindicated. 
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Table 4.1: Baseline demographic and clinical characteristics by treatment 
group 
Characteristic 
N (%) 
Warfarin LMWH VC Filter VC Filter + 
Anticoag. 
None 
Total N=12,965 3,946 (30.4) 458 (3.5) 536 (4.1) 574 (4.4) 7,451 (57.5) 
Age category* 
65-69 
70-74 
75 and older 
 
1,038 (26.3) 
1,124 (28.4) 
1,793 (45.3) 
 
176 (38.4) 
124 (27.1) 
158 (34.5) 
 
124 (22.4) 
154 (27.9) 
275 (49.7) 
 
166 (28.8) 
158 (27.4) 
252 (43.8) 
 
2,119 (27.9) 
2,086 (27.5) 
3,392 (44.7) 
Gender* 
Male 
Female 
 
1,833 (46.4) 
2,122 (53.7) 
 
242 (52.8) 
216 (47.2) 
 
222 (40.1) 
331 (59.9) 
 
270 (46.9) 
306 (53.1) 
 
3,917 (51.6) 
3,680 (48.4) 
Race* 
White 
Black 
Other 
 
2,614 (66.1) 
338 (8.6) 
1,003 (25.4) 
 
244 (53.3) 
22 (4.8) 
192 (41.9) 
 
185 (33.5) 
40 (7.2) 
328 (59.3) 
 
320 (55.6) 
50 (8.7) 
206 (35.8) 
 
4,491 (59.1) 
589 (7.8) 
2,517 (33.1) 
Region* 
Midwest 
Northeast 
South 
West 
 
1,046 (26.5) 
83 (2.1) 
2,421 (61.2) 
405 (10.2) 
 
117 (25.6) 
14 (3.1) 
289 (63.1) 
38 (8.3) 
 
126 (22.8) 
15 (2.7) 
368 (66.6) 
44 (8.0) 
 
138 (24.0) 
20 (3.5) 
369 (64.1) 
49 (8.5) 
 
1,593 (21.0) 
175 (2.3) 
5,144 (67.7) 
685 (9.0) 
Plan type* 
FFS 
HMO 
PPO 
 
1,898 (48.0) 
1,547 (39.1) 
510 (12.9) 
 
214 (46.7) 
175 (28.2) 
69 (15.1) 
 
200 (36.2) 
285 (51.5) 
68 (12.3) 
 
219 (38.0) 
280 (48.6) 
77 (13.4) 
 
2,941 (38.7) 
3,615 (47.6) 
1,041 (13.7) 
CCI Score* 
0-1 
2-3 
4-5 
5+ 
 
1,079 (27.3) 
1,240 (31.4) 
843 (21.3) 
793 (20.1) 
 
125 (27.3) 
171 (37.3) 
80 (17.5) 
82 (17.9) 
 
63 (11.4) 
164 (29.7) 
143 (25.9) 
183 (33.1) 
 
135 (23.4) 
173 (30.0) 
143 (24.8) 
125 (21.7) 
 
1,821 (24.0) 
2,349 (30.9) 
1,593 (21.0) 
1,834 (24.1) 
Timing of cancer treatment 
before index event * 
Greater than 6 months 
3-6 months 
1-3 months 
Less than 1 month 
 
 
3,181 (80.4) 
103 (2.6) 
158 (4.0) 
513 (13.0) 
 
 
278 (60.7) 
15 (3.3) 
28 (6.1) 
137 (29.9) 
 
 
404 (73.1) 
21 (3.8) 
36 (6.5) 
92 (16.6) 
 
 
435 (75.5) 
13 (2.3) 
30 (5.2) 
98 (17.0) 
 
 
6,547 (86.2) 
172 (2.3) 
234 (3.1) 
644 (8.5) 
Initial event* 
Lower DVT 
Upper DVT 
PE 
 
2,484 (62.8) 
150 (3.8) 
1,321 (33.4) 
 
299 (65.3) 
33 (7.2) 
126 (27.5) 
 
291 (50.5) 
12 (2.1) 
273 (47.4) 
 
291 (50.5) 
12 (2.1) 
273 (47.4) 
 
5,212 (68.6) 
943 (12.4) 
1,442 (19.0) 
Comorbidities      
Leukocytosis* 181 (4.6) 21 (4.6) 55 (10.0) 39 (6.8) 421 (5.5) 
Leukocytopenia* 40 (1.0) 14 (3.1) 8 (1.5) 5 (0.9) 100 (1.3) 
Thrombocytosis* 65 (1.6) 6 (1.3) 17 (3.1) 13 (2.3) 173 (2.3) 
Thrombocytopenia* 177 (4.5) 25 (5.5) 37 (6.7) 30 (5.2) 450 (5.9) 
Hypocoagulatory Disorder* 244 (6.2) 27 (5.9) 28 (5.1) 26 (4.5) 297 (3.9) 
Anemia* 928 (23.5) 143 (31.2) 160 (28.9) 135 (23.4) 2,146 (28.3) 
Liver disease* 502 (12.7) 93 (20.3) 128 (23.2) 91 (15.8) 1,055 (13.9) 
Renal disease* 854 (21.6) 90 (19.7) 195 (35.3) 144 (25.0) 1,927 (25.4) 
Hypertension* 3,011 (76.1) 336 (73.4) 460 (83.2) 450 (78.1) 5,892 (77.6) 
Prior bleed* 413 (10.4) 52 (11.4) 154 (27.9) 79 (13.7) 990 (13.0) 
Obese 321 (8.1) 37 (8.1) 50 (9.0) 60 (10.4) 569 (7.5) 
Myocardial infarction 399 (10.1) 50 (10.9) 66 (11.9) 65 (11.3) 891 (11.7) 
Congestive heart failure* 954 (24.1) 81 (17.7) 144 (26.0) 111 (19.3) 1,679 (22.1) 
Peripheral vascular disease* 896 (22.7) 99 (21.6) 159 (28.8) 141 (24.5) 2,029 (26.7) 
Cerebrovascular disease* 731 (18.5) 60 (13.1) 174 (31.5) 129 (22.4) 1,431 (18.8) 
Dementia* 110 (2.8) 6 (1.3) 35 (6.3) 17 (3.0) 245 (3.2) 
Chronic pulmonary disease* 1,292 (32.7) 144 (31.4) 209 (37.8) 191 (33.2) 2,685 (35.3) 
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Table 4.1: Baseline demographic and clinical characteristics by treatment 
group 
Characteristic 
N (%) 
Warfarin LMWH VC Filter VC Filter + 
Anticoag. 
None 
Rheumatic disease 196 (5.0) 24 (5.2) 31 (5.6) 27 (4.7) 366 (4.8) 
Peptic ulcer disease* 96 (2.4) 11 (2.4) 38 (6.9) 15 (2.6) 256 (3.4) 
Diabetes w/o complications* 1,277 (32.3) 153 (33.4) 211 (38.2) 193 (33.5) 2,692 (35.4) 
Diabetes w/ complications* 436 (11.0) 43 (9.4) 78 (14.1) 63 (10.9) 1,091 (14.4) 
Paraplegia/hemiplegia* 103 (2.6) 10 (2.2) 56 (10.1) 29 (5.0) 207 (2.7) 
Skin ulcers/cellulitis* 534 (13.5) 57 (12.5) 95 (17.2) 91 (15.8) 1,186 (15.6) 
Tumor site      
Oral 67 (1.7) 10 (2.2) 14 (2.5) 13 (2.3) 153 (2.0) 
Stomach* 59 (1.5) 12 (2.6) 19 (3.4) 13 (2.3) 91 (1.2) 
Colon* 321 (8.1) 54 (11.8) 46 (8.3) 61 (10.6) 562 (7.4) 
Liver* 69 (1.7) 17 (3.7) 14 (2.5) 10 (1.7) 132 (1.7) 
Pancreas* 89 (2.3) 42 (9.2) 19 (3.4) 16 (2.8) 174 (2.3) 
Lung* 409 (10.3) 89 (19.4) 76 (13.7) 80 (13.9) 815 (10.7) 
Breast 469 (11.9) 53 (11.6) 49 (8.9) 54 (9.4) 846 (11.1) 
Melanoma 106 (2.7) 6 (1.3) 14 (2.5) 16 (2.8) 165 (2.2) 
Uterine* 73 (1.9) 18 (3.9) 14 (2.5) 27 (4.7) 120 (1.6) 
Cervix* 35 (0.9) 8 (1.8) 10 (1.8) 12 (2.1) 49 (0.6) 
Ovarian* 80 (2.0) 24 (5.2) 20 (3.6) 18 (3.1) 116 (1.5) 
Prostate* 701 (17.7) 62 (13.5) 124 (22.4) 108 (18.8) 1,177 (15.5) 
Bladder* 196 (5.0) 25 (5.5) 48 (8.7) 31 (5.4) 321 (4.2) 
Kidney* 110 (2.8) 16 (3.5) 28 (5.1) 22 (3.8) 230 (3.0) 
Brain* 58 (1.5) 12 (2.6) 50 (9.0) 29 (5.0) 108 (1.4) 
Thyroid 21 (0.5) 1 (0.2) 5 (0.9) 5 (0.9) 62 (0.8) 
Lymphoma 335 (8.5) 52 (11.4) 55 (10.0) 47 (8.2) 628 (8.3) 
Myeloma 86 (2.2) 10 (2.2) 15 (2.7) 12 (2.1) 127 (1.7) 
Metastatic disease* 692 (17.5) 175 (38.2) 157 (28.4) 134 (23.3) 1,160 (15.3) 
*Comparisons between groups significant at p<0.001 
LMWH = low molecular weight heparin; VC = vena cava; FFS = fee-for-service; HMO = health maintenance 
organization; PPO = preferred provider organization; CCI = Charlson comorbidity index; DVT = deep vein 
thrombosis; PE = pulmonary embolism 
 
  
 102 
Table 4.2:Exposure treatment effect in unweighted and weighted (IPTW) 
competing risk models. 
 Unweighted Weighted 
R
e
cu
rr
e
n
t 
V
T
E
 Treatment HR 95% CI HR 95% CI 
Warfarin Ref. Ref. Ref. Ref. Ref. Ref. 
LMWH 0.94 0.76 1.17 0.86 0.68 1.08 
Vena cava filter 1.41 1.14 1.74 1.79 1.48 2.17 
Vena cava filter  
and anticoagulation 
1.90 1.62 2.23 1.94 1.65 2.28 
None 0.31 0.27 0.34 0.34 0.31 0.39 
M
a
jo
r 
b
le
e
d
in
g
 
Warfarin Ref. Ref. Ref. Ref. Ref. Ref. 
LMWH 0.56 0.32 0.98 0.48 0.27 0.85 
Vena cava filter 5.49 4.27 7.06 5.92 4.66 7.53 
Vena cava filter  
and anticoagulation 
3.18 2.45 4.15 3.35 2.59 4.32 
None 1.00 0.85 1.18 1.05 0.89 1.24 
D
e
a
th
 
Warfarin Ref. Ref. Ref. Ref. Ref. Ref. 
LMWH 2.02 1.75 2.34 1.36 1.16 1.60 
Vena cava filter 5.03 4.44 5.69 3.41 2.98 3.91 
Vena cava filter  
and anticoagulation 
2.39 2.08 2.75 1.91 1.66 2.19 
None 1.15 1.07 1.24 1.16 1.08 1.25 
HR = hazard ratio; CI = confidence interval; LMWH = low molecular weight heparin 
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Table 4.3: Event specific hazard ratios and 95% confidence intervals from 
IPTW competing risks analysis with all covariates included. 
 Recurrent VTE Major Bleed Death 
 HR 95% CI HR 95% CI HR 95% CI 
Treatment          
Warfarin Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
LMWH 0.90 0.72 1.13 0.51 0.28 0.93 1.52 1.29 1.80 
VC Filter 1.85 1.53 2.24 5.70 4.42 7.36 3.45 2.94 4.04 
VC Filter + 
anticoagulation 
2.01 1.71 2.37 3.47 2.68 4.50 1.80 1.53 2.12 
None 0.34 0.30 0.38 1.12 0.94 1.32 1.34 1.24 1.44 
Age category          
65-69 Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
70-74 0.96 0.85 1.09 0.99 0.82 1.20 1.09 1.00 1.20 
75 and older  0.80 0.71 0.90 1.00 0.83 1.20 1.30 1.19 1.41 
Race          
White Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
Black 1.10 0.91 1.32 1.33 1.04 1.70 1.32 1.15 1.52 
Other 1.04 0.68 1.60 0.98 0.51 1.86 0.97 0.68 1.38 
CCI Score          
0-1 Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
2-3 1.10 0.94 1.29 1.32 1.02 1.72 1.22 1.08 1.37 
4-5 1.03 0.82 1.31 1.46 1.05 2.02 1.39 1.20 1.62 
5+ 1.23 0.86 1.77 1.30 0.83 2.03 1.48 1.19 1.83 
Timing of cancer 
treatment before index 
event 
         
Greater than 6 months Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
3-6 months 0.73 0.49 1.07 0.97 0.61 1.57 1.27 1.06 1.52 
1-3 months 0.82 0.59 1.12 0.93 0.62 1.39 1.32 1.14 1.53 
Less than 1 month  0.87 0.71 1.06 0.94 0.70 1.26 1.27 1.15 1.40 
Index event          
Lower DVT Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
Upper DVT 0.86 0.71 1.04 0.81 0.63 1.05 0.74 0.64 0.85 
Pulmonary embolism 1.83 1.64 2.03 1.16 0.98 1.37 1.65 1.54 1.78 
Comorbidities          
Leukocytosis 1.18 0.94 1.47 1.62 1.26 2.08 1.36 1.21 1.53 
Leukocytopenia 0.95 0.58 1.57 1.39 0.80 2.43 1.10 0.86 1.40 
Thrombocytosis 1.08 0.85 1.38 1.07 0.80 1.42 1.12 0.98 1.27 
Thrombocytopenia 1.07 0.75 1.54 0.89 0.54 1.46 1.08 0.87 1.34 
Hypocoagualotory 
disorder 
0.97 0.44 2.13 0.66 0.22 2.05 2.05 1.40 3.00 
Anemia 0.35 0.30 0.41 0.77 0.65 0.91 0.97 0.90 1.04 
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Table 4.3: Event specific hazard ratios and 95% confidence intervals from 
IPTW competing risks analysis with all covariates included. 
 Recurrent VTE Major Bleed Death 
 HR 95% CI HR 95% CI HR 95% CI 
Liver disease 1.09 0.92 1.28 0.96 0.77 1.19 1.15 1.06 1.26 
Renal disease 1.14 0.98 1.33 1.22 1.01 1.48 1.24 1.14 1.36 
Hypertension 1.15 1.00 1.32 0.94 0.76 1.16 0.85 0.77 0.93 
Prior bleed 1.19 1.01 1.41 2.53 2.10 3.04 1.20 1.08 1.33 
Obese 1.21 1.02 1.43 1.13 0.89 1.44 0.96 0.84 1.09 
Myocardial infarction 0.90 0.75 1.08 1.11 0.90 1.36 0.93 0.84 1.04 
Congestive heart 
failure 
0.85 0.74 0.98 1.18 0.98 1.40 1.23 1.13 1.34 
Peripheral vascular 
disease 
1.02 0.90 1.16 1.01 0.85 1.20 0.92 0.85 1.00 
Cerebrovascular 
disease 
0.86 0.74 0.99 1.26 1.06 1.49 1.01 0.93 1.10 
Dementia 0.85 0.62 1.19 0.68 0.43 1.07 1.38 1.17 1.63 
Chronic pulmonary 
disease 
1.02 0.90 1.15 1.05 0.89 1.24 1.22 1.13 1.32 
Rheumatic disease 1.16 0.93 1.45 1.24 0.94 1.64 1.07 0.92 1.24 
Peptic ulcer disease 0.83 0.58 1.18 0.96 0.70 1.32 1.01 0.83 1.22 
Diabetes w/o 
complications 
0.88 0.77 1.00 1.10 0.92 1.30 0.97 0.90 1.06 
Diabetes w/ 
complications 
0.89 0.72 1.10 1.03 0.81 1.31 1.00 0.88 1.12 
Paraplegia/Hemiplegia 1.12 0.84 1.51 1.61 1.18 2.20 1.47 1.24 1.73 
Skin ulcers/Cellulitis 0.85 0.74 0.98 0.89 0.72 1.10 1.00 0.90 1.10 
Tumor site          
Oral 0.68 0.43 1.06 1.20 0.74 1.94 1.05 0.87 1.27 
Stomach 1.66 1.14 2.42 0.57 0.25 1.29 1.39 1.15 1.69 
Colon 0.99 0.81 1.20 1.17 0.90 1.52 1.07 0.96 1.19 
Liver 0.74 0.45 1.21 0.48 0.21 1.08 1.09 0.91 1.29 
Pancreas 0.67 0.43 1.04 1.09 0.66 1.81 1.64 1.41 1.89 
Lung 0.72 0.59 0.88 1.14 0.87 1.49 1.27 1.16 1.40 
Breast 1.02 0.87 1.20 0.98 0.75 1.28 0.88 0.78 0.99 
Melanoma 0.86 0.61 1.23 0.99 0.60 1.63 0.88 0.73 1.07 
Uterus 0.75 0.49 1.13 0.60 0.28 1.26 1.19 0.95 1.50 
Cervix 1.03 0.56 1.88 1.47 0.64 3.37 1.29 0.94 1.77 
Ovarian 0.89 0.57 1.39 1.10 0.55 2.19 1.24 1.02 1.51 
Prostate 0.68 0.43 1.06 1.14 0.93 1.40 0.88 0.80 0.98 
Testicular 1.66 1.14 2.42 - - - 1.02 0.70 1.47 
Bladder 0.99 0.81 1.20 1.37 1.02 1.84 1.24 1.08 1.42 
Kidney 0.74 0.45 1.21 1.10 0.75 1.62 1.04 0.88 1.22 
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Table 4.3: Event specific hazard ratios and 95% confidence intervals from 
IPTW competing risks analysis with all covariates included. 
 Recurrent VTE Major Bleed Death 
 HR 95% CI HR 95% CI HR 95% CI 
Brain 0.67 0.43 1.04 0.81 0.46 1.43 1.32 1.10 1.60 
Thyroid 0.72 0.59 0.88 2.17 1.19 3.98 0.80 0.50 1.26 
Lymphoma 1.02 0.87 1.20 0.97 0.71 1.32 1.25 1.11 1.40 
Myeloma 0.86 0.61 1.23 1.56 1.02 2.40 0.91 0.72 1.15 
Metastatic disease 1.14 0.24 5.37 0.60 0.46 0.79 1.85 1.69 2.03 
HR = hazard ratio; CI = confidence interval; LMWH = low molecular weight heparin; 
VTE = venous thromboembolism; DVT = deep vein thrombosis; VC = vena cava; CCI 
= Charlson comorbidity index; IPTW = inverse probability of treatment weight 
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Figure 4.1a: Cumulative incidence functions of recurrent VTE - Competing risks 
time-to-event analysis by treatment group over 180 days of follow-up. Cumulative 
incidence is the percent of the cohort experiencing each event. Cumulative incidence 
is unweighted and no demographic or clinical characteristics are controlled. 
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Figure 4.1b: Cumulative incidence functions of major bleed - Competing risks 
time-to-event analysis by treatment group over 180 days of follow-up. Cumulative 
incidence is the percent of the cohort experiencing each event. Cumulative incidence 
is unweighted and no demographic or clinical characteristics are controlled.  
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Figure 4.1c: Cumulative incidence functions of death - Competing risks time-to-
event analysis by treatment group over 180 days of follow-up. Cumulative incidence 
is the percent of the cohort experiencing each event. Cumulative incidence is 
unweighted and no demographic or clinical characteristics are controlled.   
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Appendix Table 4A: Coding algorithms used for the analysis 
Deep vein thrombosis ICD-9-CM:  
Lower DVT - 451.11, 451.19, 451.81, 453.4, 453.41, 
453.42 
Upper DVT - 451.2, 451.9, 453.1, 453.2, 453.8, 453.9 
Pulmonary embolism ICD-9-CM: 415.1x 
Imaging studies 
Echocardiography 
 
 
 
Chest X-Ray 
V/Q Scan 
CT scan/CT Angiography 
MRI/MRI Angiography 
Ultrasound  
 
CPT: 
93306,93307,93308,93325,93312,93313,93314,93318,
93320,93321,93325,76881,76882,93970,93971,93975,
93976,75820,75822 
CPT: 71020 
CPT: 78585 
CPT:71275, 21250, 71260, 71270, 73200, 73201, 73202, 
73700, 73701, 73702, 73206, 73706 
CPT: 71555, 73218, 73220, 73718, 73720, 73225, 73725 
75820, 75822, 76882, 93970, 93971, 93975, 93976 
Hypocoagulation defects ICD-9-CM: 2860 2861 2862 2863 2864 2865 28652 
28653 28659 2866 2867 2869 
Other coagulation 
defects or hemorrhage 
ICD-9-CM: 2870 2871 2872 2878 2879 7827 
Thrombocytopenia ICD-9-CM: 2873 2874 2875 
Low white cell count ICD-9-CM:  2885 
High white cell count ICD-9-CM:2886 
Hypercoagulation 
defects 
ICD-9-CM:28981 28982 
Anemia ICD-9-CM: 280-285 
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Appendix 4B: Standardized differences relative to warfarin group 
(Significant value >0.10) 
 LMWH Filter Filter + 
Anticoagulation 
None 
Age (categorical) 0.1070 0.0424 0.0661 0.0147 
Plan type 0.1294 0.0967 0.0417 0.0019 
Region 0.0849 0.0749 0.0323 0.0080 
Gender 0.0784 0.0414 0.0162 0.0072 
Index event 0.0323 0.1906 0.0618 0.0097 
Race 0.1341 0.0577 0.0452 0.0101 
CCI (categorical) 0.1088 0.1639 0.0630 0.0042 
Leukocytosis 0.0471 0.0014 0.0689 0.0108 
Leukocytopenia 0.0038 0.0087 0.0043 0.0063 
Thrombocytopenia 0.0638 0.0175 0.0132 0.0113 
Thrombocytosis 0.0072 0.0468 0.0379 0.0034 
Hypocoagulatory 
disorder 
0.0160 0.0724 0.0450 0.0046 
Anemia 0.0349 0.0239 0.0609 0.0100 
Liver dysfunction 0.0078 0.0325 0.0231 0.0047 
Renal dysfunction 0.0635 0.0707 0.0271 0.0136 
Hypertension 0.0357 0.0424 0.0634 0.0041 
Prior bleed 0.0027 0.0360 0.0206 0.0023 
Obesity 0.0030 0.0175 0.0046 0.0041 
Treatment timing 0.0608 0.0706 0.0339 0.0051 
Tumor site     
Oral 0.0265 0.0173 0.0126 0.0050 
Stomach 0.0227 0.0218 0.0068 0.0040 
Colon 0.0260 0.0547 0.0175 0.0047 
Liver 0.0053 0.0423 0.0004 0.0079 
Pancreas 0.0198 0.0146 0.0335 0.0001 
Lung 0.0304 0.0960 0.0346 0.0068 
Breast 0.0092 0.0249 0.0117 0.0027 
Melanoma 0.0420 0.0699 0.0460 0.0030 
Uterine 0.0420 0.0699 0.0460 0.0030 
Cervix 0.0003 0.0217 0.0037 0.0109 
Ovarian 0.0226 0.0098 0.0220 0.0028 
Prostate 0.0477 0.0554 0.0234 0.0088 
Bladder 0.0016 0.0317 0.0126 0.0021 
Renal 0.0635 0.0707 0.0271 0.0136 
Brain 0.0503 0.0473 0.0014 0.0150 
Thyroid 0.0950 0.0064 0.0074 0.0039 
Lymphoma 0.0106 0.0777 0.0050 0.0015 
Myeloma 0.0201 0.1132 0.0160 0.0023 
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Appendix 4B: Standardized differences relative to warfarin group 
(Significant value >0.10) 
Metastasis 0.0166 0.0806 0.0685 0.0020 
Myocardial infarction 0.0244 0.0653 0.0309 0.0050 
Congestive heart 
failure 
0.0531 0.0904 0.0288 0.0051 
Peripheral vascular 
disease 
0.0624 0.1103 0.0303 0.0023 
Cerebrovascular 
disease 
0.0109 0.0974 0.0285 0.0136 
Dementia 0.0044 0.0586 0.0376 0.0085 
Chronic pulmonary 
disease 
0.0530 0.0432 0.0054 0.0006 
Rheumatic disease 0.0453 0.1112 0.0202 0.0059 
Peptic ulcer disease 0.0349 0.0039 0.0095 0.0064 
Diabetes w/o 
complications 
0.0022 0.0536 0.0579 0.0079 
Diabetes w/ 
complications 
0.0252 0.0517 0.0212 0.0004 
Paraplegia/hemiplegia 0.0751 0.0258 0.0373 0.0102 
Depression 0.0706 0.0236 0.0167 0.0013 
Skin ulcers/cellulitis 0.0677 0.0894 0.0488 0.0012 
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CHAPTER 5: EVALUATION OF A QUALITY IMPROVEMENT INTERVENTION TO 
INCREASE VENA CAVA FILTER RETRIEVAL AT THE UNIVERSITY OF KENTUCKY 
HOSPITAL 
 
Introduction 
 
The recent attention into retrieval rates of inferior vena cava filters elicited several 
institutional interventions aimed at improving retrieval in the patient population. 
This has been spurred by reports of overall low retrieval rates as well as FDA safety 
communications calling for improved, as well as earlier retrieval of IVCFs.  28,30 In 
response to these communications, the University of Kentucky Healthcare (UKHC) 
Division of Vascular and Interventional Radiology (VIR) instituted a retrospective 
review of retrieval rates along with a prospective letter mailing intervention to 
increase retrieval in patients in whom an IVCF is no longer indicated. The design 
and impact of this intervention is described herein. 
 
Methods 
 
As part of a clinical practice improvement initiative, a registry of all IVCFs placed at 
the UKHC hospital in Lexington, KY between October 2011 and February 2016 was 
created and housed within the Department of Radiology. A study coordinator 
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retrospectively collected all data to create the database. Patients from VIR, surgery, 
and cardiology services were included; however, detailed information was only 
available within the VIR service. Information collected included patient identifying 
information, referring physician, patient’s primary care physician, filter indication 
and procedure details including date, and the retrieval date. There was no 
prospective follow-up or data collection implemented due to the inability to extend 
manpower. 
 
Starting January 2014, all patients with IVCFs implanted by VIR and their primary 
care or referring physicians were followed-up with a one-time letter sent within 3 
months by the implanting physician and study coordinator regarding the need for 
eventual IVCF retrieval. Contact information to the VIR clinic was provided and 
contact was encouraged by the primary care physician or patient. Other than the 
letters mailed, standard care was provided throughout the intervention period. 
 
Patients were assumed to be eligible for retrieval until death was observed. The 
date of retrieval was noted, otherwise patients were censored at the beginning of 
the intervention period (for those in the pre-intervention group), or censored at the 
end of the data collection period (February 2016). Patients who died within 30 days 
of IVCF placement who did not already have retrieval were excluded from the 
cohort. Death was considered a competing event in the calculation of the cumulative 
incidence of retrieval using the method by Fine and Gray to allow for comparison 
between the pre- and post-intervention groups. The mean, standard deviation (SD), 
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median, and interquartile range (IQR) of the time-to-retrieval was also calculated 
and compared.  
Results 
 
There were a total of 184 and 93 IVCFs placed at UKHC in the pre- and post-
intervention periods. Of those, 10 and 3 patients were excluded from follow-up 
because they were deceased within 30 days after IVCF placement. Of the 90 patients 
in the intervention period, all patients were sent letters and 87 letters were sent to 
primary care providers (N=3 patients did not have a provider noted in the medical 
record). 
 
Of those in the pre-intervention period, 7/174 (4%) had their IVCF retrieved while 
7/90 (7.8%) of those in the post-intervention period were retrieved. In the time-to-
event analysis, which accounted for death during follow-up, the observed retrieval 
rate at a total of 802 days of follow-up prior to the letter intervention was 4.4% 
(Figure 5.1). In the post-intervention period, the observed retrieval rate at 265 days 
of follow-up was 8.1% (Figure 5.1). At an equivalent follow-up period with a 
cumulative incidence estimate available (288 days), the pre-intervention group’s 
estimated retrieval rate was <1%, giving a relative rate of retrieval of 12.8 between 
the two periods. Overall, the cumulative incidences between the two groups were 
significantly different (p=0.043). The time-to-retrieval in the pre-intervention 
period was a mean (SD) of 503 (207) days with a median (IQR) of 505 (301-742). In 
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the post-intervention period, time-to-retrieval was a mean (SD) of 119 (83) days 
and with median (IQR) of 128 (38-164) days (Table 5.1). Due to the intervention 
implemented, minimal financial impact to the clinic was expected and; thus, not 
evaluated. 
Discussion 
 
The minimal intervention implemented in the VIR clinic at the UKHC hospital 
resulted in a significant increase in the IVCF retrievals. Overall, the magnitude of this 
impact was on the order of a relative rate of 12.8 when limiting the analysis to an 
equivalent follow-up time. Likewise, there was a decrease in the time-to-retrieval, 
showing that retrievals were occurring at earlier intervals. This can be expected to 
decrease the risk of complications reported with longer indwell times such as IVCF 
fracture, migration, and IVC thrombosis. 
 
Despite the large relative change in IVCF retrieval, UKHC’s observed rates of 4.4% 
and 8.1% represent some of the lowest reported retrieval rates in the literature. 
Only one other known institution has reported a similar rate of 8.5%.  64 Due to this 
low rate, that institution also implemented an intervention that increased their 
retrieval rate to over 50%. 39  
 
These low rates can be due to several factors. For one, UKHC is a level 1 trauma 
center serving a largely rural population, including the health disparate Appalachian 
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region, making follow-up difficult. The patient case-mix at UKHC is also known to be 
the worst in the state with higher comorbidity burdens along with the highest 
utilization of IVCFs. 70 More importantly, these retrieval rates are indicative of 
practice culture. However, it should not be inferred that UKHC is dramatically 
different from other institutions where retrieval rates have been reported to be 
much higher than that observed in our institution. 28 Rather, it is likely that a 
publication bias is present wherein institutions are not willing to discuss low 
retrieval due to concerns about how releasing these figures would change the 
perception of quality.  
 
Although in context this minimal intervention can be perceived as successful, how it 
compares to other interventions is important for planning future improvements to 
the clinical workflow. This intervention included only mailed letters and 
retrospective collection of patient data. Other interventions instituted at other 
hospitals have generally included three facets: 1) patient and physician education 
regarding IVCFs; 2) a method of tracking patients (e.g. automated alerts through 
electronic medical records or active tracking); and 3) an individual who takes 
responsibility for the entire process. 128 Patient education has included pre-
discharge education sessions as well as informed consent prior to implantation. 41,129 
Physician education examples have included continuing medical education grand 
rounds, which have both increased retrieval along with reduced overall utilization 
of IVCFs. 130 Many studies also institute IVCF “registries” so that patients are 
catalogued continuously in a dedicated record developed specifically for the 
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population. 39 Further, the movement of responsibility for follow-up from the 
patient’s referring or primary care physician to the implanting physician creates an 
environment of quality assurance and cross-communication between specialties.  
41,42 The addition of these workflows and responsibilities has been shown to not 
increase workload significantly and has also been shown to increase clinic revenue 
because of increased patient follow-up and billable clinical visits. 78 All of these 
factors should be incorporated into a future intervention to further increase the 
retrieval rates at UKHC. Moreover, such an intervention should be expanded to 
incorporate inter-departmental collaboration and communication in all implanting 
and referring specialties, not only VIR.  
Conclusion 
 
Utilizing a minimal letter mailing intervention, retrieval rates at our institution were 
increased approximately 12-fold with dramatic changes in the time-to-retrieval. 
However, given the post-intervention retrieval of only 8.5%, much more progress 
can be made to increase retrieval rates with a more thorough intervention. Lessons 
from other institutions that have implemented such interventions will be utilized to 
design a future intervention in order to transform the practice environment and 
ensure patient safety associated with IVCFs. 
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Figure 5.1: Cumulative incidence plot of time to retrieval after vena cava filter 
placement 
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Table 5.1: Time to retrieval comparison pre and post letter mailing 
intervention 
 Pre-intervention (N=7) Post-intervention (N=8) 
Mean (SD) 503 (207) days 119 (83) days 
Median (IQR) 505 (301-742) days 128 (38-164) days 
Standard deviation (SD); Interquartile range (IQR) 
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CHAPTER 6: A LITERATURE REVIEW OF INTERVENTIONS TO IMPROVE 
RETRIEVAL RATES OF VENA CAVA FILTERS AND LESSONS LEARNED FOR 
FUTURE EFFORTS 
 
Introduction 
 
In response to the observed poor retrieval rates at UKHC hospital and the small 
impact of the letter intervention, a literature review was undertaken to explore 
interventions instituted in other institutions. The overall goal was to define the key 
aspects of interventions and the overall impact an intervention could have on 
retrieval rates. A sub-aim of the review was to evaluate financial aspects of these 
interventions to understand the feasibility of interventions  
 
Methods 
 
Abstract and full-text search terms including “vena cava filters”, “IVC filters”, and 
“inferior vena cava filters” were used in conjunction with “retrieval” in 
MEDLINE/PubMed, Google Scholar, and Cochrane databases. Published studies from 
January 2003 up to August 1, 2016 were included. Identified abstracts were 
screened by two independent reviewers, one health services researcher and one 
interventional radiology resident. Reviewers selected studies that indicated that an 
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intervention was implemented and compared to a control group or a pre-
intervention period. Of those identified from abstract review only, full-text versions 
of the articles were acquired. Additional articles were discovered from identification 
in the references of collected manuscripts. Articles that did not meet the 
requirements of evaluating an intervention during full-text review were excluded.  
 
After relevant studies were identified, the two reviewers independently read the 
manuscripts and extracted a priori defined data of interest including the study 
setting and year, type of institution and country of study, details of the intervention 
and the intervention staff, the comparison or control group, sample size, retrieval 
rates and indwell times, retrieval failures, complications, and loss to follow-up rates. 
All studies were included which reported both a pre-intervention and post-
intervention comparison of retrieval rates. The only exclusion criteria of studies 
consisted of no pre-intervention measure being present to evaluate the impact of 
the intervention. Data were entered into a spreadsheet, which was consolidated and 
reviewed by an additional attending interventional radiologist reviewer for 
correctness. An a priori meta-analysis was planned. Based on the extracted 
information, the large heterogeneity in measurement definitions, interventions, and 
patient populations, no further analyses were deemed feasible. Ultimately, the goal 
was to make general recommendations for future interventions based on the 
findings from the reviewed studies. A brief narrative of each study is included. 
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Results 
 
A total of 288 abstracts were screen from all sources with 18 included for full text 
review. Of these, 5 studies were excluded as they either described an intervention 
with no control or comparison group (N=4) and one study was a review article 
itself. An additional 3 studies were identified from full-text review of other studies 
and underwent abstract screening and full-text review. One of these additional 
identified studies was excluded, as it did not include a comparison group or period. 
A total of 15 studies underwent detailed review and are described below. 
Summaries of the study characteristics and interventions implemented are provided 
in Table 6.1. Sample size, retrieval rates, and other study data are provided in Table 
6.2 and 6.3. 
 
Twelve of the 15 studies were conducted in the U.S., one each in Ireland, the United 
Kingdom, and New Zealand (Table 6.1). Of these, 13 were conducted in single, public 
institutions, primarily tertiary care centers, with 5 additionally indicated as level 1 
trauma centers. The other two studies included an evaluation of a national military 
medical center, which tracked patients across multiple settings, and an evaluation of 
14 urban hospitals linked within a single, integrated, regional healthcare system 
(Kaiser Permanente Northern California). Five of the studies included an 
intervention only in trauma patients for both prophylactic and secondary 
prevention efforts.  
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Absolute changes in retrieval rates ranged from 0% to nearly 70%. Relative changes 
ranged from 0% to over 2,200% changes in retrieval rates (Table 6.3). One study 
showed no change in their retrieval rate (45%) while showing a slight decrease in 
the average indwell time. 1 This study may have been limited by a small sample size 
(N=66 for pre- and post-intervention periods combined). The largest absolute and 
relative increase was from a pre-intervention retrieval rate of 3.1% to 73% an 
absolute change of 69.9% and a relative change of 2,254.8%. Ten out of the 15 
studies reviewed at least doubled the baseline retrieval rate after the intervention 
was in place. All but two of the studies achieved post-intervention retrieval rates 
≥50%.  
 
Time-to-retrieval, or the indwell time for the IVCF, was reported for both the pre- 
and post-intervention periods in 11 studies. Of those, only 3 showed a decrease in 
the indwell time after the intervention. While some other studies showed increases 
in indwell times, most of the studies were limited in these comparisons due to 
sample size. 
 
Charlton-Ouw 2015 
This article details the implementation of planned retrievals at a single institution. 75 
Charlton-Ouw and colleagues note that their institution is unique in that it has a 
large number of uninsured or underinsured persons (Houston, TX), thus, they also 
included a financial feasibility analysis due to this issue. 
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The authors report that they focus their analysis on trauma patients only and 
describe that they are in a level 1 trauma center with >6000 trauma admissions 
annually. Prospective enrollment into the retrieval program began in May 2011 with 
patients being referred to the program via electronic medical record, ordering 
system, or by telephone referral. The study involved collaboration between 
trauma/general surgery services and the interventional radiology department. After 
written consent , patients were followed-up by a clinic nurse or a study coordinator 
via mail, telephone, and e-mail. Determination of the need for IVCF retrieval was 
made by the study physicians (vascular surgeons) in consultation with the patient’s 
primary healthcare providers. Patients not enrolled in the program were provided 
usual care. 
 
The explicit goal of this program was to remove eligible filters within 6 months after 
placement, noting that this should be regardless of insurance status. They also note 
that an initial goal of retrieval prior to discharge failed due to difficulties in 
scheduling as well as ongoing indications for IVCFs. Patient were in the study until 
the filter was removed or until the filter was deemed permanent. Patients with 
filters that could not be removed or deemed permanent were followed yearly for an 
abdominal X-ray and initiated on daily aspirin. 
 
For the cost analysis, commercial and Medicare insured individuals were grouped 
together while those with no insurance or Medicaid was grouped. Cost-to-charge 
ratios and payment-to-charge ratios were assessed for procedures. For patients 
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with no insurance or Medicaid, their costs were counted as losses to the hospital. 
Data analysis included univariate analyses to determine the effectiveness of the 
program. 
 
Prior to the retrieval program, 64 trauma patients received an IVCF with only 2 
being retrieved (3.1%). During the 2 years of the program, 247 trauma patients 
received IVCFs, 111 (45%) were enrolled into the retrieval program and 136 were 
followed in the standard of care arm. Those involved in the program had higher 
retrieval compared to those that were not: 73% vs. 18%, odds ratio 12.6 [6.6-24.3]. 
This retrieval rate represents attempted retrievals whereas the success rate of 
retrieval was 85%. The mean time to retrieval was 6.2 months (range 0.5-31.8 
months). The financial analysis showed that overall, the hospital revenue from 
retrieval higher than the cost, which was a balance between payments received 
from those with insurance (60% of sample) making up for losses from those without 
insurance. This financial analysis is only generalizable to this individual hospitals 
practice, however. They describe the population as generally younger trauma 
patients that are uninsured, which makes follow-up and continuity of care a 
challenge.  They recognize the need to make follow-up of patients dependent on the 
physicians and healthcare team rather than the patient. The opt-in feature of the 
program, via physician referral and patient agreement, creates the opportunity for 
some selection bias to be present in this study. 
 
Davies 2015 
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This study was based in New Zealand through a partnership of Departments of 
Vascular Surgery and Interventional Radiology and the Venous Thromboembolism 
Clinic in a single institution. 40 The partnership developed a clinical pathway, i.e. a 
defined, streamlined clinical workflow for IVCF retrieval. IVCF placement between 
June 2010 and June 2012 were analyzed retrospectively as the control group with 
information collected including acute vs. elective, medical vs. surgical referrals, 
vascular surgeons vs. interventional radiologists performing the implant, etc. For 
the clinical pathway intervention, all placed IVCFs during July 2012 through June 
2014 were included with retrievals documented through August 2014. All patients 
with IVCF placement were identified in a monthly report and entered into a 
dedicated IVCF database that was maintained by nurses in the Venous 
Thromboembolism Clinic. Patients with their IVCF in situ longer than 6 weeks were 
each discussed with the VTE consultant and the patient was subsequently followed-
up in the clinic or via telephone consultation. If retrieval was warranted, an 
appointment was made or, if the filter was to remain in place, an additional follow-
up consultation was scheduled. IVCFs were deemed permanent if the indication for 
placement was expected to extend for a long period or if retrieval was considered 
too risky. Statistical analyses included Kaplan-Meier survival plots including 
stratified analyses for key variables. They comment that patients were censored if 
they died, which was not incorporated in the statistical analysis.  
 
In the control group, 39 patients had an IVCF placed. Of these, 15 underwent 
retrieval (14 successful) and 9 died. Time to retrieval was 97 (range 15-293) days. 
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Of those 24 with no retrieval, 5 were deemed permanent, 2 had scheduled 
retrievals, and 8 were lost to follow-up. The Kaplan-Meier estimate at 12 months 
was 63%. The authors note that there were differences between retrieval based on 
referring specialty (surgical 78% vs. medical 40%) and elective (85%) versus acute 
(55%) care settings. 
 
In the post-intervention group, 56 patients had an IVCF placed with 29 retrievals, 12 
deaths, and 7 deemed permanent. The Kaplan-Meier estimate at 12 months showed 
100% retrieval. Similar results for differences between acute vs. elective and 
medical vs. surgical referrals were present. Pre-intervention the time-to-retrieval 
was 7.4 months and post-intervention it was 4.1 months (overlapping CIs) – 
suggesting an improvement in this metric as well. Overall, this study had much 
higher pre- and post-intervention retrieval rates than most other studies. This could 
be drive by hospital practices already established, but is also confounded due to the 
small sample size and the way in which patients were censored. Further, given the 
large proportion of patients who died in each period, the use of Kaplan-Meier 
methods will overestimate the retrieval rate since death is considered a censoring 
event instead of a competing risk, i.e. the retrieval rate is credited each time 
someone dies wherein they were still eligible for retrieval up to their death. The 
authors note the need for dedicated follow-up so that patients are not lost after 
implantation. They also note the need to place the burden of follow-up on either the 
implanting physician or a dedicated team aware of the IVCF status. 
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Gasparis 2011 
This intervention was implemented in a tertiary care hospital in the United States.  
129 The study presents results from the prospective intervention from January 2010 
to January 2011. A specialized “DVT team” was developed including a vascular nurse 
practitioner (NP) and a physician. The NP followed-up with patients and managed 
the development of a dedicated database. Phone calls and letters were sent to 
patients and referring physicians suggesting the best retrieval. In addition, patients 
were educated prior to discharge regarding IVCF retrieval benefits and risks. A 
“rigorous” coordination system between the NP and referring physician was 
maintained, including accommodating patient and physician schedules and having 
dedicated room in the interventional procedural suite. IVCFs could be deemed 
permanent prior to insertion if (1) the patient could not be anticoagulated for a long 
period of time (e.g. due to fall risk, intracranial bleed, etc.), or (2) patients with short 
life span. IVCFs were made permanent if the patient refused retrieval, IVC thrombus 
was present, they had recurrent VTE, or patients had a short life span. Patients who 
died during follow-up were excluded. The comparison group’s retrieval rate (18%) 
was reported from a prior study. Statistical analysis included basic Fisher’s exact 
test with no survival analysis included. 
 
During the 12-month period, 42 patients had an IVCF placed by vascular surgeons, 
with 40 being included in the analysis. Of these, 13 were placed as permanent. Most 
were placed for absolute contraindications to anticoagulation (58%), relative in 
25%, and 17% were used prophylactically. An additional 5 IVCFs were converted to 
 129 
permanent after placement – leaving 27 eligible for retrieval. Attempted retrieval 
was done in 22 of 27 patients with 86% success, giving a successful retrieval rate of 
70% and 81% retrieval attempt rate. Post-intervention time-to-retrieval was 21 
days (range 4-140 days) while pre-intervention time was not reported.  They report 
a significant benefit of the intervention and note an added benefit that no patients 
were lost to follow-up.  
 
Inagaki 2015 
This study reports an intervention to increase IVCF retrieval implemented with 
Boston Medical Center during August 2012 to September 2014 and compared it 
retrospectively with data from September 2003 to July 2012. 39 Starting with the 
intervention, prospective data was collected for each patient including physician 
specialty, indication, filter type, retrieval, etc. IVCFs were placed by multiple 
departments included interventional radiology, vascular surgery, and cardiology. A 
multidisciplinary task force encompassing the implanting departments with trauma 
surgery and hematology was established and a new IVCF retrieval protocol was 
developed. The protocol included four facets: (1) patient educational pamphlets, (2) 
additional IVCF procedure form, (3) a centralized IVCF registry, and (4) a dedicated 
administrative coordinator. Patient education materials included descriptions of the 
risks, benefits, and process of implantation and retrieval and emphasized that most 
IVCFs should be removed once anticoagulation is tolerated. The procedure form 
documented the indication for placement and the estimated duration it would 
remain implanted with permanent, immediate (<1 month), short-term (1-6 months), 
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and long-term (≥6 months) filter placement. An additional form was completed at 
retrieval to document success and any reasons for failure. The administrative 
coordinator maintained the IVCF registry and also coordinated between 
departments to ensure patient follow-up through the process. They note that this 
coordinator took on these roles as part of the daily job duties with negligible effect. 
Patients were contacted by phone or mail, differing slightly between departments, 
using standardized guidelines to determine suitability for retrieval. Statistical 
analyses included chi-squared and ANOVA tests. 
 
The clinical pathway was detailed in the article and is reproduced in Figure 6.1. The 
pathway included flow based on indication (VTE or prophylactic), accounted for 
time since implant, and if the patient was anticoagulated. In the comparison group, 
1,088 IVCFs were placed with 784 (72%) being placed as retrievable devices, 47 
(4%) of these died, and 17 (2%) were later deemed permanent. Of the 720 
remaining eligible for retrieval, 99 (14%) had attempted retrieval; with 82 (83% ) 
successful; with median indwell time of 119 days (range 0-1882 days). In 
comparison, the post-intervention group included 151 IVCF placements, 32 (21%) 
were inserted as permanent, 14 (9%) of patients died, and 31 (21%) became 
permanent – leaving 74 (49%) eligible for retrieval. Retrieval attempts were 
performed in 49 (66%) of these with 40 (82%) being successful and median indwell 
time of 175 days (range 8-664). Reasons for failure were reported and included the 
IVCF being imbedded in most cases and abnormal positioning of the IVCF being 
second most common. Between the pre- and post-intervention periods, there was a 
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significant decrease in the proportion of prophylactic indications for IVCF 
placement (suggesting a potential Hawthorne effect or other practice changes 
during the time period), differences in the IVCF models used, and changes in the 
implanting service. Further, there were large differences in retrieval based on the 
classification of the retrieval: immediate IVCFs retrievals attempted in 92% of 
patients (successful in 83%) and median indwell time of 23 days; short-term IVCFs 
retrievals attempted in 62% of patients (successful in 82%) and median indwell of 
164 days; and long-term IVCFs retrievals attempted in 50% (successful in 75%) and 
median indwell of 245 days – all significant differences. 
 
Irwin 2010 
This article discussed an intervention implemented in a level 1 trauma center in the 
United States between Q2 2007 and Q2 2008 with retrospective data back to 2003 
for comparison. 76 The authors distinguish that when retrievable IVCFs became 
available in 2003, the trauma team attempted to coordinate retrieval with the 
interventional radiology department. They noted that the overwhelming issue was a 
lack of patient follow-up, problematic because many patients would be indicated for 
retrieval later. In response, a multidisciplinary team was formed consisting of 
trauma nurses and surgeons and nurses from several departments. The team met 
each morning (M-F) and reviewed patient needs and to coordinate care. The nurse 
for the interventional radiology department would then follow-up with scheduling. 
They note that this team secured communication between services and improved 
patient follow-up between departments. 
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Prior to implementation, 82 IVCFs were placed with 53 removed (65%) and 15 
remaining in place without indication. After implementation of the team approach, 
of 33 IVCFs placed, 28 were removed (84%) and 3 remained in place without 
indication. The majority of IVCF placement in the trauma setting was for 
prophylactic indications over both time periods, and those with prophylactic 
indications had higher retrieval than those with active VTE (82% vs. 53%). They 
report multiple reasons for the 35 IVCFs that were not removed in the whole cohort 
including 8 transferred care to another facility, 3 lost to follow-up, 4 failed attempts 
at retrieval, 6 with contraindications to anticoagulation, 9 with IVC thrombosis, 2 
with DVT while on anticoagulation, 3 who had need for multiple surgeries. 
Indwelling times were not reported but multiple filter repositioning procedures 
(N=30) were reported. 
 
Kalina 2012 
This study describes the impact of having a filter registry in a level 1 trauma center 
in the United States. 131 The filter registry was established in 2006 and its impact 
was evaluated using retrospective data. Information collected included Injury 
Severity Score, indications, etc. and was maintained by acute practice nurses (APN) 
working in trauma. The registry was updated every 2 weeks from inpatient charts. 
Patient cases were presented by the APNs to trauma physicians and APNs scheduled 
procedures or consultations accordingly. Outpatient follow-up was conducted with 
the in-house clinic by APNs as well. The filter registry was also reviewed monthly at 
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the trauma department so that implementation plans could be coordinated. Data 
analysis included basic statistical tests (Chi-square) and stepwise logistic to find 
independent factors associated with non-retrieval.  
 
During the study period, 142 pre-registry and 165 post-registry IVCFs were placed. 
Significant differences existed in the length of stay, indications for placement, and 
the specific IVCFs utilized between the two periods. The reported retrieval rate in 
the pre-registry period was 15.5% (22 of 120) compared to 31.5% (52 of 113) in the 
post-registry period (P<0.001). The largest reason for non-retrieval was loss to 
follow-up, which was 21.1% and 27.6% in the two periods. In controlled analyses, 
IVC thrombosis, DVT, and loss to follow-up predicted non-retrieval.  
 
Ko 2009 
This study was based in a tertiary care hospital with a level-1 trauma center. 132 The 
author compared pre-intervention retrieval rates from 2004 to 2007 and 
implemented an intervention in August 2007. A physician assistant (PA) was given 
the duty to compile a prospective database of patients receiving an IVCF and 
subsequently coordinated the retrieval procedure to follow. Reasons for leaving the 
IVCF implanted were documented in the medical chart. Inpatients with IVCFs in 
place were highlighted on the rounding list daily and ongoing education of all 
trauma providers was given on the proper indications for IVCFs to re-enforce when 
they should be retrieved. Patients were electronically tracked with automated 
reminder e-mails sent to their admitting attending physician. Coordination between 
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hospital departments of vascular surgery, trauma, and interventional radiology was 
encouraged for inpatients and outpatients to increase retrieval. Basic statistical 
analyses (Chi-squared) were conducted. 
 
In the pre-intervention period, 94 patients received IVCFs while 61 patients 
received the devices in the post-intervention period (an increase in utilization on a 
per trauma patient basis between the periods). Of the 94 patients in the pre-
intervention period, 76 (80.9%) were deemed eligible for retrieval and retrieval was 
attempted in 32 (42.1%) of these with 28 (36.8%) being successful with an average 
indwell time of 24 days. In the post-intervention period, of the 37 (60.7%) were 
deemed eligible for retrieval and 35 (94.6%) of these underwent an attempted 
retrieval with 31 (83.8%) being successful at an average indwell time of 20 days. 
Except for the indwell time, each comparison (eligibility, attempt %, retrieval %) 
were statistically different. Reasons for non-eligibility were reported and differed 
between the two periods. In the pre-intervention period, 39 of 66 (59.1%) non-
retrievals were due to “clinical oversight,” i.e. loss to follow-up, and “medical 
reasons” (10, 15.2%). There were no cases of “physician preference” in the pre-
intervention period. In the post-intervention group, “physician preference” was the 
most common reason, 11 of 30 (36.7%), representing a potential bias introduced by 
knowing that your practice is being evaluated, or differences between the 
prospective and retrospective data collection.  
 
Lee 2012 
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This study was based in the UK and was inspired by a warning by the FDA-
equivalent Medicines and Healthcare products Regulatory Agency (MHRA) 
regarding the complications related to IVCFs that remain indwelling. 133 The 
intervention design removed the responsibility of follow-up from the referring 
physician and placed it on the intervention radiology who performed the 
implantation. They used a pre-intervention comparison during May 2007 to April 
2008 and implemented their intervention from May 2008 to April 2008. The 
radiologist-led approach to the follow-up of patients comprised of a log-sheet that 
generated standardized reports. These reports were faxed to the referring physician 
and suggested a retrieval date. In cases where retrieval was refused or not yet 
appropriate, additional reports were generated every 30 days. Statistical analyses 
included basic bivariate tests. Of the 28 IVCFs placed in the pre-intervention period, 
14 (50%) retrievals were attempted (10 successful, 35.7%). Of the 14 not retrieved, 
6 reasons for non-retrieval were undocumented while the other 8 were, leaving an 
effective retrieval rate of 14/20 (70%). In the post-intervention period, 29 IVCFs 
were inserted and 16 (55%) retrievals were attempted with 13 (44.8%) being 
successful. Of those not retrieved, only 1 was lost to follow-up, leaving an effective 
attempted retrieval rate of 16/17 (94.1%) (these figures were calculated and not 
reported in the original article).  The authors note the importance of choosing a pre-
specified time period to pursue retrieval (here 30 days) in that it is likely a clinically 
accepted interval and that retrieval rates beyond this time decrease dramatically 
(e.g. due to loss to follow-up and difficulty in retrieval) along with increased risk of 
complications.  
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Logan 2016 
This report details an audit instituted at a tertiary care center in Ireland.  134 Audits 
of retrieval rates were conducted before and after the implementation of a 
coordinated management strategy for IVCF follow-up using The Royal College of 
Radiology’s audit template. This audit template for IVCF states that 100% of 
retrievable IVCFs should have a retrieval attempt at all possible. 
 
The intervention included a multidisciplinary team of interventional radiologists 
and hematologists. A framework was developed with a 3-point approach of (1) a 
specialist nurse keeping a registry, (2) hematology consultation if IVCFs are to 
remain in situ or for complex removals, and (3) beds in a day ward were made 
available. There was a 7-month lead-in period and then a 15-month evaluation 
period is presented from November 2013 to December 2014. This is compared to 
the retrospective period of January 2012 to March 2013. 
 
Prior to the intervention, 33 patients received IVCFs largely for indications of 
planned surgeries or concurrent bleeding, low platelets, or active cancer. Thirty-
three patients also received IVCFs in the intervention period, with a larger 
proportion receiving them for bleeding/low platelet indications along with a 
significant decrease in IVCF use for surgery indications. Between the two periods, 
more IVCFs were deemed permanent (12% vs. 39%) during the interventional 
period while the proportion removed was the same (15%). There was a noted 
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increase in documented retrieval plans (70% vs. 91%) between the two periods. 
There was also a reduction in average indwell time (61 vs. 44 days) and fewer 
patients were considered lost to follow-up (27% vs. 9%) 
 
 
Lucas 2012 
This study presented a unique patient population consisting of military trauma 
patients at a national military medical center. 135 The authors describe most of their 
patients coming from the theater of war, passing through medical facilities in 
Germany, then moving throughout the country in military, veteran, and civilian 
medical facilities – making tracking and follow-up of these patients difficult. An IVCF 
tracking system was implemented incorporating medical record review and 
communications between providers to increase retrieval rates in this population 
starting in January 2007, compared to the 2 years prior. The registry included all 
IVCF placements unless the patient died within 30 days of placement. Basic 
statistical testing between groups was utilized. 
 
The control and registry groups comprised 20 and 93 patients, respectively. In the 
control period, 6 (30%) retrievals were attempted and successful while 65 (70%) 
attempted and 56 (605) successful retrievals were conducted in the registry period. 
The number lost to follow-up decreased from 65% to 5% between the two periods 
as well as the time to retrieval (210 to 84 days). The authors note a sub-analysis 
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within both periods showing that there was a non-significant difference between 
times to attempted retrieval for successful versus failed retrievals. 
 
Lynch 2011 
This report describes an intervention implemented in a tertiary care center in the 
United States. 41 A retrospective period (May 2002 to October 2005) and an 
interventional period (October 2005 to May 2010) were compared. At this facility, 
they note the need for proper patient selection and follow-up. Thus, they outline 
that patients only received a retrievable filter if their need for one would be 
temporary, otherwise a permanent device would be placed, a decision that was also 
part of the informed consent process with patients. Retrievable IVCFs made of 42% 
of the IVCFs placed. Starting in the interventional period, the responsibility of 
follow-up was placed on the implanting interventional radiologist instead of the 
referring physician, including initiated follow-up of patients who received IVCFs 
prior to the intervention implementation. Patients were tracked in a departmental 
quality assurance database (iSchedule) and a custom Access database. If an IVCF 
was not removed in 90 days, a medical record review was performed and patients 
were given a status of “declared permanent,” “candidate for future removal,” or 
“candidate for immediate removal.” Patients eligible for future removal were 
reviewed again in 1-3 months. To follow-up, patients were contact via form letter 
that reviewed why the initial implant was done as well as the rationale for removal. 
If no response, additional letters (up to 3) were sent at 1-3 month intervals. Initially, 
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a phone call was given after failed communication but was abandoned due to 
workload for a final letter, and patients were declared lost to follow-up at that point. 
 
Before the intervention, 154 IVCFs were placed and 973 were placed afterward (a 
large increase in overall utilization, 5.8/month increased to 17.5/month).  Of those 
in the pre-period, 37 (24%) were removed compared to 574 (59%). Additionally, 
IVCFs placed in the pre-period that were prospectively contacted resulted in an 
additional 47 IVCF removals. Loss to follow-up remained similar during those time 
periods (18.2% vs. 16.2%). The time to retrieval increased dramatically from a 
mean/median of 103/91 days in the pre-period up to 307/224 days in the post-
period. The proportion of those declared permanent also decreased from 25.3% to 
16.7% between the periods. A large number also remained candidates for retrieval, 
(32% and 85 in pre- and post-periods), indicating that patient contact remained. Of 
all attempted retrievals reported, there were a low number of failures (9/667, 
1.3%). Listed indications for permanence in 202 were need (101, 50%), death (72, 
35.6%), and patient refusal (20, 9.9%). The authors note that the patient population 
resides in a generally rural and affluent area, which made follow-up easier than 
other settings. They also note the utility gained from an electronic medical record so 
that such an intervention can be implemented by a single individual.  
 
Minocha 2010 
The authors implemented an intervention starting in January 2009 and compared it 
to retrospective data from the 8 years prior at an urban tertiary care center.  42 A 
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dedicated IVCF clinic was established with a dedicated clinic database. The clinic 
staff included a nurse coordinator and interventional radiologist; tasks were added 
to their clinical responsibility. The nurse coordinator updated the prospective 
database with all patients receiving IVCFs by interventional radiology. Before 
placement, the interventional radiologist consulted with the referring physician to 
confirm the indication for IVCF placement, including the need for permanent versus 
optional devices. The IVCF clinic nurse and radiologist monitored the database and 
coordinated retrieval with the referring physician when indicated. Referring 
physicians were contacted 2-3 weeks after placement to discuss the possibility of 
removal otherwise, or if the device was to be made permanent. Retrieval procedures 
were initially scheduled after patient visits to the clinic. This was replaced by 
telephone calls, unless the case was complicated, due to the inefficiency of having 
multiple visits. Basic statistical analyses were used in addition to Kaplan-Meier 
survival analysis.  
 
Each year, the proportion of optional IVCFs increased from 21% in 2001 to 64% in 
2009. Of the 369 implanted in the pre-intervention period, 108 (29%) were 
retrieved compared to 60 of 100 placed (60%) in the post-intervention period. 
Between those two periods, there was a shift in the IVCFs utilized and no difference 
in the retrieval failure rate (6% vs. 5%). There was a general increase in the number 
of IVCFs placed per month over these two periods from a median of 3 during 2000-
2008 up to a median of 10 per month in 2009. Of those IVCFs not retrieved in the 
post-intervention phase, 33/40 (82.5%) were deemed permanent. The median time 
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to retrieval, in which 50% of all IVCFs are placed, was 1.5 months via Kaplan-Meier 
estimation. Estimated retrieval at 3 months was near 80% according to the survival 
analysis. Only 2/100 patients experienced complications in the post-intervention 
period and only 1 was considered lost to follow-up.  
 
O’Keeffe 2011 
This study describes an intervention instituted at a level 1 trauma center in the 
United States. 136 At the time of IVCF placement, a fluorescent label was placed on 
each patient’s chart along with an arm bracelet. Such patients were tracked by 
trauma nurse practitioners (NPs), which confirmed patient contact information 
prior to discharge. Three months after discharge, the NPs contacted patients to 
schedule pelvic and lower extremity venous duplex ultrasound. If no DVT were 
found along with no other contraindications, the NP would schedule IVCF retrieval 
with the radiology department. In cases of uncertainty, the attending trauma 
surgeon was consulted for final decision. Non-trauma patients receiving IVCFs 
received standard care. All IVCFs placed and included in the final analysis were for 
prophylactic indications only. The authors compared retrieval between trauma and 
non-trauma patients during the same time period using basic statistics as well as 
multivariable regression.  
 
Among the trauma group, 91 patients received IVCFs and met criteria for inclusion. 
Of those, 14 were deemed ineligible for retrieval (3 deaths, 4 DVT present, 7 
surgeon judgment). Of the 77 eligible for retrieval, 42 (54.5%) were removed. The 
 142 
non-trauma group consisted of 76 patients and 45 were deemed ineligible for 
retrieval (10 deaths, 13 DVT present, 22 still indicated). Of the 31 eligible non-
trauma patients, 6 (19.4%) were removed. Overall, the authors reported that there 
was a total retrieval of There was a difference in median age between the two group 
of over 20 years, large differences in gender, and shorter indwell times in the non-
trauma group (median 14.5 vs. 48.5 days). Regression analysis found that trauma, 
younger age, and the specific trauma team (i.e. specific to one NP in particular) 
utilized predicted retrieval overall. Distance from hospital and insurance status 
were not significant. There is remaining concern over how balanced one can 
consider the trauma vs. non-trauma comparison, especially for wholly prophylactic 
indications.  
 
Sutphin 2015 
This article describes an intervention at a tertiary care hospital with a level-1 
trauma center. 78 The article specifically mentions utilizing the DMAIC (Define, 
Measure, Analyze, Improve, Control) Methodology of Six Sigma as their process for 
implementation. To define the problem, they retrospectively analyzed retrieval at 
their institution and found that of all patients receiving IVCFs, 92% were lost to 
follow-up and 8% were retrieved. Two measures were determined to evaluate, 
mainly the retrieval rate achieved as well as the proportion of patients followed-up 
in the clinic. The authors created a process to increase these metrics including 
increased communication between referring and implanting physicians on how to 
schedule retrieval. A multidisciplinary team also met to outline issues related to this 
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workflow and categorized each issue into barriers associated with providers, 
patients, clinical, and systems and further divided into controllable or 
uncontrollable (Figure 6.1 reproduced). Key factors included provider knowledge 
and follow-up, patient knowledge and follow-up after the procedure, lack of a 
clinical database and a shortage of permanent filters for patients in whom they were 
indicated. New workflows were designed after recognizing these shortfalls. One 
workflow addressed patients with an IVCF already in place. A letter was sent to the 
primary physician to schedule a visit with a lower venous ultrasound study. Letters 
were repeated every two weeks up to three letters. The second workflow addressed 
prospective patients and included automatic scheduling of a clinic visit 4 weeks 
after IVCF placement as outpatient or 4-6 weeks after discharge as inpatient. The 
clinic visit included consulting and educating the patient about the potential 
retrieval. In addition, an IVCF database was maintained by a physician assistant, 
who also investigated non-compliant patient cases. Core monthly meetings and 
quarterly team meetings evaluated the intervention for adjustments. The cohort 
was divided into baseline (52 patients, pre-intervention), “letters” (43 patients 
retrospectively contacted), and prospective (45 patients, scheduled follow-up at 
placement) for evaluation. Deceased patients were excluded from eligibility, making 
up 15 (28.8%), 6 (14%), and 12 (26.7%) patients in each group. Basic statistical 
analyses were conducted. 
 
The baseline group had a retrieval rate of 8% (4/51). This increased to 40% 
(17/43) in the letters group, and 52% (22/45). Between the groups, the average 
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time to retrieval was 64, 137, and 59 days, with no reported failures. In addition to 
the retrievals, ~20% of patients in the letters group and ~50% of those in the 
prospective group were followed-up in clinic. This increased the revenue per 100 
IVCFs implanted from $2,249 in the baseline group, $10,518 in the letters group, 
and up to $17,022 in the prospective group – showing nearly eight-fold increase in 
revenue with prospective intervention. The financial analysis is unique among 
studies and the inclusion of an intervention for a retrospective group shows 
feasibility beyond only a prospective intervention. 
 
Wang 2016 
This unique study presents the systemic effect of multiple continuing medical 
education seminars on the practice patterns in an integrated healthcare system 
(Kaiser Permanente Northern California). 130 A system-wide IVCF tracking database 
was also implemented. Twelve in-hospital CME-approved grand rounds were given 
by a vascular and interventional radiologist specializing in IVCFs. These 
presentations were also broadcast to satellite clinics and 2 more medical facilities. 
The 14 facilities serve a combined 3.5 million members of the healthcare system. A 
new practice model for IVCFs was also introduced and included: (1) the radiology 
department assumed responsibility for follow-up; (2) a color-coded database alerts 
users when filters are approaching 9- or 12-week indwell times, the database was 
also capable of presenting dashboards to each facility if requested; (3) 
recommendation made to follow ACCP guidelines for IVCF use; (4) established 
collaboration with the anticoagulation clinic; (5) a monthly procedural code 
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generated list was made by each facility to double check no patient oversight; (6) a 
9-12 week retrieval interval was generally recommended. Outcomes measured 
were IVCF utilization and retrieval as well as concordance with ACCP and SIR 
guideline recommendations for IVCF indications.  
 
There was an 18.7% decrease in overall utilization of IVCFs, with changes ranging as 
low as decreases of 38.7% to increases in 16.7% at individual facilities. There was a 
significant correlation in the decrease in IVCF utilization and overall physician 
attendance. In the entire health system, this represented a net decrease in IVCF 
utilization of 22.2%. Prior to the intervention, 38.9% (111 attempts, 92 successful) 
of IVCFs were retrieved compared to 54.0% (127 attempts, 109 successful) in the 
post-intervention group (15.1% change). There was no significant change in indwell 
time (mean 10.2 vs. 10.8 weeks) or successful attempts (82.3% vs. 85.8%). There 
was a significant correlation in physician attendance and increased retrieval 
attempts. There were no differences in guideline concordance between the two 
periods, but overall compliance with ACCP guidelines was 75.9% (other institutions 
report 33.3% to 54% compliance with these conservative guidelines). The authors 
note that there are differences between West and East coast IVCF practices, and also 
differences between practices by patient payer status and the need for “defensive” 
medicine. They note these factors are decreased in a closed healthcare system like 
Kaiser Permanente.  
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Overall, differences in institutional characteristics, baseline practices, and 
interventional approach showed a broad range of impacts of these interventions. 
Absolute changes in retrieval rates ranged from 0% to nearly 70%. Relative changes 
ranged from 0% to over 2,200+% changes in retrieval rates (Table 6.3). 
 
Discussion 
 
During this literature review, several key points were recognized and noted 
including: definition of retrieval (attempted vs. successful), inclusion and exclusion 
criteria implemented in each study, the statistical analyses utilized, and the 
potential of observed “Hawthorne” effects. Additionally, few studies reported on the 
financial aspects of the interventions and there was a large discussion about the 
responsibility of follow-up being shifted. Each is discussed below with case 
examples to illustrate how these points can impact how these interventions are 
evaluated.  
 
Definition of retrieval  
Studies differed on how they reported attempted versus successful retrievals 
although all studies used successful retrievals as the primary metric. Nearly all 
(13/15) reported the number of failed retrievals which ranged from none to nearly 
30%; thus, the attempted retrieval rate can at least be calculated if it is not explicitly 
reported. Generally, retrieval failures can be expected to be 15% of all attempts, 
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although this can be variable depending on a combination of institutional, physician, 
and patient factors. In most of these studies, the differences in failed retrievals 
between pre- and post-intervention periods were not significantly different, 
although these comparisons were limited because of sample size. Further, if 
differences exist between the pre and post periods, in the failure rate, reporting and 
comparing these figures can be more important, more so if the intervention can be 
expected to impact failure rates in some way. Further, evaluation of these 
interventions must put in context the goal of the program. Follow-up is generally the 
goal in that if patients are followed-up with, then retrievals will naturally increase. 
Thus, both attempted and successful retrieval rates should be reported in such 
evaluations. Similarly, as the goal is often to retrieve earlier, comparison of indwell 
times between intervention periods is called for. 
 
Inclusion and exclusion criteria 
There was wide variation in the patient populations between studies (e.g. trauma, 
prophylactic, etc.) along with variation in the definition of eligible and included 
patients in each study. A clear definition of the patient population is paramount to 
evaluation and how these inclusion and exclusion criteria impact the assessment 
should be considered. More importantly, the same definition should be applied 
across pre- and post-intervention periods to allow an unbiased assessment of the 
program.  
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Statistical analyses 
Most studies utilized “simple” statistical analyses in that they included only 
bivariate tests of significance, mostly chi-squared, Fisher’s exact, or equivalent non-
parametric or multiple groups tests. Two studies, Minocha and Davies utilized 
survival analysis in their studies. In each study, details about follow-up, censoring 
events, and competing events are limited. In Minocha’s study, there were few 
patients lost to follow-up and it is not discernible how many died and were 
considered censored due to death. In the Davies study, they specify that patients 
were censored at death including 9/39 (23.1%) patients in the pre-intervention 
period and 12/56 (21.4%) patients in the post-intervention period. 
 
The general assumption in Kaplan-Meier survival analyses is that censoring is 
uninformative, which can be interpreted as patients who are censored should not be 
different that patients that remain in the risk set. In the case of random censoring, 
e.g. true loss to follow-up, this assumption may generally hold. In the case of death 
as a censoring event, however, those that die are likely generally different. Thus, 
death is informative and should be considered a competing event, or a competing 
risk, and accounted for in estimates of the cumulative incidence of retrieval.  74 
Ignoring competing risks will inflate the cumulative incidence as those who die are 
removed from the risk set (denominator) when the Kaplan-Meier product limit 
estimator is calculated. This essentially will bias the estimated retrieval rate from 
these methods; a bias that is on a magnitude determined by the actual death rate in 
the cohort. In the Davies study, more than 1 out of 5 patients died during follow-up, 
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a figure that indicates that the Kaplan-Meier estimates are tremendously biased. 
Davies and colleagues report a 12-month retrieval rate of 100% although 29 of 56 
(51.7%) patients actually had retrieval. 
 
To deal with this issue two approaches could be taken, which should likely be 
determined by the amount of detailed follow-up data included. For one, competing 
risks could be accounted for using estimation techniques like Fine and Gray’s 
estimate of the cumulative incidence. This would require clear definitions of what 
constitutes loss to follow-up, censoring, and competing events. Further, studies 
should consider the impact of when follow-up begins. This is imperative where 
patients are assessed for ongoing indications for IVCFs and, intuitively, the follow-
up for retrieval has not clinically been initiated. The other approach is more 
conservative and could involve calculating the retrieval rate in basic statistical 
analyses, i.e. like the majority of the studies in this review. Most important here is to 
develop a clear definition of who would be included in the denominator and to 
ensure that a set follow-up time is achieved, so not to punish the retrieval rate due 
to limited follow-up in those enrolled late into the study. For example, the base 
calculation of the 51.7% retrieval in the Davies study includes patients who had 
planned procedures and ongoing indications for retrieval. These patients should 
likely be excluded from any calculation of retrieval (including the survival analysis).  
 
I may also be more prudent for studies to investigate retrieval rates within a defined 
time period, especially given the large interest in having shorter indwell times to 
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decrease device related complications. 30 Thus, we propose investigating retrieval 
rates with 90-180 days as an outcome versus longer periods. Such a calculation 
should consider the above recommendations of clear definitions of outcomes, as 
well. This will avoid potential biases related to follow-up and how eventually 
patients can be removed from the cohort. 
 
Hawthorne effect of intervention 
The classical dynamic explains how individuals behave differently when they are 
aware of ongoing evaluation. This could certainly be the case in most of these 
studies as those who implemented the interventions had their practice directly 
affected. Interesting questions can be posed to add to the understanding of the 
longevity of these policy changes.  
 
However, there also remains the possibility that some pervasive effects could occur 
due to the ongoing evaluation. One example where this may have occurred is in the 
article by Logan et al. In this study, during the pre-intervention period, 12% of all 
patients eventually had their IVCFs deemed permanent. Based on the study 
definition of retrieval rate, this removed these patients from the denominator. In the 
post-intervention period, this proportion rose to 39% in the post-intervention 
period. While this could be influenced by several factors, a possible pervasive factor 
could have included physicians within the clinic becoming more likely to deem 
IVCFs as permanent, which would inflate the estimated retrieval rate due to the way 
this study defined this metric. 
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Financial analyses 
Two studies, Sutphin et al and Charlton-Ouw et al, featured financial analyses in 
their evaluation of retrieval interventions. The Charlton-Ouw financial analysis was 
done to account for the known issue at this institution of patients being uninsured 
or having less generous insurance (i.e. Medicaid). 75 Thus, these patients 
represented potential losses for the IVCF clinic in the hospital, especially if follow-up 
was increased and more procedures performed. Their analysis showed that the 
charges from patients with insurance (commercial and Medicare) were enough to 
“cover” the uninsured group and still result in small revenue for the clinic. While 
similar considerations may be relevant at other institutions that treat large 
uninsured populations, this financial analysis is not generalizable. 
 
The financial analysis by Sutphin provided a more generalizable analysis of the 
financial impact of such an intervention and provides a picture of how increased 
manpower and relatively simple interventions can be allotted to improve clinic 
revenue. Using the standardized metric of clinic revenue per 100 IVCFs placed, they 
show that the baseline revenue was $2,249/100 IVCFs in the baseline group, 
$10,518/100 IVCFs in the letters group, and up to $17,022/100 IVCFs in the 
prospective group. As described, the letters intervention with retrospective patients 
required little application of person-time to implement, i.e. letters were sent and 
patients or their primary provider could then follow-up. This is somewhat 
analogous to the simple letter campaign conducted within the UKHC IR clinic. Thus, 
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it is intuitive that clinic revenue will increase linearly with improvements in 
retrieval rates and Sutphin has shown it here.  
 
Costs to the clinic are not only procedurally based. Retrievable IVCF equipment and 
devices are more costly than that of permanent IVCFs. In the context of few 
retrievals occurring, these devices become de facto permanent; thus, a permanent 
device could have been used in its place. A study by d’Othée and colleagues showed 
that when both types of devices are available, a minimum retrieval rate of 41% is 
needed for retrievable devices to be cost-effective compared to permanent devices. 
77 All this shows that retrieval impacts costs in multiple ways. Dedication to good 
practice of retrieving devices can increase both procedural revenue and help recoup 
costs from increased device costs.  
 
Responsibility for patient follow-up 
Multiple studies in this review pointed at that the responsibility of patient follow-up 
was shifted from the patient’s referring or primary physician to the physician who 
performed the implant or the clinic itself. Lynch’s article discusses how he himself 
took on this responsibility to increase retrieval rates, which represents a paradigm 
shift in physician-to-physician and physician-to-patient communication in this 
setting, both prior to and after IVCF placement. 41 Minocha and colleagues 
implemented a similar practice with a dedicated interventional radiologist and 
nurse conducting follow-up. 42 Each of these studies also included the creation of an 
IVCF registry or database which assists these clinicians in implementing these plans. 
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Further, some studies also point out the importance of IVCF retrieval plans being 
included in discharge plans, enhancing the communication between providers.  81 In 
Logan’s study, this was shown by tracking retrieval rates in those who had thorough 
documentation of the IVCF implant as well as plans for retrieval in the discharge 
notes. In the total population, the baseline retrieval rate was 45%, but increased to 
91% in patients who had plans documented. 
 
Applicable guidelines 
In general, two guideline statements can be thought to cover the practice of 
implanting IVCFs and included the American College of Chest Physician (ACCP) 
guidelines on the management of VTE 4 and the Society for Interventional Radiology 
(SIR) guidelines for management of pulmonary embolism. 32 In medicine, the ACCP 
guidelines are generally considered “conservative” calling for use of IVCFs only if 
there are clear contraindications to anticoagulation. The ACCP guidelines do not call 
for prophylactic use. The SIR guidelines are more liberal allowing for prophylactic 
use in those who do not have an active VTE but are considered contraindicated or 
are high risk. 
 
Only one study in this review evaluated these SIR and ACCP guidelines in their 
institution. The study by Wang et al of 14 medical centers included evaluation of the 
concordance of IVCF practices with these guidelines. 130 What they observed was 
that around 80% of all implantations were supported by ACCP guidelines and 20% 
were supported only by SIR guidelines. Thus, for this study, it seems the institutions 
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are practicing conservatively. However, this study was conducted within a self-
contained health system where patients and physicians are insured and employed 
by the insurer (Kaiser Permanente) in fully owned medical centers. Because of this, 
the authors cite that factors that may lead to more liberal use, e.g. defensive 
medicine practices and need to increase reimbursement, are not present in this 
setting. To compare, a study not included in this review showed that in two 
hospitals in New York, compliance with ACCP guidelines was lower at 41.3% and 
reached 95.7% compliance with SIR guidelines. 33 The main discrepancy being 
prophylactic use of IVCFs. 
 
Conclusions 
 
As has been shown, there is wide variation in practices of IVCF utilization and 
retrieval. This is due to a combination of physician preferences, practice 
environment, patients, and healthcare system qualities. 78 In the end, the general 
issue seems to be patient follow-up, which is a result of the aforementioned 
characteristics. To improve IVCF utilization, continuing medical education of 
accepted indications for use, indications for retrieval, and how these influence 
effectiveness and complications related to IVCFs is needed and has been shown to 
decrease utilization and increase retrieval. Patient education is also needed to 
ensure informed consent is provided to provide what is generally seen as a “low-
value” healthcare service and to reinforce the concept of compliance with future 
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follow-up. A method of tracking these patients in combination with an individual or 
team of individuals who take clinical responsibility for this important quality of care 
issue is needed. 128   
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Figure 6.1: Action items for improvement of IVCF retrieval rates 
 
 
 
Reproduced from Sutphin (2015) 78 with permission 
 
Table 6.1: Characteristics of studies evaluating interventions to increase inferior vena cava retrieval rates 
Study citation Study Year(s) Setting Intervention Intervention staff Implanting 
services 
Control/Comparison 
group 
Indications for 
insertion 
Charlton-Ouw 
2014 (USA) 75 
Pre: 4/2009-
2011; Post: 
5/2011-2013 
Level 1 
trauma 
center 
Mail, email, telephone 
follow-up with patients 
after EMR referral 
Clinic nurse or study 
coordinator. Vascular 
surgery, trauma, IR 
physicians in 
multidisciplinary 
team. 
IR: 23%; VS: 
3%; trauma: 
74% 
Retrospective, pre-
intervention 
Trauma patients, 
prophylactic and 
secondary 
Davies 2015 
(NZ) 40 
Pre: 6/2010-
6/2012; Post: 
7/012-6/2014 
Tertiary 
center 
Clinical coding registry and 
PACS review, monthly 
report. Phone and/or 
scheduled clinic follow-up. 
Clinical pathway 
developed. Focused on 
filters placed >6 weeks 
VTE clinic nurses 
coordinated effort 
IR, VS Retrospective, pre-
intervention 
Med-surg 
patients 
Gasparis 2011 
(USA) 129 
Post: 1/2010-
1/2011 
Tertiary 
center 
NP coordinated with 
patients and referring 
physician for follow-up. 
Educated patients pre-
discharge about IVCF 
benefits and risk. Dedicated 
time in suite. 
Dedicated NP 
maintained database 
and follow up. 
Dedicated "DVT 
Team" with NP and 
physician. 
VS None: compared to 
baseline retrieval rate 
that was from previous 
study 
Med-surg 
patients 
Inagaki 2016 
(USA) 
Pre: 9/2003-
7/2012; 
Post:8/2012-
9/2014 
Tertiary 
center 
Retrospective review 
followed by prospective 
retrieval program; EMR 
review. Task force, 
standardize retrieval 
process. 1) patient 
educational pamphlets, 2) 
procedure form, 3) 
centralized registry, 
dedicated coordinator 
Multidisciplinary task 
force from VS, IR, 
cardiology, trauma, 
and hematology. 
Retrieval coordinator 
VIR, VS, Cards Retrospective, pre-
intervention 
Med-surg 
patients 
Irwin 2010 
(USA) 
1/2003-6/2008 Level 1 
trauma 
center 
Team met each morning 
(M-F) to review patient 
care. Coordinated with IR 
staff to schedule retrievals. 
Multidisciplinary task 
force of clinical 
nurses, executed by 
IR clinical nurse, led 
by trauma nurses in 
consultation with 
VIR Retrospective, pre-
intervention 
Trauma patients, 
prophylactic and 
secondary 
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trauma surgeons 
Kalina 2012 
(USA) 
Pre: 1/2003-
12/2005 
Post: 1/2006-
12/2009 
Level 1 
trauma 
center 
Filter registry. APNs 
managed data collection 
every 2 weeks, presented 
cases to trauma physicians, 
directly scheduled 
procedures. Registry 
reviewed monthly by 
department 
Trauma surgeon, 
acute care nursing 
staff 
Placement: 
trauma, VIR 
Retrieval: VIR 
Retrospective, pre-
intervention 
Trauma 
Ko 2009 (USA) Pre: 1/2004-
2/2007 
Post: 8/2007-
7/2008 
Level 1 
trauma 
center 
Institutional protocol 
developed, automated 
email sent to ordering 
physician as reminder. 
Highlighted on rounding 
list for physicians. 
PA, coordination 
between trauma, VS, 
IR 
VS and IR. 
Mostly VS: 
60% pre and 
90% post 
Retrospective, pre-
intervention 
Trauma patients: 
1. very high risk; 
2. 
contraindication 
to anticoag 
Lee 2012 (UK) Pre: 5/2007-
4/2008 
Post: 5/2008-
4/2009 
Tertiary 
center 
 
Proactive f/u organized by 
IR instead of referring 
physician. Clinical team 
contacted every 30 days by 
radiologist via fax to 
schedule retrieval. 
IR VIR Retrospective, pre-
intervention 
Various 
Logan 2016 
(IRL) 
Pre: 1/1/2012-
3/31/2013 
Post: 11/2013-
12/2014 
Tertiary 
center 
Nurse in charge of filter 
registry; consult with 
hematology to decide 
eligibility for retrieval; bed 
available for retrieval at 
short notice 
Multidisciplinary 
team with 
interventional 
radiologists, 
hematologists, and 
nursing staff 
VIR Retrospective, pre-
intervention 
Various: major 
indications 
varied pre vs. 
post 
Lucas 2012 
(USA) 
Pre: 12/2005-
12/2006 
Post: 1/2007-
1/2011 
National 
Military 
Medical 
Center 
Tracking system, medical 
record review and provider 
communication; Follow-up 
plans at the time of 
discharge 
Administrative 
trauma coordinator 
in charge of tracking 
system, 
Multidisciplinary 
meeting and 
communication with 
providers 
N/R Retrospective, pre-
intervention 
Military combat 
trauma 
Lynch 2011 
(USA) 
Baseline/retrosp
ective: 5/2002-
10/2005 
Tertiary 
center 
Chart review and multiple 
f/u letter communications. 
IR was given responsibility 
A single 
interventional 
radiologist 
VIR Retrospective, pre-
intervention. 
Additional f/u with 
SIR guideline 
indications: 
various 
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Post: 10/2005-
5/2010 
of follow-up. Informed 
consent included 
discussion of IVCFs. 
Registry maintained in 
iSchedule and Access 
database. Non-retrieval 
flagged if >90 days. Letters 
for f/u sent, up to 4 
past patients. 
Minocha 2010 
(USA) 
Pre: 1/2000-
12/2008 
Post: 1/2009-
1/2010 
Tertiary 
center 
Retrospective for pre-
intervention pts and 
prospective for post-
intervention pts. Dedicated 
registry. Contacted 
referring physician every 2-
3 weeks until removed or 
deemed permanent. 
Interventional 
radiologist and nurse 
coordinator - 
dedicated IVCF clinic 
VIR Pre: before IVC filter 
clinic 
Post: after IVC filter 
clinic established in 
1/2009 
SIR guideline 
O'Keeffe 2011 
(USA) 
1/1/2006-
12/31/2006 
Level 1 
trauma 
center 
Prospective only: label, 
tracked by NP for f/u 
venous duplex US. F/u in 
90 days for imaging and 
removal.  
Multidisciplinary 
team with trauma 
surgeons, 
radiologists, and NPs, 
while NPs are in 
charge of aggressive 
patient follow up 
N/R Trauma (intervention):  
vs. Non-trauma 
(standard care): 
Prophylactic use 
only in trauma 
and non-trauma 
groups 
Sutphin 2015 
(USA) 
Baseline: 
1/2012-8/2012 
Letter (retro): 
9/2012-4/2013 
Prospective: 
5/2013-
12/2013 
Tertiary 
center 
DMAIC methodology from 
Six Sigma. Retrospective 
letters to patients and 
physicians. Auto scheduling 
in 4-6 weeks. Correcting 
issues of physician, 
patients, clinical, and 
systems. Separate 
pathways for past and 
future patients. 
Multidisciplinary 
team, IR 
physician/nurse, 
internal medicine 
nurse, and hospital 
quality facilitator 
N/R Baseline: no follow-up 
“Letters”: Patients 
receiving retrospective 
f/u. Post: Prospective 
f/u after full 
implementation 
Various 
Wang 2016 
(USA) 
Pre: 12/2011-
03/2013 
Post: 2/2013-
5/2014 
14 urban 
centers in 
northern 
CA 
(Kaiser 
Gave 12 CME grand rounds. 
Deployed IVC clinic model 
and tracking system in IR 
clinics. 9/12 week dwell 
alerts, optional dashboards. 
Board-certified VIR 
physician, clinical 
model coordinated IR 
with anticoagulation 
clinics at each 
VIR - IR 
(57/59) or NIR 
(2/59) 
physicians 
Pre- vs. post-
intervention, each for 
one year period. 
Changes tracked at 
each institution and 
Various 
 
Table 6.1: Characteristics of studies evaluating interventions to increase inferior vena cava retrieval rates 
Permane
nte) 
Recommended 
conservative ACCP 
guidelines.  
institution overall. 
 
 
 
Table 6.2: Results from studies evaluating interventions to increase inferior vena cava filter retrieval rates 
Study citation Comparison 
(N) 
Intervention 
(N) 
Comparison 
retrieval (%) 
Intervention 
retrieval (%) 
Comparison 
indwell time 
Intervention 
indwell time 
Failed 
retrievals 
Complications Loss to f/u 
Charlton-Ouw 
2014 (USA) 
64 111 3.1% 73% N/R 6.2±4.0 months 15% 1.95% 1 patient  
Davies 2015 (NZ) 39 56 63% 100% 7.4 months 4.1 months 3.2% N/R 0%  
Gasparis 2011 
(USA) 
14 40 Retrieval: 18% Attempt: 81% 
Retrieval: 70%  
N/R 21 days (4 to 
140) 
14% 0% None 
Inagaki 2016 
(USA) 
720 74 Attempt: 14% 
Retrieval: 11%  
Attempt: 66% 
Retrieval: 54% 
119 days 130 days Pre: 17% 
Post: 18% 
N/R 34% lost to 
follow up 
Irwin 2010 (USA) 82 33 65% 84% unclear unclear 3.5% N/R 9.56% 
Kalina 2012 
(USA) 
120 113 15.5% 31.5% N/R N/R N/R N/R Pre: 21.1% 
Post: 27.6% 
Ko 2009 (USA) 76 37 Attempt: 42% 
Retrieval: 37% 
Attempt: 95% 
Retrieval: 84% 
24±30 days 20±15 days Pre: 12.5%  
Post: 11%  
0% 0% 
Lee 2012 (UK) 28 29 50% 55% 10 days 
(median) 
16 days (median) Pre: 28.6%  
Post: 18.8% 
0% Pre: 21%  
Post: 3%  
Logan 2016 (IRL) 33 33 45% 
(84% with 
retrieval plan) 
45% 
(91% with 
retrieval plan) 
61 days 
Failed: 94 days 
44 days 
Failed: 92 days 
Pre: 15% 
Post: 9% 
N/R Pre: 27% 
Post: 9% 
Lucas 2012 (USA) 20 93 Attempt: 30% 
Retrieval: 30% 
Attempt: 70% 
Retrieval:60% 
210±190 days 84±101 days Pre: 0 
Post: 13.8% 
N/R Pre: 65% 
Post: 5% 
Lynch 2011 
(USA) 
154 973 24% 59% Mean: 103 days 
Median: 91 days 
Mean: 307 days 
Median: 224 days 
1.3% N/R Pre: 18.2% 
Post: 16.2% 
Minocha 2010 
(USA) 
369 100 29% 60% N/R Mean: 45 days Pre: 6%  
Post: 5%  
2% Post: 2.5% 
O'Keeffe 2011 
(USA) 
31  77 19.4% 54.5% 14.5 days 48.5 days N/R 1.2% N/A 
Sutphin 2015 
(USA) 
36 Letters: 25 
Prospective:4
2 
8% Letters: 40% 
Prospective: 
52% 
64 days Letters: 137 days 
Prospective: 59 
days 
None N/R Unclear.  
19% of letters 
and 49% of 
prospective 
patients not 
retrieved still 
had ongoing f/u 
Wang 2016 (USA) 285 235 38.9% 54.0% 71.4 days (10.2 
weeks) 
75.6 days (10.8 
weeks) 
Pre: 17.7% 
Post: 14.2% 
1.6% 0% 
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Table 6.3: Impact of interventions to increase vena cava filter 
retrieval rates 
Study Pre-
intervention 
retrieval rate 
Post-
intervention 
retrieval rate 
Absolute 
change 
Relative 
change 
Charlton-
Ouw 2014 
(USA) 
3.1% 73% 69.9% 2254.8% 
Davies 2015 
(NZ) 
63% 100% 37.0% 58.7% 
Gasparis 
2011 (USA) 
18% 70% 52.0% 288.9% 
Inagaki 2016 
(USA) 
14% 
 
66% 
 
52.0% 371.4% 
Irwin 2010 
(USA) 
65% 84% 19.0% 29.2% 
Kalina 2012 
(USA) 
15.5% 31.5% 16.0% 103.2% 
Ko 2009 
(USA) 
42% 
 
95% 
 
53.0% 126.2% 
Lee 2012 
(UK) 
50% 55% 5.0% 10.0% 
Logan 2016 
(IRL) 
45% 45% 0.0% 0.0% 
Lucas 2012 
(USA) 
30% 70% 40.0% 133.3% 
Lynch 2011 
(USA) 
24% 59% 35.0% 145.8% 
Minocha 
2010 (USA) 
29% 60% 31.0% 106.9% 
O'Keeffe 
2011 (USA) 
19.4% 54.5% 35.1% 180.9% 
Sutphin 2015 
(USA) 
8% 52% 44.0% 550.0% 
Wang 2016 
(USA) 
38.9% 54.0% 15.1% 38.8% 
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CHAPTER 7: CONCLUSIONS AND FUTURE DIRECTIONS 
 
These studies have evaluated the utilization and retrieval of VCFs in both Kentucky 
and Nationally to put in context the quality of care surrounding this medical device. 
IVCFs are commonly utilized in the U.S. population with patient selection generally 
consisting of those with significant comorbidities that may affect their risk for VTE 
or bleed events. In these patients, and in a medical environment that encourages 
defensive medicine, IVCF use has increased to nearly 1-in-5 and 1-in-10 patients 
with PE and DVT. Further, IVCF use is in nearly equal quantities as prophylactic 
devices, an indication that is both refuted and supported by conflicting guidelines 
and remains, technically, off-label use, with little evidence for effectiveness. In fact, 
IVCF utilization has been used as one of several procedures to track low quality 
hospitals, physicians, and clinics as a procedure that has not be definitively shown 
to be effective. It is telling that when physicians are educated on the evidence 
behind these devices, the utilization decreases significantly and the retrieval 
increases significantly. 130 
 
In Kentucky, utilization was on par with national estimates, with similar findings in 
the epidemiology of use. Use is high in those with bleeding, cancer, or other 
conditions related to VTE or bleed risk. Interestingly, compared to another study in 
California, IVCF utilization between hospitals in Kentucky was less variable, and 
explained strongly by patients’ clinical characteristics. The fact that use was less 
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variable shows that there is even more variability between states, regions, etc. in 
how these devices are used. Often, when variability on this scale is observed, there 
can be inferred a large quality of care issue. That is, when your propensity to receive 
a certain procedure is largely determined by where or by whom you receive care, 
the standard of care needs to be evaluated. 
 
This is precisely the motivation for future work that have been driven by these 
studies as I transition from observational to interventional considerations. As 
Chapter 5 shows, quality of care at the University of Kentucky hospital VIR clinic is 
poor in terms of VCF retrieval and follow-up care. Chapter 6 was devoted to 
reviewing what other institutions have implemented to increase their own retrieval 
rates. Our aim was to glean a list of concepts from these interventions that are 
associated with success, i.e. increases in retrieval rates and decreases in the time-to-
retrieval. Since that time, the initial planning of a quality of care intervention has 
begun, including a letter of intent to the translational research institute at the 
University. This intervention will acknowledge and look to improve upon the poor 
retrieval rates in the VIR clinic by incorporating learnings from the literature review 
including: 1) a prospective patient registry; 2) dedicated follow-up visits with the 
implanting VIR physician; 3) certified mail letters sent to patients and physicians. 
Using these interventions, we hypothesize that we can increase the retrieval rate in 
the VIR clinic to over 50%, shorten the time-to-retrieval, maximize anticoagulation 
and VTE therapy, as well as increase clinic revenue from additional patient visits 
and procedures. We hope that the intervention will be successful, most importantly, 
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but also that it will also pay for itself so that instituting it permanently can be 
broadly supported by the institution.  
 
Lastly, future work also hopes to fill significant knowledge gaps regarding the 
optimal time for retrieval. The Morales study that informed the FDA safety 
communication synthesized the data and developed simulation models specified for 
a prophylactic indication. 31 Thus, as mentioned earlier, there is a general lack of 
knowledge regarding the optimal retrieval time in a patient with active VTE disease. 
Such information must account for confounding factors, patient age, VTE type, etc. 
and must be specialized to some distinct patient subgroups (e.g. cancer). Future 
work will expand on the Morales model by adding inputs that account for the risk of 
recurrent VTE (DVT or PE), VCF-related complications, and complications from 
anticoagulation. The establishment of a time-scale for retrieval and a deeper 
understanding of the net clinical benefit has the potential to influence the quality of 
care with VCFs, ensuring that the right device is used in the right patient at the right 
time. 
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